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  Zusammenfassung 
 
 
Zusammenfassung 
 
Die in vitro Rekonstruktion von dreidimensionalem knochenartigen Gewebe 
erfordert die Verfügbarkeit einer ausreichenden Menge von Zellen, ein 
geeignetes Trägergerüst zur Zellbesiedlung, sowie eine geeignete 
Kultivierungsmethode, die eine homogene Zellverteilung und Gewebeneu-
bildung in der gesamten Gerüststruktur ermöglicht. Zielsetzung dieser 
Dissertation war die Untersuchung von trabekulären Knochenzellen auf deren 
Eignung zur Geweberekonstruktion von Knochen, sowie die Entwicklung eines 
Herstellungsverfahrens zur Produktion von implantierfähigem menschlichen 
Knochengewebe in vitro. Hierzu wurde zunächst die Isolierung, Kultivierung 
und Expansion humaner trabekulärer Knochenzellen etabliert. Die Zellen 
wurden im größeren Maßstab in Wannenstapel erfolgreich expandiert und der 
mesenchymale Stammzellcharakter dieser Zellen durch ihr adipogenes, 
chondrogenes und osteogenes Potenzial verifiziert. Ein geeignetes 
Trägergerüst aus Poly-(lactid-glycolid)-Copolymer und Kalziumphosphat 
wurde mit den trabekulären Knochenzellen besiedelt. Die Kultivierungs-
verfahren unter statischen und dynamischen Bedingungen wurden 
miteinander verglichen. Die dynamische Kultivierung erfolgte in einem 
neuentwickelten Rotationskultivierungssystem, dass eine wipp- und 
rotationsartige Bewegung kombiniert und in einem Perfusionsbioreaktor. 
Unter Verwendung des Rotationskultivierungssystems, konnte im Vergleich 
zu den bislang bekannten Kultivierungstechniken, eine ausreichende Medium- 
und Sauerstoffversorgung, eine deutlich bessere Zellverteilung und eine 
deutlich bessere neu gebildete extrazelluläre Matrixverteilung im Inneren des 
Gerüsts erreicht werden. Histologische Untersuchungen, sowie unterstützende 
biochemische Analytik bestätigen eine de novo Knochenbildung. Die Qualität 
der Neubildung wurde durch die wipp- und rotationsartige Bewegung stark 
verbessert. Hinsichtlich einer klinischen Anwendung des kultivierten Zell-
Gerüst-Konstrukts zur Regeneration von Knochendefekten in vivo, ist dieser 
Kultvierungsansatz sehr vielversprechend. 
 
Schlagwörter : Mesenchymale Stammzellen, Osteogenese, Geweberekonstruktion. 
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  Abstract 
 
 
Abstract 
 
This dissertation set out to address the goal of optimizing and developing three 
dimensional cultivation conditions by exposing human mesenchymal-like stem 
cells in conjunction with a porous scaffold, to the correct mechanical and 
biochemical stimulus in an optimal microenvironment to improve current 
protocols and strategies in bone tissue engineering. Trabecular bone was 
demonstrated to be a good and readily available source of mesenchymal 
progenitor cells. A high yield isolation procedure was established from small 
bone tissue biopsies and the isolated cells were successfully expanded 
reproducibly on a large scale in cell factories. Their multilineage 
differentiation potential, displaying the ability to differentiate into the 
adipogenic, chondrogenic and osteoblastic lineage was also successfully 
demonstrated. For three dimensional bone-like tissue formation in vitro, these 
cells were cultivated in conjunction with a Poly-(lactic-co-glycolide)/calcium 
phosphate scaffold statically, as well as dynamically in a fixed bed perfusion 
bioreactor and in a novel tilted rotating system. Despite improved nutrient 
delivery in both dynamic systems, ubiquitous cell and newly deposited 
extracellular matrix distribution throughout the whole scaffold structure was 
observed to occur when cultivated in the tilted rotating bioreactor system. 
Improved osteogenesis through the tilted rotating movement was supported by 
in depth histological analysis and biochemical analysis of bone-specific 
markers. The viable reconstructed cell-scaffold construct generated in vitro in 
the tilted rotating system showed high resemblance to native bone tissue in 
terms of osteocytic cell shape held within the extracellular matrix, interacting 
with each other through specific bone gap junctional proteins with a very high 
chance of being integrated in vivo representing a promising tool for bone defect 
regeneration. 
 
Keywords: Mesenchymal stem cells, osteogenesis, tissue engineering. 
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1. General Introduction 
 
1.1. Overview and State of Research 
 
1.1.1. The Bone and Joint Decade: 2000-2010 
 
In January 2000, the world health organization (WHO) declared 2000-2010 to 
be the “Bone and Joint Decade” with the goal of raising awareness regarding 
the growing burden of musculoskeletal diseases on society as well as 
healthcare systems worldwide and, further, to advance research in prevention, 
diagnosis and improving treatment of these disorders (Lidgren, 2000). In this 
context, more than 150 different musculoskeletal disorders exist, which can 
lead to limited mobility, complete disability and in some cases even death. 
Primarily, the focus of the initiative of the bone and joint decade lies on 
osteoarthritis, rheumatoid arthritis, osteoporosis, spinal disorders, low back 
pain and trauma cases to the extremities (Lidgren, 2003).  
Musculoskeletal conditions have a major impact on society due to their 
frequency and the associated resulting chronic disability. As a result, in 
developed countries, they lead to high rates of sick leave from work and, 
further, constitute the second most common reason for consulting a doctor 
(Woolf and Pfleger, 2003). In Germany alone, up to 50% of all women and 15% 
of all men over 65 will eventually suffer from an osteoporotic fracture, more 
than half of the population over 60 is predicted to suffer from arthritis and 
more than 50% of all women and men over 30 will complain of back pain. In 
fact, in Germany, musculoskeletal conditions are responsible for 40% of all sick 
leave absences (Dreinhoefer, 2000; http://www.boneandjointdecade.de). 
If the therapeutic approaches in treating these diseases fail, as for instance by 
the administration of estrogen replacement therapy, calcitonin or 
bisphosphonates (Rodan and Martin, 2000), then these conditions could 
eventually lead to extensive bone and to eventual fractures. Healing the 
resulting skeletal defects will mostly require bone tissue replacement to 
restore the function of the traumatized or lost bone, which remains an 
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important clinical challenge, especially in non-union cases when bone is not 
able to regenerate itself and the body needs outside help to overcome this 
limitation. Current clinical therapies for bone substitution include:  
1. Autogenous bone grafts are well recognized as the gold standard with 
the best clinical results. Healthy bone is usually harvested from the iliac 
crest and implanted at the site of repair in the same patient, thus 
circumventing immunological incompatibilities as well as providing high 
viability and vascularization of the graft to be implanted. However, this 
method is associated with severe pain at the site of harvest for the 
patient as well as a significant risk of infection with a substantial 
morbidity rate (Goulet et al., 1997). Further limitations include the 
limited availability and size of the excised healthy bone tissue as well as 
difficulties in shaping the graft to fill the defect and the requirement for 
several procedures to complete the treatment (Kakar and Einhorn, 
2005). 
2. When autogenous graft material is not available, donated bone tissue 
from another individual can be transplanted into a patient, known as 
allograft or homograft. Allografts are often taken from cadaver and 
stored on ice. A major limitation associated with this procedure is the 
immunological rejection of the implant material, potential disease 
transmission and new bone is slower both in formation and in vascular 
penetration compared to autografts as it is devoid of viable osteogenic 
cells and therefore making it less effective, as well as limiting its 
application in orthopedic surgery (Brown and Cruess, 1982).  
3. Acellular matrix based therapies: Structural implant like titanium fiber 
metals or ceramics (hydroxyapatite and/or tricalcium phosphate) are 
implanted to replace the missing bone tissue. Despite the mechanical 
support offered for instance by metals, their lack of biologic activity 
leads to poor integration into the host tissue. Ceramics, on the other 
hand, are very brittle and provide poor support. Moreover, despite their 
porous nature, they have a very slow resorption rate, therefore limiting 
their use (Bruder and Fox, 1999). To overcome these limitations, 
osteoinductive factors like bone morphogenetic proteins are provided at 
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the site of repair but the optimal dose of the protein as well as its mode 
of delivery has not been established yet (Gerhart et al., 1993). 
The complications mentioned in the above methods associated with bone 
grafting procedures, point to the need of an alternative bone substitute 
solution that (i) minimizes dissection around the donor site, (ii) causes no 
immunologic reaction and (iii) is readily available off the shelf. The emerging 
field of bone tissue engineering with the goal to generate biological substitutes 
to replace damaged or lost bone tissue addresses this need. Tissue engineering 
has been defined as the application of the combined principles and methods of 
engineering and life sciences for the development of biological substitutes to 
restore, maintain or improve organ function (Langer and Vacanti, 1993; 
Vacanti, 2006). 
 
1.1.2. Tissue Engineering of Bone  
 
The aim of implanting tissue engineered bone is to activate bone regenerative 
abilities at a specific anatomic location in the body that has been damaged and 
needs to be restored or replaced. Ideally, in a way, that allows the newly 
formed bone to be completely integrated with the surrounding skeleton of the 
patient (Nerem, 2006). For an approach to reconstruct bone in vitro, which can 
best mimic an autogenous bone graft, the following essential fundamentals are 
required: Firstly, an osteogenic cellular component that is able to give rise to 
new bone tissue, needs to be provided at the site of treatment. Cells are either 
introduced from an external source or are recruited from within the body to 
the site of repair. Secondly, nutrients and stimulatory factors must be 
available for cellular proliferation and maturation, leading to matrix 
deposition and eventual mineralization of the newly laid down tissue. Finally, 
a scaffold* must be introduced to provide a substrate for the cellular 
attachment and serving as a temporary structural template supporting 
attachment, migration and proliferation of the cells (Bruder and Fox, 1999; 
Kakar and Einhorn, 2005). Successful protocols for bone regeneration will 
provide the scaffolds and associated cells to establish active contours and 
communication sites, which will enable complete functional integration of the 
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newly implanted tissue with the surrounding host tissue (Caplan, 2003). One 
scenario of a clinical relevant approach for bone tissue engineering would 
involve the use of autologous patient derived cells (to reduce graft versus host 
reaction) brought in close proximity in conjunction with a biodegradable 
scaffold in an environment leading to cell-cell interaction as well as cell-
scaffold interaction. This is best achieved in a bioreactor**, which is designed 
to control the cellular environment via enhanced mass transfer leading to 
spatial and uniform cell distribution throughout the three dimensional scaffold, 
responding to signals for proliferation and differentiation (Vunjak-Novakovic, 
2004). 
 
*A scaffold is defined as a porous structure (made up of ceramic, polymer or natural 
compound), which either provides support at site of defect or within which cells are seeded, 
providing a geometrical structure for cells to reorganize and form three dimensional 
multicellular tissues. 
**A bioreactor is defined as a device in which biological processes develop under regulated and 
controlled conditions (e.g. monitored temperature, pH, balanced nutrient supply and waste 
removal) (Martin et al., 2004). 
 
1.1.3. Basic Bone Biology and Natural Formation of Bone  
 
Bone is a composite material consisting of mineral, organic matrix (mainly 
composed of collagenous proteins), cells and water with its structure and 
composition varying with the tissue site as well as with age, diet and health 
status (Boskey, 2005). In general, there are two forms of bone: compact bone 
(cortical) and trabecular bone (cancellous). They share the same composition 
and mainly differ in their porosity, with compact bone being only 10% porous, 
thus rendering it stronger with a higher density than trabecular bone, which 
has a porosity ranging from 50-90% (Buckwalter et al., 1996b). Compact bone 
makes up ca. 80% of the mature skeleton and is mainly found in the diaphyses 
(the main mid section) of long bones, while cancellous bone is mainly found in 
short bones (e.g. tarsals, vertebral bodies) and flat bones (e.g. skull, pelvis) as 
well as in the metaphyses (the area between the diaphyses and the growth 
plates) of long bones (Buckwalter et al., 1996b). Histologically, bone can be 
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divided into woven and lamellar bone. Woven bone only appears in the 
embryonic skeleton as well as in fracture healing and repair processes with the 
later developed mature skeleton mainly composed of lamellar bone (Gratzl, 
2002). Woven bone is characterized by an irregular pattern of collagen fibrils 
and random mineralization patterns while collagen fibrils in lamellar bone are 
tightly organized in parallel sheets, forming distinct lamellae with uniform 
distribution of minerals within the matrix (Cooper et al., 1966). There are 
three forms of lamellar bone (Figure 1): the trabecular lamellae of cancellous 
bone, the inner and outer circumferential lamellae of compact bone and the 
lamellae of osteons (also known as Haversian systems). Each lamella consists 
of collagen fibrils, the alignment direction of which alternates in adjacent 
lamellae. Osteons, longitudinally aligned cylindrical units, form the bulk of the 
diaphysal cortex and are formed by circular lamellae sheets surrounding 
central canals containing blood vessels and lymphatic vessels known as the 
Haversian canals (Kuehnel et al., 2002). Small canals termed canaliculi, 
branch from the central canal in a radial pattern delivering nutrients to the 
cells embedded in the matrix in spaces known as lacunae. The external surface 
of bone is covered by the periosteum, which consists of an outer fibrous layer 
containing bundles of strong collagenous fibers termed Sharpey’s fibers and an 
inner cellular layer containing cells capable of forming bone. Oblique vascular 
channels known as Volkmann’s canals connect the osteons to each other and to 
the periosteum. Both canal systems supplying bone tissue with a rich 
vasculature with no cell lying more than 300 µm away from a blood vessel 
(Buckwalter et al., 1996b). The bone marrow is contained in the central cavity 
of the diaphyses in compact bone as well as in the spaces in-between the bone 
trabeculae in cancellous bone. 
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.3.1. Bone Cells and Matrix Formation in vivo  
 skeletal system is continuously remodeling with specialized bone cells 
ping the balance between bone resorption and formation. Bone cells 
inate from a mesenchymal stem cell line including the undifferentiated 
s, osteoblasts, bone lining cells and osteocytes and from a haematopoietic 
m-cell line represented by the macrophages from which the osteoclasts arise 
ll, 2005; Gay, 2005).  
differentiated Bone Cells –Mesenchymal Stem Cells 
eral studies have provided evidence for the presence of a pool of 
ifferentiated progenitor cells within bone tissue, residing in the bone 
als, periosteum and the bone marrow (Friedenstein et al., 1976; Beresford, 
9; Diaz-Flores et al., 1990; Nakahara et al., 1990). Caplan called these cells 
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mesenchymal stem cells (Caplan, 1991). A stem cell is defined by textbooks as 
a cell that can divide asymmetrically to generate one daughter cell that is a 
stem cell and another daughter cell, which produces differentiated 
descendants (Weismann, 2000) including chondrogenic cells that form 
cartilage, osteogenic cells forming bone, adipogenic cells to form fat next to 
other cells fabricating connective tissue (summarized in Figure 2). 
Mesenchymal stem cells function to generate replacement for the 
differentiated cells, especially in cases of injury and disease repopulating the 
affected tissue with progenitor cells (also known as homing) to later become 
part and function in the tissue again (Verfaille, 2006). Their self- renewing 
activity decreases with progressing age after peaking in the late 20s in 
humans (Caplan, 2005). 
 
Osteoblasts 
 
Osteoblasts, are cells arising from the multipotent mesenchymal stem cells 
that form bone (Aubin, 2001). They line the surface of bone, tightly packing 
against neighboring osteoblasts with a round polyhedral morphology and 
extended cytoplasmic processes to communicate with other cells (Buckwalter 
et al., 1996b). Their function lies in matrix production by mostly secreting 
collagenous proteins (mainly collagen type I in addition to small amounts of 
type III, type V and type XII) next to other noncollagenous proteins (5% of the 
bone matrix) including osteopontin, osteocalcin and bone sialoprotein forming 
the organic matrix of bone known as osteoid (Heinegard and Oldberg, 1998). 
Matrix production is followed by mineralization, which is also facilitated by 
osteoblasts through a mechanism that is not completely understood so far. One 
hypothesis is that mineralization is initiated in association with extracellular 
matrix vesicles (Anderson, 1995). Matrix vesicles are defined as extracellular 
membranous particles released by budding from the surface of osteoblasts to 
be deposited into the newly formed matrix (Anderson, 1969). 
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Figure 2 Schematic diagram showing the multipotential capacity of mesenchymal
stem cell. Fibroblast like cells derived from bone marrow and periost have the ability to
differentiate into bone, cartilage, muscle, marrow stroma, tendon and other connective
tissue. The diagram is adapted from Caplan (2005). 
 
Some time after the expulsion of the vesicles into the collagenous extracellular 
matrix, crystalline minerals first arising inside the vesicles, perforate the 
vesicle membranes and serve as templates for further mineralization. The rate 
of mineral crystal proliferation is governed by an interaction between the 
levels of ionic calcium and phosphate available in the extracellular fluid, the 
enzyme alkaline phosphatase that is enriched in the extracellular matrix 
vesicle membrane and the adjacent collagen fibrils (Anderson, 2003). Once the 
process has been initiated, mineral deposition occurs in and on the collagen 
fibrils in a spatially oriented axial and lateral manner (Arsenault et al., 1991). 
Mineralization gives bone its mechanical properties. Failure to mineralize the 
organic matrix by active osteoblasts, however, leads to weak bone and 
pathological fractures as in the case of rickets and osteomalacia. Osteoblasts in 
bone tissue either remain on the surface of bone, assuming a flat cell form and 
decreased synthetic activity or they surround themselves with matrix and 
become osteocytes, eventually disappearing from the site of bone formation.  
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Osteocytes 
 
The most abundant cell in bone is the osteocyte, forming 90% of all cells 
(Donahue, 2005). They develop from osteoblasts that have become entrapped 
in their deposited mineralized matrix. Osteocytes have a stellate morphology 
with extensive dendritic-like processes found in the canaliculi of bone tissue 
(Kato, 1997; van der Plas and Nijweide, 2005). From their position deep inside 
the matrix of bone and through their long cytoplasmic processes, they 
communicate with neighboring osteocytes and surface osteoblasts and are able 
to detect mechanical loading signals, transducing them to an appropriate 
remodeling response (Palumbo et al., 1990; Yellowley et al., 2000).  
 
Bone lining cells 
 
Morphologically, they have an elongated flattened shape lying on the surface of 
the bone matrix with cytoplasmic extensions penetrating the matrix to 
communicate with the dendritic extensions of the osteocytes. They are also 
called resting osteoblasts or surface osteocytes and may have a role in 
attracting osteoclasts to specific sites for remodeling (Buckwalter et al., 1996b).  
 
Osteoclasts 
 
Osteoclasts are multinucleated cells identified as bone-resorbing cells and are 
generated from fusion of haematopoietic cells of the monocyte-macrophage 
lineage (Suda et al., 1992). In balanced states, bone remodeling usually 
involves equal participation of bone resorption activity by osteoclasts and bone 
formation by osteoblasts. Disturbing this balance like excessive bone 
resorption leads to osteopenic conditions (e.g. osteoporosis and arthritis), as 
opposed to osteopetrosis, which is a disorder characterized by extremely dense 
bone and calcified marrow which is caused by failure of resorption. Upon 
maturation of the osteoclasts, they cycle between active and inactive states of 
bone resorption. Morphologically, osteoclasts have a characteristic ruffled 
border (Scott and Pease, 1956) that consists of finger like cytoplasmic 
projections providing a high surface area. When actively resorbing, osteoclasts 
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flatten against and attach to the bone surface through the cytoplasmic 
protrusions, through which acidified solution is secreted and at which 
hydrolytic and photolytic enzymes are concentrated and released (e.g. carbonic 
anhydrase, acidic collagenase), dissolving the mineral deposits and breaking 
down the matrix (Hall and Kenny, 1985). 
 
Bone Cell Interaction; Intercellular Communication 
 
The interaction amongst osteogenic and osteolytic cells in between themselves 
as well as with the extracellular matrix is essential for skeletal development. 
The cells are in contact with each other through long cytoplasmic processes 
containing gap junctions. Gap junctions are membrane-spanning intercellular 
channels that allow for the passage and exchange of small molecules and ions 
between the cytoplasm of two communicating cells (Lecanda et al., 1998). Each 
gap junction pore requires the contribution of two adjacent cells and is formed 
by juxtaposition of two hexameric hemi-channels, known as connexons. Thus, 
two connexons of two cells interact in the extracellular space to form the 
complete intercellular channel, the gap junction. Each connexon in turn is 
composed of six similar proteins, which are termed connexins. Connexin 43, a 
gap junction channel protein, was found to be the most abundant one in 
osteoblasts and osteocytes (Civitelli et al., 1993; Mason et al., 1996; Kato et al., 
1997; Thi et al., 2003). Figure 3 shows a schematic drawing adapted from 
Makowski et al. (Makowski, 1977), demonstrating the structure of a gap 
junction. This interconnection between osteoblasts, osteocytes and bone lining 
cells via gap junctions forms a ‘social network’ of cells that enables them to 
pass information between themselves in a coordinated manner, regulating the 
movement of ions in and out of the network as well as transmitting and 
amplifying signals from and to the extracellular matrix, whether it be 
mechanical signals or passage of ions, thus playing a pivotal role in bone 
formation (Yellowley et al., 2000; Cheng et al., 2001; Donahue et al., 2005). 
Figure 4 shows a scanning electron micrograph adapted from Doty (1981), 
displaying two adjacent bone cells communicating via a gap junction. 
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Bon
oss
intr
meFigure 4 Scanning electron microscopy micrograph adapted from Doty 1981
showing a gap junction between two adjacent bone cells (indicated by
arrows). An osteoblast (OB) communicating with an osteocyte (OC) through
cytoplasmic processes surrounded by unmineralized osteoid (UO). X 24,000. Adapted
from: Doty, S. B. (1981). Figure 3 Drawing of a gap junction structure adapted from Makowski 1977
The illustration show two adjacent cell membranes of two cells in juxtaposition, with
connexons spanning the membrane of each cell. Each connexon is made up of 6 units
the connexins. A gap junction is formed through the interaction of two hexons forming
a channel like structure. Adapted from: Makowski, et al. (1977).  -11- 
.4. In vivo Bone Formation  
e can be either formed via intramembranous ossification or endochondral 
ification (Scott and Hightower, 1991). The basic mechanism for 
amembranous skeletal bone formation begins with the accumulation of 
senchymal stem cells, followed by their direct differentiation into 
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osteoblasts, which actively secrete a specialized, densely fibrous extracellular 
matrix (osteoid) into which calcium phosphate crystals are deposited, 
culminating in a mineralized matrix (Doll, 2005). In endochondral ossification, 
the accumulated mesenchymal cells differentiate into chondrocytes first 
depositing a cartilage model (or anlage) of the future bone growing as a result 
of the proliferation of the chondrocytes and the secretion of matrix. The 
mesenchymal stem cells of the perichondrium, located at the mid-portion of the 
cartilaginous shaft, produce a layer of osteoblasts that deposit mineralized 
bone on the surface leading to gradual transformation of the perichondrium to 
the periost (Rosenberg and Roth, 2007). The cartilage is gradually resorbed by 
active osteoclasts while new bone tissue is being deposited by osteoblasts 
(Syftestad et al., 1985; Ferretti et al., 2006). Figure 5 shows the development of 
the osteoblasts into osteocytes embedded in the mineralized matrix as well 
into bone lining cells (osteoblasts aligned on the surface of the bone tissue). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Micrograph showing bone cells in the process of bone formation
(lower mandibular bone, human tissue). Haematoxylin&Eosin staining showing
active osteoblasts (1) and bone lining cells (2) and osteocytes in lacunae embedded in
the matrix (3). (4) Blood vessels. Magnification: x250. 
 
 
 
Long bones such as the femur and humerus and bones of the vertebral column 
are formed this way. In intramembranous ossification, no cartilage is formed 
and the mesenchymal cells organize themselves into layers or membranes that 
contain blood vessels and osteogenic cells depositing matrix and mineralizing 
it. Flat bones of the skull, face and pelvis are formed this way as well as the 
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formation of new bone during healing of fractures (Buckwalter et al., 1996a; 
Thompson et al., 2002).  
 
1.1.5. In vitro Bone Formation  
 
Techniques for the isolation of bone derived mesenchymal cells and techniques 
for directing the cells into the osteogenic lineage have been established (Owen, 
1988; Bruder and Caplan, 1990; Jaiswal et al., 1997; Pittenger et al., 1999; 
Buttery et al., 2001). To induce osteogenesis in vitro, the conditions necessary 
for in vivo bone formation provided by the active bone cells have to be 
mimicked by distinct additives to induce cells to produce an extracellular 
matrix and eventually mineralize it. Theses additives, which are classically 
added to osteoinductive medium for in vitro cell culture, include ascorbic acid, 
β-glycerophosphate and dexamethasone. Ascorbic acid is known to induce 
matrix deposition, stimulating the cells to synthesize collagen (Blanck and 
Peterkofsky, 1975; Jeffrey and Martin, 1966). β-glycerophosphate serves as a 
source for organic phosphate and encourages mineral deposition (Chung et al., 
1992; Sottile et al., 2003). The effect of dexamethasone depends on the stage of 
differentiation of the osteoblasts (Cooper et al., 1999) and includes induction of 
alkaline phosphatase expression and an increase in the number and size of 
mineralized nodules (Cheng et al., 1994).  
To better understand the process of in vitro bone formation, several studies 
have described the developmental sequence of the differentiation stages a cell 
undergoes in vitro to form bone (Owen et al., 1990; Stein and Lian, 1993; 
Siggelkow et al., 1999; Aubin, 2001). These can be summarized into the 
following three distinct stages:  
1. Cell proliferation and extracellular matrix formation: 
In this phase, the cells cultured in osteogenic medium gradually develop the 
osteoblast phenotype and start depositing the extracellular matrix with 
collagen type I as the major constituent, making up 30% of the dry non-
mineralized matrix (Boskey, 2005). In general, type I collagen peaks during 
the proliferation phase and declines thereafter. 
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2. Cell differentiation and extracellular matrix maturation and 
organization:  
The extracellular matrix is organized in this phase and prepared for the final 
mineralization. The proliferation of cells shuts down in this phase and proteins 
associated with the differentiated osteogenic cell phenotype like alkaline 
phosphatase are highly expressed in this phase declining thereafter. 
3. Extracellular matrix mineralization:   
The final phase in the osteoblast differentiation culminates in ordered mineral 
deposition along the collagen fibrils of the extracellular matrix.  
 
Stein and Lian (1993) have elaborated two transition points osteogenic cells 
have to pass through before terminal mineralization occurs. The first is at the 
end of the proliferation period (phase 1), at which collagen type I production 
rate is down regulated after reaching a peak and expression of the proteins 
responsible for the maturation of the extracellular matrix (e.g. alkaline 
phosphatase) is initiated. The second transition point is from phase 2 into 
phase 3, at the onset of mineralization after alkaline phosphatase expression 
peaks and is down regulated thereafter. The developmental sequence of 
osteoblast differentiation is illustrated schematically in Figure 6, showing a 
reciprocal pattern between proliferation and differentiation (Stein and Lian, 
1993).  
 
Time
Col 
ALP
ase 
 
 
 
 
 
 
 
 
 
 
Figure 6 Schematic illustration of a proposed model for the three stage
developmental sequence of osteogenic cells during in vitro bone formation. The
relationship between proliferation and differentiation during development of the osteogenic
phenotype showing the proliferation phase terminating with the down regulation of
collagen type I (col), the matrix maturation phase marked by a peak in alkaline
phosphatase expression (ALPase) which is down regulated upon transiting into the final
mineralization phase. Illustration adapted from: Stein and Lian (1993). 
 
Chapter 1   General Introduction 
 
 
-15- 
1.1.6. Bone Tissue Engineering Strategy for the Generation of an 
in vitro Bone Construct 
 
To successfully achieve bone tissue engineering (Section 1.1.2.), the three main 
requirements, namely, appropriate cells, a scaffold and a three dimensional 
cultivation environment (bioreactor) are elaborated in the following sections. 
 
1.1.6.1.  Stem Cells in Bone Tissue Engineering 
 
One of the major limitations in engineering tissue constructs for clinical use is 
the availability of sufficient human derived cells. Stem cells, derived from 
either embryonic or adult tissue are considered to be an attractive cell source 
as they have the advantage of being able to undergo extensive in vitro 
replication on a sufficient scale for therapeutic applications without losing 
their ability to differentiate into various lineages, thus serving as ideal blocks 
for tissue regeneration (Gregory et al., 2005; Bianco and Robey, 2001). Which 
stem cells are most suited for tissue engineering purposes is still controversial. 
Embryonic stem cells are cells derived directly from the inner cell mass of pre-
implantation embryos after the formation of a blastocyst. They are 
characterized by their self-renewal and their capacity to differentiate into all 
cell phenotypes (pluripotent). Despite their pluripotency and extensive 
proliferative potential, there are major ethical limitations and legal 
controversies as well as the associated danger of them inducing a tumor, which 
has restricted their use so far. 
Considering these controversies, researchers were prompted to study adult 
stem cells, cells residing in adult tissue as a possible source for tissue 
engineering purposes. In spite of their limited differentiation potential, 
compared to embryonic stem cells, their established and ease of isolation in 
vitro as well as their extensive expansion potential, has rendered them an 
attractive choice for tissue reconstruction in vitro (Fibbe, 2002; Tuan et al., 
2003). 
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1.1.6.2. Scaffolds in Bone Tissue Engineering   
 
A scaffold is designed to either just provide support at the site of repair or to 
deliver cells as well supporting their regenerative capability by providing 
temporary mechanical load at the site until it has been replaced by newly laid 
down tissue (Hollister et al., 2005).  
To enhance bone regeneration, a scaffold should meet a number of 
requirements. Ideally, it should have the following properties (Bruder and Fox, 
1999; Hutmacher et al., 2001; Vunjak-Novakovic, 2003; Caplan, 2005): 
 
i. Scaffolds should be biocompatible (non-immunogenic), bioresorbable 
(totally eliminated in the body without residual by-products remaining) 
or biodegradable (when the material is broken down into by-products, 
which are moved away from the site but not necessarily totally 
eliminated from the body, ideally resulting in non toxic by-products). 
ii. Possess a suitable surface chemistry allowing optimal cell attachment, 
proliferation and differentiation. 
iii. Sufficient mechanical strength to initially maintain and support the 
defect site to be repaired. 
iv. Be highly porous with an interconnected pore network for homogenous 
cell growth and flow transport of nutrients and metabolic waste, 
allowing bioactive molecules to have access to the cells as well as 
facilitating later neovascular invasion. 
v. Ability of being reproducibly processed into a variety of shapes and sizes 
according to clinical needs. 
Various suitable materials have been developed and investigated by tissue 
engineers and can be divided into the following:  
 
1. Ceramics 
Synthetic ceramics like β-tricalcium phosphate and hydroxyapatite as well as 
natural ceramics like coralline hydroxyapatite have been used as their 
structure is very similar to the mineral phase of native bone. Despite their 
osteoconductivity and open porous structure, major drawbacks in their use 
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include their brittleness (low mechanical stability) and slow resorption rates 
(Yaszemski et al., 1996; Karageorgiou and Kaplan, 2005). 
 
2. Natural Polymers  
Polymers from natural sources include collagen, polysaccharides (e.g. agarose 
and chitosan) and hyaluronic acid. They have the advantage of low 
immunogenicity and biodegradability. Nevertheless, the low mechanical 
strength and high degradation rates results in them needing chemical 
modification, thereby reducing their biocompatibility (Salgado et al., 2004). 
 
3. Synthetic Polymers  
The versatility of chemically synthesized polymers enables fabrication of 
scaffolds with different porosities, rate of degradation and mechanical 
properties according to the needs of tissue engineers. Regulatory approved 
polymers include polycaprolactone (PCL), polyglycolide (PGA), polylactides 
(PLA) and the copolymer of PLA and PGA forming poly (lactic-co-glucolic acid), 
(PLGA). They are degraded in vivo into acidic by-products, which might result 
in inflammatory reactions. Therefore it is important that, at all times, the cell-
scaffold construct is continuously exposed to sufficient quantities of neutral 
culture media so as to wash away the acidic by-products (Hutmacher et al., 
2001). 
 
4. Composites  
By incorporating tricalciumphosphate or hydroxyapatite (ceramics) with 
synthetic polymers (e.g. PLGA), cell adhesion is improved and the mechanical 
strength can be tailored (Marra, 2005). Drawbacks of the individual 
components (brittleness and acidic metabolites) can be overcome with the basic 
ceramic nature buffering the acidic gradients of the synthetic polymers helping 
to avoid an unfavorable environment for the cells (Hutmacher, 2000).  
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1.1.6.3. Bioreactors in Bone Tissue Engineering 
 
To provide the microenvironment necessary for osteogenic cells to regenerate 
functional bone in conjunction with a three dimensional scaffold structure, 
bioreactors are applied. They are designed to meet one or more of the following 
functions (Vunjak-Novakovic et al., 2003):  
1. Lead to homogenous and uniform cell distribution within the three 
dimensional structure of the scaffold.  
2. Control the cultivation conditions in terms of temperature, dissolved oxygen 
levels, pH, nutrients and metabolites. 
3. Improve mass transport (soluble nutrients and oxygen) between the cells 
and the cultivation environment.  
4. Provide mechanical stimulatory signals of physiological relevance leading to 
improved in vitro tissue formation simulating in vivo conditions.  
 
Three bioreactors that are commonly used in bone tissue engineering are listed 
below: (illustrations are adapted from Martin, I., Wendt, D., Heberer, M., 
2004.The role of bioreactors in tissue engineering. Trends Biotechnol 22, 80-
86). 
 
Figure 7 Spinner flask bioreactor. 
1. Spinner flasks, in which the cell-scaffold 
constructs are fixed in place, attached to 
needles hanging from the lid (Figure 7). The 
surrounding medium is mixed with a magnetic 
stirrer, creating a turbulent shear at the 
surface of the construct, enhancing mass 
transfer by induced distribution of the 
oxygen and nutrients throughout the 
medium and gas exchange takes place through surface aeration. The system 
has been used for bone and cartilage tissue engineering (Sikavitsas et al., 
2002; Meinel et al., 2004a) with improved tissue formation compared to the 
static system. 
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2. Perfusion bioreactors, in which cell-
scaffold constructs are directly perfused by 
pumping medium through the pores of the 
cells-scaffold construct, overcoming mass 
transport limitations by delivering nutrients 
and oxygen to all parts of the scaffold (Figure 8). The scaffold is usually placed 
in a perfusion chamber minimizing the non-perfusing flow that goes around 
the cultured scaffold (Bancroft et al., 2003). Direct perfusion is a valuable tool 
to overcome mass transport limitations and improve tissue cultivation in vitro 
compared to the static system but the effects of the perfusion are highly 
dependent on the medium flow rate and the maturation stage of the cell-
scaffold construct. Therefore, a balance between the efficient mass transport 
and retention and maintenance of the newly synthesized extracellular matrix 
within the scaffold has to be met as increased shear stress could eventually 
lead to tissue components being flushed away from the scaffold structure 
(Martin et al., 2004).  
Figure 8 Perfusion bioreactor. 
 
3. Rotating bioreactors, in which cell-
scaffold constructs are freely suspended in a 
space between two cylinders or in which the 
cell-scaffold constructs are fixed and rotated 
during the cultivation. The bioreactor was first 
introduced by scientists at the National 
Aeronautics and Space Agency (NASA), as the 
rotating wall vessel bioreactor (Figure 9) which was originally designed to 
simulate microgravity conditions involving solid body rotation around a 
horizontal axis (Duray et al., 1997). Rotation of the medium around the 
constructs, whether free falling (Unsworth and Lelkes, 1998; Martin et al., 
2004; Marolt et al., 2006) within the vessel or fixed in place (Kasper et al., 
2007; Suck et al., 2007), enhances mass transport with low levels of shear 
stress and was shown to improve spatial cell distribution within the scaffold as 
compared to static cultivation conditions. 
Figure 9 Rotating bioreactor. 
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1.2. Rationale of the Study 
 
Successful tissue engineering of bone, essentially requires an available source 
of osteogenic cells brought into a cultivation environment, maintaining and 
promoting cell function in conjunction with a three dimensional matrix in vitro.  
A major limitation associated with three dimensional culture systems is the 
establishment of a technique that leads to the generation of tissue constructs 
showing homogenous cell distribution throughout the whole three dimensional 
structure of the scaffold, especially when scaffolds of relatively large 
parameters are used (Meinel et al., 2004b; Sikavitsas et al., 2002). Stationary 
culture is by now well known to only support cell growth at the periphery of a 
scaffold, leaving the central core free of cells due to the limited potential for 
soluble nutrients and oxygen to diffuse towards the interior. Maximum 
ingrowth has been reported between 200-400 µm from the outer scaffold 
surface (reviewed by Martin et al., 2004). To overcome this nutrient limitation, 
several dynamic cultivation systems have been investigated and are still being 
developed further to reach homogenous cell distribution and uniform tissue 
formation in vitro. Uniform cartilaginous and bone like constructs were 
successfully cultivated in rotating bioreactors using scaffolds 5-8 mm in 
diameter and 2 mm thick (Marolt et al., 2006; Vunjak-Novakovic et al., 2003). 
Furthermore, the hypothesis that perfusion increases cell ingrowth through 
the continuous exchange of medium and constant removal of metabolic waste, 
has also been supported by several groups, who have developed three 
dimensional perfusion systems for in vitro bone formation (Bancroft et al., 
2002; Holtorf et al., 2005; Sikavitsas et al., 2003; Wendt et al., 2006). To meet 
this purpose as well and to provide a microenvironment for a high degree of 
differentiation and better tissue development, two different dynamic 
cultivation models were to be examined in this study. Namely, a fixed bed 
perfusion bioreactor developed by our group, which has been shown to improve 
the cultivation of rat bone marrow derived cells in conjunction with a porous 
matrix (Barthold, 2003) as well as rabbit bone marrow derived cells (Fargali, 
2006). In addition to a novel tilted rotating bioreactor system producing a 
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tilted rotating motion, which so far has not been investigated for its 
applicability with regard to producing bone-like constructs in vitro.  
The ultimate goal of bone tissue engineering is the translation of the outcome 
of basic research into suitable clinical protocols for improved human therapy 
potentials. Within this context, the present study wished to elucidate whether 
bone-like constructs can be cultivated using human derived mesenchymal-like 
cells in conjunction with a PLGA/CaP scaffold of 10 mm diameter and 10 mm 
thickness under perfusion or modified rotating conditions.  
 
1.3. Goals of the Study 
 
This study set out to address the goal of optimizing and developing three 
dimensional cultivation conditions by exposing human mesenchymal-like stem 
cells in conjunction with a porous scaffold, to the right mechanical and 
biochemical stimulus in an optimal microenvironment to improve current 
protocols and strategies in bone tissue engineering. Furthermore, this study 
examined the hypothesis that small trabecular bone specimens contain 
mesenchymal-like cells that can be isolated and expanded to an extent 
sufficient for autologous bone tissue engineering purposes. 
 
To meet the above set goals, the current study was subdivided into 
two parts:  
 
1. Human trabecular bone was investigated as a potential source for 
mesenchymal-like cells by comparing these cells to human bone marrow 
derived cells, especially in terms of their osteogenic capacity (Chapter 2). 
 
2. Evaluation of growth and differentiation of human mesenchymal-like 
cells in conjunction with a poly (lactide-co-glycolide)-calcium phosphate 
composite scaffold in a three dimensional static and/or dynamic culture 
environment to produce spatially uniform bone like constructs in vitro 
and to provide us with a better understanding of how mechanical 
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signals and fluid dynamics affect bone tissue formation in vitro (Chapter 
3). 
 
To address the first part (Chapter 2), the following aims were set  
 
 Establishing a technique for the isolation and expansion of human 
trabecular bone derived cells.  
 Identification of a suitable expansion medium that ensures maximum 
proliferation, without loss of differentiation and that reproducibly 
supports a significant in vitro expansion of human mesenchymal-like 
cells. 
 Large scale cell expansion (up to 10x106 cells) sufficient for bone tissue 
engineering applications by using microcarriers and cell factories.  
 Evaluation of the multilineage potential of human trabecular bone 
derived cells: namely the ability of these cells to differentiate into bone, 
fat and cartilage.  
 Comparison of the osteogenic capacity of human trabecular bone derived 
cells to that of human bone marrow derived cells (i.e. developing a two 
dimensional model to study human osteogenesis in vitro).  
 
And to address the second part (Chapter 3), the following aims were 
set:  
 
 Determination of an optimal surface coating for the PLGA/CaP scaffold, 
promoting cell attachment, proliferation and differentiation of human 
trabecular bone derived cells. 
 Comparison of proliferation and osteogenic differentiation of cells in 
static culture versus dynamic culture through biochemical and 
histological analysis to determine which regime of fluid flow (static, 
perfusion or tilted rotating cultivation mode) leads to the formation of 
spatially uniform bone-like constructs in vitro.  
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2. Isolation, Expansion and Characterization of 
Human Adult Tissue Derived Mesenchymal-like 
Cells for Bone Tissue Engineering Purposes 
2.1. Introduction  
 
Tissue engineering approaches for promoting the repair of skeletal tissues, 
such as bone cartilage and tendon, have focused on cell based therapies 
involving bone marrow derived mesenchymal stem cells (Bruder and Fox, 
1999; Cancedda et al., 2000). These cells can be readily isolated and expanded 
in culture and have been selectively shown to form adipocytes, osteoblasts and 
chondrocytes in vitro (Pittenger et al., 1999). There is a growing body of 
evidence, demonstrating that multipotent progenitor cells can be obtained 
from a variety of other tissues including synovial membrane (De Bari et al., 
2001), teeth (Miura et al., 2003), skin (Nakahara et al., 1990), periosteum 
(Hutmacher and Sittinger, 2003), adipose tissue (Zuk et al., 2001; Dragoo et al., 
2003; Wickham et al., 2003; Ogawa et al., 2004), placenta (In ’t Anker et al., 
2004), in addition to evidence for circulating stem cells as in the human 
umbilical cord (Rosada et al., 2003). Since the availability of human bone 
marrow samples was limited when this study was initiated, an alternative 
source was sought, based on the studies by Noeth et al. (2002) and Nuttall et 
al. (1998), who have shown the multilineage potential of cells derived from 
human trabecular bone. This present thesis focused on the characterization 
and investigation of the potential of applying these cells to form three 
dimensional bone tissue in vitro. In the following sections, the isolation of 
mesenchymal-like cells from trabecular bone was established by comparing the 
properties of the isolated cells to the well characterized human bone marrow 
derived cells in terms of expansion and multilineage differentiation potential. 
A suitable expansion medium was developed and a method for large scale cell 
expansion was evaluated using cell factories™ and microcarrier culture. 
Finally, the osteogenic differentiation was assessed in time course studies by 
biochemical analysis determining bone specific markers supported by detailed 
histological analysis. A special focus was put on optimizing expansion and
-23- 
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 differentiation media circumventing the use of fetal calf serum (FCS). Since 
mesenchymal-like stem cells are currently extensively investigated for possible 
clinical trials for future applied cytotherapy, this study focused on using FCS 
free conditions to avoid the mmunogenicity associated with applying a 
xenogenic protein (Spees et al., 2004) and to eliminate the risk of transmitting 
bovine spongiform encephalopathy (BSE) through infected serum (Bradley, 
1999), so expansion and differentiation media were optimized using human 
serum. 
 
2.2.  Materials and Methods  
 
 Chemicals, consumables and instruments are listed in Appendix I. 
 Working solutions, buffer compositions, general cell culture methodology 
and staining methods are listed in Appendix II. 
 Human samples were collected after patients signed informed consent 
and the study was performed according to the Declaration of Helsinki. 
The local IRB has approved the study. 
2.2.1. Human Bone Marrow Derived Cells 
 
Human bone marrow aspirate from an iliac aspiration (female, age: 80 years) 
was centrifuged over a Ficoll-Paque density gradient to separate the 
erythrocytes in a 50 ml tube (Rickard et al., 1996). The cell number was 
determined with the trypan blue exclusion method (see Appendix II) and 
initially cultured in ZKT-1 basal medium (see Appendix II) supplemented with 
10% human serum and 1% penicillin-streptomycin solution in three T75 
culture flasks. Following the initial plating, non-adherent cells were removed 
on day 7 at the first change of medium. The medium was replaced thereafter 
once a week. At 80-90% confluency, the primary culture was trypsinized and 
sub-cultured (see Appendix II), initially using a plating density of 2x104 
cells/cm² and gradually going down to 1.5x104 cells/cm² and eventually to 1x104 
cells/cm². Cells were kept in culture and cryopreserved, depending on the 
harvested cell yield. 
 
Chapter 2  Materials and Methods I 
    
 
-25- 
As an additional source, cryopreserved human bone marrow cells obtained at 
passage 1 were investigated as well. The cells were derived from human bone 
marrow of a male 19 year old patient isolated as described above and 
cryopreserved. The vial containing ~3x106 cells/vial was thawed and taken up 
into 5 ml ZKT-1 basal medium supplemented with 15% fetal bovine serum and 
seeded into a T25 culture flask. Cells were sub-cultured upon confluency at a 
plating density of 1x104cells/cm² and further kept in culture and cryopreserved. 
Human bone marrow samples were obtained from the department of 
experimental trauma surgery of Hannover Medical School and from the 
department of biomaterials at Ulm University. 
2.2.2. Human Trabecular Bone Derived Cells 
 
Cells derived from human trabecular bone were isolated from explants of bone 
specimens with slight modifications to protocols from the literature (Beresford 
et al., 1984; Gronthos et al., 1997). Human bone fragments were aseptically 
collected during total knee or hip replacement, where the bones were otherwise 
discarded. Specimens were transported in NaCl directly after surgery to the 
laboratory for the cell isolation procedure. Trabecular fragments were washed 
extensively in sterile phosphate-buffered saline (1xPBS) to remove blood and 
marrow tissue. The bone was also freed of any surrounding tissue and 
dissected aseptically with a scalpel and knife into chips of 2-5 mm in diameter. 
Three to five bone chips were put into a T175 culture flask and covered with 
40ml expansion medium (ZKT-1 supplemented with 15% human serum and 
1% penicillin-streptomycin). The medium was exchanged once on a weekly 
basis. When migrating cells reached sub-confluency, cells were sub-cultivated 
at a plating density of 1x104 cells/cm² as well as cryopreserved for later usage. 
Human bone specimens were regularly obtained from the experimental 
trauma surgery department, Hannover Medical School. 
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2.2.3. Cell Viability: WST-1 
 
Cell viability was assessed using a WST-1 test, which is a colorimetric assay 
based on the cleavage of the tetrazolium salt (WST-1) by mitochondrial 
dehydrogenase in viable cells. WST-1 is cleaved to formazan by metabolically 
active cells as illustrated in Figure 10. An increase in mitochondrial 
dehydrogenase leads to an increase in the amount of formazan dye formed, 
correlating directly to the number of metabolically active cells in the sample. 
The formazan dye formed was detected using a spectrophotometer measuring 
absorbance at 450 nm with 620 nm as reference wavelength. The test was 
performed according to the instructions of the manufacturer. Briefly, 10 µl of 
the WST-1 reagent were added to 100 µl of supernatant per well (1:10), 
incubated for 2 hours at 37°C, 12% CO2, shaken on a plate shaker for 1 minute 
and then absorbance was measured against a background control (WST-1 
reagent in cell culture medium only, without cells). Samples were measured in 
at least doublets. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 WST-1 test principle (illustration adapted from Roche Diagnostics
GmbH). Cleavage of the tetrazolium salt WST-1 (4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-
2H-5-tetrazolio]-1,3-benzene disulfonate) to formazan. (EC = electron coupling reagent,
RS = mitochondrial succinate-tetrazoliumreductase system). 
 
2.2.4. Total Protein Assay: Bicinchoninic Assay-Micro BCA™ 
 
Total protein content was determined according to the manufacturer’s 
instructions. Briefly, the supernatant was removed and the cell layer washed 
with 1x PBS to be then lysed with 2% Triton-X 100 solution (for 48 well-plates: 
200 µl/well) and incubated overnight at 37°C. The cell protein solution was 
scratched out of the well and frozen in 1.5 ml safe-lock tubes at -20°C. For the 
-26- 
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assay, samples were thawed and centrifuged at 12000 rpm for 5 minutes. The 
supernatant was diluted 1:1 with distilled water and the samples were 
transferred to a 96-well plate and mixed with an equal amount of the kit 
working solution containing bicinchoninic acid (BCA). The plate was shaken 
shortly for 30 seconds at 300 rpm and incubated for two hours at 37°C. BCA 
detects Cu1+ that is formed when Cu2+ is reduced by protein in an alkaline 
environment forming a colored complex. This purple colored water-soluble 
complex is linear with increasing protein concentration. The absorbance was 
measured at 570 nm and samples were measured in doublets. 
 
 
2.2.5. Cell Proliferation: DNA Determination with CyQUANT® 
 
Adherent cells were grown in 48-well plates and, at predetermined time points, 
the medium was removed from the wells and the microplate containing 
samples were frozen until assayed at -70°C after the medium was removed. 
The CyQuant® kit is based on the use of a green fluorescent dye (CyQUANT 
GR dye), which exhibits strong fluorescence when bound to cellular nucleic 
acids (Jones et al., 2001). The frozen cells were thawed and lysed by covering 
the cell layer in the well with 200 µl of the lysis buffer, which contains the 
fluorescent dye (provided by the manufacturer) and diluted according to the 
manufacturer’s instructions with nuclease free distilled water. Samples were 
incubated at room temperature for 5 minutes, mixing the plates gently and 
protected from light. Fluorescence was then measured directly in a 
fluorescence microplate reader with filters appropriate for ~480 nm excitation 
and an emission wavelength of ~520 nm. A reference standard curve for DNA 
content was created for converting sample fluorescence values into DNA 
nanograms (or cell numbers) using known concentrations of calf thymus DNA. 
 
2.2.6. Human Serum  
 
Human Serum Selection 
The selection criteria for the most suitable preparation of human serum used 
in this study included cell morphology, cell proliferation and cell viability. Four 
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different preparations of human serum were selected from three different 
suppliers. Namely, two lots of serum from Pan Biotech (HS-1, HS-2), one lot of 
serum from PAA (HS-3) and one from the local blood bank of Hannover 
Medical School (HS-4).  
Human trabecular bone derived cells were isolated as described above (2.2.2.), 
expanded and cryopreserved, to be then used at a seeding density of 5x103 
cells/cm². They were cultivated in T25 culture flasks for cell growth 
assessment and, further, regarding morphology and viability assessment, the 
cells were cultivated in 48-well plates. Cells were kept in ZKT-1 basal medium, 
supplemented with 1% penicillin-streptomycin and 15% of the appropriate 
human serum in a humidified atmosphere at 37°C and 12% CO2. The medium 
was changed every 72 hours.  
Cell growth was monitored by determining the number of population 
doublings, applying the formula (log N / log 2), where N is the cell count 
harvested of a confluent monolayer divided by the number of cells initially 
seeded (Stenderup et al., 2003). The number of viable cells was determined 
using the trypan blue exclusion method (see Appendix II).  
Metabolic activity and viability was measured using the WST-1 test as 
previously described (2.2.3.). For morphological observation, the cells were 
examined under a phase contrast light microscope (Axiovert 120, Zeiss, Jena).  
 
Human Serum Concentration 
To determine the best human serum concentration for the proliferation and 
differentiation of human trabecular bone derived cell, four different serum 
concentrations were tested, including 1%, 5%, 10% and 15% human serum. 
Proliferation was assessed by the determination of total protein content 
throughout the cultivation period using the micro BCA™ assay (section 2.2.4.), 
as well as DNA content at the beginning (day 1) and at the end of the 
cultivation period (day 29) using the CyQUANT® assay (section 2.2.5.). Further, 
to examine the effect of supplemented serum concentrations on osteogenic 
differentiation, cells were expanded in the appropriate expansion medium and 
induced to differentiate in osteogenic medium for 14 days, to be then stained 
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for alkaline phosphatase. For the experiments, trabecular bone derived cells 
were seeded in 48-well plates at 5x103 cells/cm2. 
 
Serum Rich vs. Serum Reduced Expansion and Differentiation 
Media  
 
To compare serum rich expansion and differentiation media to serum reduced 
media, twenty different media formulations were tested. ZKT-1 basal medium 
supplemented with 1% penicillin-streptomycin served as the basic components 
in all twenty combinations (Table 1). To substitute for the growth factors 
available in serum, the following cytokines were added: recombinant platelet 
derived growth factor (PDGF) at 10 ng/ml, recombinant fibroblast growth 
factor (FGF) at 10 ng/ml, recombinant epidermal growth factor (EGF) at 5 
ng/ml and recombinant insulin-like growth factor (IGF) at 15 ng/ml (Barthold, 
2003). The cytokines were reconstituted according to the manufacturer’s 
instructions and stored at -70°C. Serum reduced media were further 
supplemented with a mixture of insulin (10 µg/ml), transferrin (5 µg/ml), 
albumin (1 mg/ml) (ITA). This mixture is usually added to serum free 
formulations that substitute in a purified form for the factors normally 
supplied by serum. Cells were seeded at 5x103 cells/cm2 in 48-well plates and 
the medium was changed every 72 hours. Proliferation was monitored by the 
WST-1 proliferation assay.  
Differentiation was induced by exchanging the expansion media (at day 9) 
with ZKT-1 basal medium, supplemented with 1% human serum and 
osteogenic factors (1x 10-8 M dexamethasone, 10mM beta-glycerophosphate 
and 200µM ascorbic acid). Membrane bound alkaline phosphatase activity was 
measured on both day 9 and 12 (as described in section 2.2.10.) 
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 Table 1. 
Nr Expansion Media  
ZKT-1 supplemented with  
1 15% HS 
2 10% HS 
3  0% HS 
4  1% HS 
5  1% HS+ITA 
6  1% HS+ITA+PDGF 
7  1% HS+ITA+EGF 
8  1% HS+ITA+IGF 
9  1% HS+ITA+FGF 
10  1% HS+ITA+PDGF +EGF+IGF+FGF 
11  1% HS+ITA+PDGF+EGF 
12  1% HS+ITA+PDGF+FGF 
13  1% HS+ITA+PDGF+IGF 
14  1% HS+ITA+EGF+FGF 
15  1% HS+ITA+EGF+IGF 
16  1% HS+ITA+FGF+IGF 
17  1% HS+ITA+PDGF+EGF+FGF 
18  1% HS+ITA+ PDGF+EGF+IGF 
19  1% HS+ITA+PDGF+FGF+IGF 
20  1% HS+ITA+EGF+FGF+IGF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Twenty different combinations of tested media. For differentiation 
purposes the media were supplemented with the conventional osteogenic supplements: 
β-glycerophosphate 10mM, ascorbic acid 200 µM and dexamethasone at 10nM. HS: 
Human serum. ITA: Insulin, transferrin and albumin mixture. All media were 
supplemented with 1% penicillin-streptomycin. PDGF: Platelet derived growth factor. 
EGF: Epidermal growth factor. FGF: Fibroblast growth factor. IGF: Insulin-like growth 
factor. 
 
2.2.7. Large Scale Cell Expansion 
 
Cell culture was usually performed on a small scale, in traditional T culture 
flasks ranging from T25 (25cm²) to T175 (175 cm²). Typical cell yields ranged 
from 250x10³ to 8x106 cells per flask. To produce higher cell numbers in one 
batch, the following two methods were optimized that offered an increased 
surface area compared to conventional monolayer culture in T flasks. 
2.2.7.1. The Cell Factory™ 
 
The protocol for culturing cells in the cell factory was adapted from the 
manufacturer of the cell factory (Nunc, Wiesbaden). A cell factory consists of 
polystyrene trays, treated for optimal cell attachment and spreading 
(Maroudas et al., 1977), assembled by sonic wedging on one another. They are 
available in 1, 2, 4, 10 and 40 tray versions for easy scale-up. One tray has a 
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culture area of 632 cm2 (dimensions, 333 x 204 x 57 mm) and a suggested 
working volume of ca. 200ml per tray (Figure 11). In this study, four tray 
factories were used with an overall surface area of 2,528 cm2. The cell 
suspension was prepared in an aspirator bottle with a sterile connector for the 
silicon tubing. Expansion medium, 1xPBS buffer, trypsin-EDTA solution or the 
cell suspension were all transferred into aspirator bottles and connected as 
needed to the cell factory, which is equipped with an identical connector for the 
silicone tubing (both supplied by the manufacturer). When cell suspension was 
to be poured into the cell factory, the bottle was gently agitated to evenly 
suspend the cells, allowing the fluid to flow into the trays. After the filling 
process, the autoclavable connector was removed and replaced by an adaptor 
cap (Nunc, Wiesbaden). The cell factory was placed in an incubator at 37°C 
with 12% CO2. The trays were seeded at 10x103 cells/cm2 and cultured in 150 
ml expansion medium per tray. Cells were harvested at confluence (see 
Appendix II) using 20 ml trypsin-EDTA and 40 ml 1xPBS per tray.  
 
B A 
 
 
 
 
 
Figure 11 Cell factory™ illustrations adapted from Nunc
(www.nuncbrand.com). (A) 1 tray, 2- 4-10 or 40 tray version of the cell factory. (B) The
cell factory has two openings (ports): one to insert tubing into for liquid filling and the
other for ventilation, connected to a filter. 
 
2.2.7.2. Spinner Flask-Microcarrier Culture  
 
Two different types of microcarrier were tested for adherent cell growth:  
1. MicroHex™ (Nunc, Wiesbaden), microscopic non-porous polystyrene 
hexagons with a side length of 125 µm, a thickness of 25 µm and a 
surface culture area 760 cm²/g. 
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2. Cytodex3® (Amersham Bioscience, Otelfingen, Switzerland) made up of 
a collagen coated dextran matrix with a diameter of 135-215 µm and a 
surface culture area 2700 cm²/g. 
Microhex™ microcarriers were supplied sterile and ready to use, while 
Cytodex3® microcarriers were equilibrated in 1xPBS overnight (100 ml PBS/g 
of microcarrier) at 4°C, after which they were autoclaved at 115°C for 20 
minutes. A total surface area of 380 cm² was chosen equivalent to 0.5 g 
Microhex™ and 0.14 g Cytodex3® in a final medium volume of 86.8 ml ZKT-1, 
supplemented with 15% human serum (typical expansion medium) in a 125 ml 
spinner flask (Bellco). The spinner flask is equipped with a central magnetic 
stirrer shaft to ensure cells being suspended in the medium and side rams for 
sampling, the cap of which was loosened in the incubator to ensure aeration 
with CO2 enriched air and gas exchange. Inoculated spinner flasks were placed 
on a magnetic stirrer (with variable possible rpm settings) in a 37°C incubator 
with 12% CO2. The medium volume, calculated according to the volume 
applied in the cell factories and T flask culture, was taken as ca. 0.24 ml/cm². 
Human mesenchymal-like cells were used at passage 4 and an inoculum of 
10x103 cells/cm² (3.8x106 cells per spinner) was applied to ensure uniform 
coverage of all the microcarriers (same seeding density as previously applied in 
cell factories and T flasks). Cells in suspension without microcarriers were also 
cultivated as a control. Cells were inoculated into the spinner containing 50 ml 
medium (with or without the microcarriers) and stirring was started 
immediately. The stirring speed in the spinner was initially set to a low speed 
(20 rpm) to ensure cell attachment and coverage of all microcarriers increasing 
initial contact time of the cells with the microcarriers. After 24 hours, the rest 
of the medium was added and the speed increased to 30 rpm. The stirring 
speed was adjusted to prevent sedimentation and eventual clumping of the 
microcarriers by increasing the rpm’s gradually so as not to reach too high 
shear forces, which might prevent cell attachment. The culture was 
continuously stirred throughout the cultivation. Cell attachment and growth 
on the microcarriers was assessed using a phase contrast microscope (Axiovert 
120, Zeiss, Jena) by placing a few drops of the suspension onto a glass slide 
and medium samples were daily drawn for glucose and lactate analysis of the 
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cell suspension. To separate the cells from the microcarriers at confluence, 
according to microscopic observations, the stirring was stopped and the 
microcarriers settled relatively fast so the medium was easily aspirated and 
cells could be harvested. The cell covered microcarriers were first washed with 
10 ml 1xPBS, decanted, replaced by 10 ml trypsin-EDTA and incubated for 15 
min at 37°C with occasional agitation. Serum containing expansion medium 
was added and mixed vigorously to detach all cells and break up cell clumps 
before filtration of the cell suspension through a 70 µm filter to retain the 
microcarriers. The cell suspension was then centrifuged at 800 rpm for 3 
minutes and the cell pellet re-suspended in fresh medium and cells counted 
with the trypan blue exclusion method (Appendix II). 
The spinner flasks were siliconized in order to prevent microcarriers covered 
with cells sticking to the walls of the vessel. This was done by wetting the 
inside with a silicone solution (Sigmacote®) before sterilization (Malda et al., 
2004). After drying in air, the spinner vessel was rinsed with deionized water 
several times to be then heat sterilized before culture initiation. 
 
2.2.8. Glucose and Lactate Analysis  
 
Glucose and lactate concentrations in the medium were analyzed by YSI 2700 
Select Biochemistry Analyzer. The measurement is based on an immobilized 
biosensoring technique. The sample passes through a membrane, which 
contains three layers. An enzyme specific for both glucose (glucose oxidase) 
and for lactate (lactate oxidase) is immobilized between the two membrane 
layers, polycarbonate and cellulose acetate. The substrate is oxidized as it 
enters the enzyme layer, producing hydrogen peroxide, which passes through 
cellulose acetate to a platinum electrode, where the hydrogen peroxide is 
oxidized. The resulting current is proportional to the concentration of the 
substrate.  
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2.2.9. Multilineage Potential of Human Trabecular Bone Derived 
Cells 
 
Human trabecular bone derived cells were analyzed for their capacity to 
differentiate towards the adipogenic, chondrogenic and osteogenic lineage. To 
induce differentiation into the corresponding lineages, trabecular bone derived 
cells were cultured with special induction media to lead to the specific 
differentiation. The phenotype was confirmed by histological analysis (section 
2.2.13.). Cells were seeded at 1x104 cells/cm2 and cultivated in ZKT-1 basal 
medium, supplemented with 15% human serum and 1% penicillin-
streptomycin until sub-confluence (80-90% confluence) was reached after 5-7 
days of culture. The cell layers were then treated with the special 
differentiation media listed below. Control cultures were maintained in 
parallel without adipogenic, chondrogenic or osteogenic supplements, 
respectively.  
All concentrations given below are final concentrations in cell culture medium.  
 
2.2.9.1. Adipogenesis 
 
For adipogenic differentiation, the expansion medium was exchanged with 
adipogenic medium as described by Erices et al. (2000) and Zuk et al. (2001). 
ZKT-1 basal medium was supplemented with 10% fetal bovine serum and 1% 
penicillin-streptomycin as well as with insulin (5 µg/ml), 
isobutylmethylxanthine (0.5 mM), indomethacin (200 µM) and hydrocortisone 
(0.5 mM). The medium was changed every 72 hours. After 21 days of 
induction, lipid vacuoles were visualized histologically with Nile Red staining 
(see section 2.2.13.5.).  
 
2.2.9.2. Chondrogenesis 
 
The in vitro chondrogenic assay was performed as described in the literature 
(Sottile et al., 2002). Upon sub-confluence, the medium was changed to 
chondrogenic induction medium made up of ZKT-1 basal medium 
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supplemented with 1% penicillin-streptomycin, ascorbic acid (50 µg/ml), bovine 
serum albumin (1.25 µg/ml), dexamethasone (1x10-7 M) insulin (6.25 µg/ml), 
proline (40 µg/ml), sodium pyruvate (100 µg/ml),  transferrin (6.25 µg/ml) as 
well as TGF-beta 1 (10 ng/ml), which was added fresh at each medium 
exchange every 72 hours. 
The chondrogenic potential was demonstrated histologically by Alcian blue 
staining after a 21 day cultivation period in chondrogenic medium (see section 
2.2.13.6.). 
 
2.2.9.3. Osteogenesis  
 
Osteogenic differentiation was induced by culturing the cells for a minimum of 
two weeks for up to 30-40 days in osteogenic medium. The osteogenic medium 
was prepared by adding 1x 10-8 M dexamethasone, 10 mM beta-
glycerophosphate and 200 µM ascorbic acid to ZKT-1 basal medium, 
supplemented with 10% human serum and 1% penicillin-streptomycin. 
Medium was changed every 72 hours and samples of the supernatant were 
frozen in 1.5 ml safe-lock tubes at -20ºC. The osteogenic differentiation was 
assessed in time course studies over thirty days by measuring C Terminal 
Type I Collagen (CICP) levels, indicating collagen production and alkaline 
phosphatase at several time points. Histologically, alkaline phosphatase, 
calcein, von Kossa and alizarin red staining were routinely performed. 
 
2.2.10. Alkaline Phosphatase Activity Assay 
 
The alkaline phosphatase enzyme activity was determined by a biochemical 
colorimetric assay as described by the manufacturer (Sigma Fast ™ 
p-Nitrophenyl Phosphate tablet set, pNPP). 
Briefly, a reaction mixture was made by dissolving the supplied tablet set in 
20 ml deionized water, yielding a solution of 1.0 mg/ml p-nitrophenyl 
phosphate in 0.2 M Tris buffer and 5 mM Magnesium chloride. P-nitrophenol 
is formed through the enzymatic hydrolysis of p-nitrophenyl phosphate, used 
by the cellular enzyme alkaline phosphatase as the substrate, so its rate of 
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formation is proportional to the enzyme’s activity. P-nitrophenol can be 
quantified by measuring its absorbance at 405 nm using a spectrophotometer. 
A standard curve was obtained from serial dilutions of a p-nitrophenol 
solution. The alkaline phosphatase enzyme activity was expressed in milli 
units (mU) per well. One unit is defined as the amount of the enzyme Alkaline 
phosphatase (ALP) that will produce 1 nmol of p-nitrophenol/min (milli 
units/well, mU per well). Values were normalized to total protein content of 
the cell layer in the well using the above mentioned protein assay (mU/mg). 
Unknown samples were measured in at least doublets. The activity of cellular 
alkaline phosphatase was determined either as cell-membrane bound alkaline 
phosphatase or as soluble alkaline phosphatase in the supernatant. Control 
wells without cells were also run with the assay. 
 
2.2.10.1. Membrane Bound Alkaline Phosphatase Activity Assay 
 
Briefly, the cell layer was washed with 1xPBS, incubated with 200 µl of the 
above described reaction solution for 30 minutes at 37°C. Aliquots of 50 µl of 
the reaction solution were then transferred to a 96-well plate to measure the 
absorbance of the formed p-nitrophenol at 405 nm in a spectrophotometer. 
 
2.2.10.2. Soluble Alkaline Phosphatase Activity Assay 
 
The activity of the alkaline phosphatase enzyme was also determined in the 
supernatant. Medium samples were taken every 72 hours throughout the 
cultivation period and frozen at -20ºC in 1.5 ml safe-lock tubes until analysis. 
Samples were thawed at room temperature and aliquots of 40 µl of the 
supernatant were transferred to a 96-well plate. 160 µl of the above described 
reaction solution were added and the plate was shaken at 700 rpm for 30 
seconds, to be then incubated for 24 hours at 37ºC. Absorbance was measured 
at 405 nm.  
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2.2.11. Collagen Type I Assay 
 
The amount of collagen type I COOH terminal propeptide was determined in 
the conditioned medium using the procollagen-C enzyme immunoassay kit 
(Metra™ CICP EIA kit, Quidel) (Reinholz et al., 2000). The test was performed 
according to the manufacturer’s instructions. Briefly, the assay is a sandwich 
enzyme immunoassay in a microplate format, utilizing a monoclonal anti-
CICP antibody coated on the plate, a rabbit anti CICP antibody and a goat 
anti-rabbit alkaline phosphatase conjugate and a p-nitrophenylphosphate 
substrate to quantify human CICP in the samples. Samples were diluted 1:2 
with the supplied assay buffer and applied onto the coated plate and further 
handled according to the manufacturers instructions. Samples were measured 
in at least doublets. 
 
2.2.12. Calcein for Mineralization  
 
Calcium deposited in the extracellular matrix was quantified with the calcein 
assay. The calcein molecule is known to bind to the calcium ions during 
hydroxyapatite crystal formation (Uchimura et al., 2003; Hale et al., 2000) and 
is a widely accepted method for the quantification of calcium deposition. 
Cells were seeded at 5x10³ cells/cm² or 10x10³ cells/cm² in 48-well plates and 
grown in osteogenic medium. At time of analysis, medium was discarded and 
the cell layers were washed with warm 1xPBS and then fixed with cold 100% 
ethanol for 30 minutes at room temperature. The ethanol was removed and the 
cell layers were rinsed twice with deionized water. The cell layers were stained 
with calcein solution (5 µg/ml), kept in the dark at 4°C overnight. The calcein 
solution was removed the next day followed by rinsing the cell layers three 
times with deionized water. The fluorescence of the cell incorporated calcein 
was quantified using a fluorescence microplate reader and the absorbance was 
measured at 485 nm excitation and 535 nm emission. Samples were measured 
in at least doublets. 
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2.2.13. Histochemical Analysis  
 
For osteogenic identification, cells were stained for alkaline phosphatase as an 
early marker for osteogenesis and terminal mineralization was visualized by 
von Kossa, Alizarid Red and calcein. For adipocyte identification, Nile red 
staining was applied and for chondrocyte visualization, Alcian blue staining 
was undertaken. Cells were viewed under a phase contrast light and 
fluorescent microscope (Axiovert 120, Zeiss, Jena) and photomicrographs were 
taken with a digital camera (DXN 1200F, Nikon, Duesseldorf). 
 
2.2.13.1. Alkaline Phosphatase Staining 
 
Alkaline phosphatase was detected histochemically with a Sigma Alkaline 
phosphatase activity staining kit as described by the manufacturer. Briefly, 
the cell layer was fixed with 4% paraformaldehyde solution (PFA) for 30 
minutes at room temperature, rinsed with deionized water, covered with the 
staining mixture and incubated at 37°C for 10 minutes. The staining-solution 
was prepared by dissolving an NBT/BCIP (NBT=Nitroblue tetrazolium salt, 
BCIP=5 –Brom-4-Chlor-3-Indolylphosphat) tablet in 10ml deionized water. 
The reaction was stopped by thoroughly rinsing three times with deionized 
water. Membrane bound alkaline phosphatase presence is indicated through a 
blue-black turbidity, which is formed due to a reaction between the two 
colorless NBT and BCIP substrates catalyzed by alkaline phosphatase.  
 
2.2.13.2. Alizarin Red Staining  
 
To detect mineralized nodules and determine mineralization extent of the 
extracellular matrix, culture medium was removed from the cell layer, rinsed 
with 1xPBS and fixed with 4% PFA for 30 minutes at room temperature. The 
cell layer was rinsed twice with deionized water and stained for 10 minutes 
with 1% alizarin red solution (Gregory et al., 2004; Romeis und Boeck, 1989). 
The cell layer was then rinsed with HPLC water (pH 7) and air dried. Alizarin 
red selectively binds to calcium, staining calcium depositions red. 
-38- 
Chapter 2  Materials and Methods I 
    
 
2.2.13.3. Von Kossa Staining  
 
Von Kossa staining was performed according to Puchtler and Meloan (1978) 
and Romeis and Boeck (1989) with slight modifications. The cell layer was 
fixed with 100% ethanol, rinsed with deionized water, covered with 5% AgNO3 
solution (see Appendix II) and incubated in the dark for 30 minutes. The 
solution was aspirated and the layer was rinsed with deionized water. To 
develop the brown-black colour of calcium phosphate deposits, the cell layer 
was incubated with 5% Na2CO3 solution (see Appendix II) for 20 seconds to 2 
minutes. After color development, the solution was aspirated off and the cell 
layer rinsed with deionized water, mounted with glycerol gelatin and covered 
with a coverslip. 
 
2.2.13.4. Calcium Staining with Calcein  
 
The cell layer was fixed with 100% ethanol for 30 minutes at room 
temperature, rinsed three times with water and was then covered with calcein 
solution (5µg/ml) overnight at 4°C (Hale et al., 2000). After overnight staining, 
the cell layer was rinsed three times with deionized water. The fluorescence of 
the incorporated calcein was also visualized under a fluorescent microscope 
(Axiovert 120, Zeiss, Jena). 
 
2.2.13.5. Nile Red Staining for Adipocytes 
 
Cell layers were rinsed with 1xPBS and then fixed with 4% PFA for 30 
minutes at room temperature, followed by rinsing with deionized water. The 
fixed cell layer was then incubated with the AdipoRed® solution (Cambrex), a 
Nile Red derivative staining solution, for 30 minutes at room temperature 
(Greenspan et al., 1985). The staining solution was then aspirated and the cell 
layer kept moist with 1xPBS and directly examined under the fluorescent 
microscope. 
 
-39- 
Chapter 2  Materials and Methods I 
    
 
2.2.13.6. Alcian Blue Staining for Chondrocytes 
 
Sulphated glycosaminoglycans and proteoglycans typically produced by 
chondrocytes were detected with Alcian blue. The staining solution was 
prepared by dissolving 0.2 g Alcian blue in 3% acetic acid solution (in deionized 
water) and filtrated through a 0.22µm filter. The cell layer was fixed with ice-
cold methanol  
(-20°C) for 30 minutes at room temperature, rinsed with deionized water and 
stained for 10 minutes with the Alcian blue staining solution, followed by 
rinsing again with deionized water (Miltenyi Biotec GmbH, MACS media, non-
haematopoietic stem cell media package insert). 
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2.3. Results and Discussion  
2.3.1. Cell Isolation and Culture of Human Mesenchymal-like 
Cells 
2.3.1.1. Human Bone Marrow-Derived Cells 
 
After preparation of the bone marrow aspirate (section 2.2.1.), a cell number of 
4.7x107 cells was initially cultured in three T75 culture flasks (2x106 cells/cm2) 
with cell attachment noted on day 7. Non-adherent cells were removed with 
the first medium change at day 7 as well. After 34 days in culture, cells were 
still made up of a mixture of cells, and colonies were observed to spread over 
the culture surface area without completely reaching confluence. Thus, it was 
decided to increase the cell-cell contact by trypsinising and re-plating the cells 
at a plating density of 4x104 cells/cm2 (into two instead of three T75 culture 
flasks) and to increase the serum content to 15% human serum instead of 10%. 
After 40 days in culture, the first confluent cell layers were harvested. A total 
of 1.3 x107 cells were harvested and sub-cultured at 4x104 cells/cm2 to keep the 
high cell density, as the initial cell-cell contact seemed to be important for cell 
proliferation. Confluency was reached after only two days and a total 1.5x107 
cells was harvested. Due to the fast expansion rate noted, the seeding density 
was decreased gradually from 4x104 cells/cm2 to 1.5x104 cells/cm2 and 1x104 
cells/cm2 so as not to risk growth inhibition through early cell-cell contact. A 
total of 6.8x107 cells were harvested from initial 8.8x106 cells (2.96 population 
doublings). Both cell densities reached confluency and 1x104 cells/cm² was 
thereafter taken as the seeding density for cell expansion. Cells were further 
sub-cultured at 1x104 cells/cm2 and 1x108 cells were harvested at day 50, after 
4 days in culture. Table 2 summarizes initial cell numbers and the 
corresponding cell yield over the first four passages. 
Cells were expanded for up to 14 passages with an average population 
doubling rate of 0.4 population doublings per day. The cells were continuously 
kept in culture for approximately 90 days after isolation, actively dividing up 
until the end of the 13th passage, where nuclei enlarged, cells broadened and 
cell growth slowed down immensely. 
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The morphology of the human bone marrow cells in their primary passage 
showed the typical star shape for the colony forming units and upon passaging 
acquired the fibroblast-like spindle shape (Figure 12).  
 
Table2. 
Cell Preparation Time 
(days) 
Cell number Population 
doublings 
Initial Preparation  4.7x 107  
Primary Culture 34 6x 106  
1st Passage 40 1.3x107 from initially 6x106 2.31 
2nd Passage 42 1.5x107from initially 9.7x106 0.61 
3rd Passage 46 6.8x107 from initially 8.8x106 2.96 
4th Passage 50 1.0x108from initially 1.4x107 2.88 
Table2 Expansion of human bone marrow derived cells over 4 passages. 
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Figure 12 Photomicrographs showing the morphology of freshly isolated human
bone marrow derived cells. (A) Typical star-shaped colonies of human bone marrow
cells in their primary passage cultivated in ZKT-1 basal medium, supplemented with 15%
human serum. (B) Human bone marrow derived cells after passaging into the third
passage at 10x103cells/cm2 and (C) after reaching confluence in the third passage. Original
magnification: x100; scale bar =100µm. 
2.3.1.2. Cryopreserved Human Bone Marrow-derived Cells 
 
The morphology (Figure 13) as well as the population doubling rate, an 
average of 0.42 population doublings per day, was found to be very similar to 
the freshly isolated bone marrow derived cells (0.4 population doublings per 
day).  
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Figure 13 Photomicrographs showing the morphology of cryopreserved
human bone marrow derived cells. (A) Cryopreserved human bone marrow cells
upon seeding at 10x103 cells/cm2 and (B) at confluence. Original magnification: x100;
scale bar=100µm. 
2.3.1.3. Trabecular Bone-Derived Cells 
 
Cells were observed to migrate from the bone explants after 7-14 days (Figure 
14). With continued incubation, cells proliferated and formed a confluent 
monolayer after approximately 30 days. No differences in growth 
characteristics or cell morphology were noted among different patient samples. 
The initial adherent cells isolated grew as spindle shaped, remaining dormant 
for 7 to 14 days, after which they began to multiply and eventually reached 
confluency after 30-40 days in culture. 
A B C 
 
Figure 14 Micrographs representative of a trabecular bone explantation; cellular
outgrowth from a human bone sample. (A) Appearance of bone fragments. (B) Cells
migrating from the bone fragments after 14 days of culture in ZKT-1 basal medium,
supplemented with 15% human serum. (C) Confluent monolayer of cells after 32 days of
explant culture. Original magnification: x100.Scale bar =100µm. 
Upon passaging, human trabecular bone derived cells showed a very similar 
morphology to passaged human bone marrow derived cells (Figure 15). Both 
cell types displayed a fibroblastic spindle-like shape with an average 
population doubling rate of 0.22 population doublings per day. 
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Figure 15 Photomicrographs showing the morphology of human trabecular
bone derived cells upon passaging. (A) Human trabecular bone derived cells upon
passaging in the third passage seeded at 10x103cells/cm2 and (B) at confluence.
Original magnification: x100; scale bar=100µm 
2.3.1.4. Discussion 
 
Human bone marrow derived cells were successfully isolated and expanded, 
despite of the relatively long lag phase in their initial culture period. Cells 
were passaged up to 14 passages with an average population doubling rate of 
0.4 population doublings per day. These results are in line with what was 
reported earlier by Bruder et al. (1997), who isolated human bone marrow 
derived cells and observed senescence to occur on average between passage 10 
and 15. Furthermore, they have shown that daily fed cultures, exposed to 
consistently high serum derived factors had grown faster and generated more 
cells than cultures which were fed only twice weekly, where the concentration 
of available mitogenic factors in the medium might have become rate limiting 
with the cells actively metabolizing the nutrients. This might explain the 
improvement in growth that was noted in this study upon increasing the 
serum concentration from 10% to 15%, at which cells seemed to have been 
taken out of their prolonged lag phase (the time from first introducing the bone 
marrow derived cells into culture until first passage).  
Sub-culturing the primary cells further, at relatively high cell densities up to 
14 passages in this study, while maintaining the large expansion and 
differentiation potential of these cells is controversial to what was reported by 
Sekiya et al. (2002) and Stute et al. (2004). Both groups have demonstrated 
that low seeding density (20 cells/cm2) was clearly better for prolonged 
expansion of bone marrow derived cells. On the other hand, Jaiswal et al. 
(1997) have used a density of 5x103 cells/cm2 and Bruder et al. (1997) have 
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passaged human bone marrow derived cells at 3x103 cells/cm2, which are close 
to the cell seeding densities that were applied in this study, starting initially 
with 4x104 cells/cm2 in the first passage of primary cells and then gradually 
going down to 1.5x104 cells/cm2 and 1x104 cells/cm2 for expansion purposes. 
Moreover, the freshly prepared bone marrow sample was seeded at 2x106 
nucleated cells/cm2, which is very similar to Bruder et al. (1997), who used an 
initial seeding density of 1.7x106 freshly isolated nucleated cells/cm2, 
harvesting the first passage after fourteen days. 
 
2.3.2. Medium Optimization 
 
In establishing and optimizing the isolation of human bone marrow derived 
cells, it was noticed that when the serum content in the expansion medium 
was increased from 10% to 15%, better cell growth and faster proliferation 
could be observed. To verify this observation and to determine the most 
suitable human serum and its concentration for optimal expansion and 
differentiation, the following experiments were undertaken. 
 
2.3.2.1. Human Serum Selection and its Effect on Cell 
Proliferation and Morphology 
 
Of the four human serum preparations, the preparation from the local blood 
bank of Hannover Medical School (HS-4) consistently yielded the highest cell 
counts. A comparison of cell counts of human trabecular bone derived cells 
expanded in the different human serum preparations is shown in Table 3. 
 
Table 3 
Human Serum Type  Cell # Day 
6 
Pan Biotech Lot No  P50208 HS-1 150x10³ 
Pan Biotech Lot No  P520221 HS-2 150x10³ 
PAA Lot No CO 2104-0167 HS-3 100x10³ 
Hannover Medical School HS-4 300 x10³ 
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The faster cell growth in the HS-4 preparation (obtained from the local blood 
bank of Hannover Medical School) was also noted in the microscopical 
analysis. Cells cultivated in parallel in the four different human serum 
preparations were initially morphologically similar, showing the typical 
spindle shaped fibroblast-like appearance. Upon further cultivation, however, 
the cells cultivated in the serum (HS-4) displayed an accelerated growth rate 
(faster confluence) and a more elongated spindle shape (Figure 16). 
 
 
A 
HS-1 HS-2 
B 
D 
HS-4 HS-3 
C 
 
 
 
 
 
 
 
 
 
 
 
Table 3 Effect of human serum type on cell proliferation. Human trabecular 
bone derived cells were seeded at 5x103 cells/cm² in T25 flasks and cultivated for 6 days 
in ZKT-1 medium supplemented with 15% of the corresponding human serum. Cell 
number was determined with the trypan blue exclusion method. n=3. 
Figure 16 Micrographs showing the effect of human serum preparation on
cell morphology and growth of human trabecular bone derived cells. Cells
were cultivated in parallel culture flaks in ZKT-1 basal medium supplemented with 15
% of the corresponding human ser preparation. Differences in cellular growth and
morphology were noted accor ing to the type of hum n erum used. (A) Cells
cultivated in HS-1: Pan Biot ch human serum lot 1. (B) HS-2: Pan Biotech human
ser  lot 2. (C) HS-3: PAA uman serum. (D) HS-4: Human serum from Hannover
Medical School. Original magnification: x100; scale bar= 100µm. 
 
Furthermore, viability of the cells was measured at the end of the cultivation 
period and it was found that the highest metabolic activity was demonstrated 
by the cells treated with the human serum (HS-4) supplied by the local blood 
bank of Hannover Medical School (Figure 17). Thus, HS-4 was selected for all 
further analyses in this study. 
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Figure 17 Effect of human serum type (or lot) on human trabecular bone
derived cell proliferation measured by WST-1. Human trabecular bone derived
cells were seeded at 5x103cells/cm² in 48-well plates and cultivated in 4 different
human serum preparations at 15% in ZKT-1 basal medium. WST-1 was determined on
day 6. The bars represent the absorbance as a percentage of the maximum absorbance
measured at 450 nm. HS-1= PanBiotech Lot1. HS-2 =PanBiotech Lot 2. HS-3=PAA.
HS-4= Medical school Hanover. Error bars, means ± standard deviation. n≥3. 
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2.3.2.2. Human Serum Concentration and its Effect on Cell 
Morphology, Proliferation and Differentiation 
 
After choosing the serum preparation for the cultivation of human trabecular 
bone derived cells, the most suitable human serum concentration was 
determined for expansion and differentiation purposes. Four different serum 
concentrations were tested, including 1%, 5%, 10% and 15% human serum.  
 
2.3.2.2.1. Effect of Serum Concentration on Cell Morphology  
 
Initially the morphology of the cells was very similar, all showing a long 
spindle fibroblast-like shape (Figure 18). Cells treated with 15% human serum 
were observed to grow faster and denser after only 5 days of culture compared 
to the lower concentrations.  
Later in cultivation, after 11 days, cells which were grown in the lowest serum 
concentration (1%) barely proliferated and were shorter and broader in shape 
compared to cells grown at the higher serum concentrations (Figure 19). Cell 
confluency was reached in the following order: 15%>10%>5%>1%.  
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 igure 18 Micrographs showing the effect of human serum concentration on
uman trabecular bone derived cell morphology after 5 day cultivation.
uman trabecular bone derived cells were seeded at 5x10³ cells/cm² in 48-well plates
nd cultured with ZKT-1 basal medium supplemented with (A) 1% human serum, (B)
% human serum, (C) 10% human serum and (D) 15% human serum. Cells were
iewed under a phase contrast light microscope after 5 days of cultivation. Original
agnification: x100; scale bar=100µm. 5% 
B 
1% 
A 
15% 
D 
10% 
C igure 19 Micrographs showing the effect of human serum concentration on
uman trabecular bone derived cell morphology after an 11 day cultivation
eriod. Human trabecular bone derived cells were seeded at 5x10³ cells/cm² in 48-well
lates and cultured with ZKT-1 basal medium, supplemented with (A) 1% human
erum, (B) 5% human serum, (C) 10% human serum and (D) 15% human serum. Cells
ere viewed under a phase contrast light microscope after 11 days of cultivation.
riginal magnification: x100; scale bar=100µm.  -48- 
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2.3.2.2.2. Effect of Serum Concentration on Cell Proliferation  
 
To quantify the effect of serum concentration on cell proliferation, total DNA 
content (Figure 20), total protein content (Figure 21) and total DNA content 
were assessed, which verified the microscopical data.  
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Figure 20 Effect of human serum concentration on DNA content of trabecular
bone derived cells. Cells were seeded at 5x10³ cells/cm² in 48-well plates and
cultured with ZKT-1 basal medium, supplemented with 1%, 5%, 10% or 15% human
serum. The red bars represent the total DNA amount in ng/ml after 1 day of cultivation
and the black bars after 29 days. M1=1% human serum. M2=5% human serum.
M3=10% human serum. M4=15% human serum. Error bars, means ± standard
deviation n≥3. 
 
The DNA amount on day 29 of cells treated with 10% human serum was very 
close to that of cells cultivated with 15% human serum. This could be 
explained by the fact that confluency was actually reached at a time point 
earlier than day 29, as was observed microscopically. With the cells in both 
media eventually filling the culture area they are provided with, they stopped 
proliferating at confluence and therefore stopped increasing in number with 
the DNA amount reaching a maximum most probably at different points but 
before day 29. 
The total protein content data show (Figure 21) that throughout the 
cultivation time, the amount of protein production for cells treated with 15% 
human serum is higher compared to the 10%. Taking this into consideration, 
15% serum supplementation was found to be most suitable for expansion 
purposes, as confluency was reached faster (higher growth rate). 
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 Figure 21 Effect of human serum concentration on total cellular protein
content of human trabecular bone derived cells. Human trabecular bone derived
cells were seeded at 5x10³cells/cm² in 48-well plates and cultured with ZKT-1 basa
medium, supplemented with either 1%, 5%, 10% or 15% human serum. Total protein
was determined over the whole cultivation period of 29 days. M1=1% human serum
black line. M2=5% human serum, red line. M3=10% human serum, green line. M4=
15% human serum, blue line. Error bars, means ± standard deviation n≥3. .2.2.3. Effect of Serum Concentration on Cell Differentiation 
ensure, that optimal cell proliferation was also followed by optimal 
erentiation, the ability of the cells treated with different expansion media 
undergo differentiation into the osteoblastic lineage was investigated by 
ating the cells with osteogenic induction medium followed by staining the 
 layer for alkaline phosphatase (section 2.2.13.1.). All cells treated with 
eogenic medium displayed an osteoblastic flattened phenotype and stained 
itive for alkaline phosphatase, the strongest staining was observed for cells 
anded in 15% human serum (Figure 22). It was thus shown, that a better 
ansion rate (a higher cell number in shorter time) was accompanied by 
imal differentiation.  
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Figure 22 Osteogenic differentiation capacity of cells treated with different serum
concentrations. Human trabecular bone derived cells were seeded at 5x10³cells/cm² in 48-
well plates and cultured with ZKT-1 basal medium supplemented with 5%, 10% or 15% human
serum. Cells were treated with osteogenic medium for 14 days and differentiation was assessed
with alkaline phosphatase staining for cells expanded in (A) 5% human serum, (B) 10%
human serum and (C) 15% human serum. Original magnification: x100; scale bar = 100µm. 
 
2.3.2.3. Discussion 
 
It was demonstrated that with increasing human serum concentrations in the 
medium, better (faster) proliferation was obtained (15%>10%>5%>1%). These 
results are in line with another study published by Stute et al. (2004). They 
compared the effects of 1%, 3% and 10% autologous human serum on the 
expansion of human bone marrow derived cells and demonstrated that 10% 
human serum was at least as good as 10% FCS. Furthermore, they showed 
that cells grown with 10% human serum had more osteogenic potential than 
those expanded in 3% and 1%.  
In this study, the use of FCS was avoided and protocols were established using 
human serum. However, a potential limitation of using 15% human serum for 
clinical purposes is the availability of human serum in these relatively large 
amounts, especially if autologous serum is to be applied*. Considering that 
15% showed the highest rate of expansion and especially because of the key 
effect noted in the isolation of human bone marrow derived cells upon using 
15% in the initial isolation phase, this concentration was considered to be 
optimal for expansion and was used in the study thereafter. This can be 
explained by a higher availability of mitogenic factors essential for the cells in 
the initial growth phase. Confluency will eventually be reached upon longer 
cultivation with media supplemented with lower amounts of serum. Having 
observed that cells cultivated with 10% human serum approached those 
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cultivated with 15% closely in protein content and DNA amounts as well as in 
alkaline phosphatase staining intensity, the concentration of 10% to induce 
osteogenic differentiation was considered to be sufficient for osteogenic 
medium supplementation. 
 
* Note  
The fact that 15% human serum was applied is not only a limitation for the 
later clinical application but the availability of human serum is not always 
provided for basic research as well. Therefore, osteogenic differentiation for 
this study was also partly verified using fetal bovine serum (see Appendix II, 
section 7.5.). 
 
2.3.3.  Cell Expansion and Differentiation Media 
 
Although very satisfactory results were obtained using human serum 
concerning both proliferation and differentiation, and the fact that serum is 
usually included in most media as a readily available supplement to promote 
cell proliferation (Gregory et al., 2004), serum free formulations are an 
attractive substitute and have been developed for various applications. 
Advantages of serum free media include: (i) growth improvement by excluding 
inhibitors found in sera, (ii) precise analysis of the effects of known factors, 
therefore facilitating the identification of new factors, (iii) enables the 
production of customized media, and finally, (iv) provides consistent lot to lot 
activity, thus eliminating the tedious task of serum screening before purchase, 
as described earlier.  
The possibility to increase the in vitro proliferation rate and osteogenic 
potential of trabecular bone derived cells was studied by investigating the 
effects of different growth factors in an attempt to develop a serum free 
medium compared to human serum supplemented medium. In the literature, 
several growth factors have been described as having a proliferative and/or 
osteoinductive effect. PDGF and EGF were reported to have an inductive effect 
on proliferation and differentiation of osteoblasts (Zheng et al., 1992), as well 
as FGF (Hankemeier et al., 2005; Martin et al., 1997; Pri-Chen et al., 1998; 
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Walsh, 2000). IGF showed an osteoinductive effect (Kveiborg et al., 2000), 
while EGF was proliferative only, inhibiting osteogenesis (Zheng et al., 1992). 
Based on these studies the cytokines were chosen in this experiment at 
different combinations and compared to the effect of serum supplemented 
medium. 
 
Cell Expansion Media  
 
Twenty different combinations of expansion media (see section 2.2.6., Table1) 
were compared in terms of proliferation, monitored by determining cell 
viability using the WST-1 proliferation assay (Figure 23). The highest 
proliferation was observed in cells expanded in 15% human serum. The serum 
reduced formulation containing PDGF as a supplement also showed very good 
proliferation. 
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 Figure 23 Proliferation of human trabecular bone derived cells in twenty
different media combinations. Comparing serum rich medium to cytokine
supplemented serum reduced media. Cells were seeded at 5x103 cells/cm2 in ZKT-1
basal medium, supplemented with either human serum (15%, 10%, 1%, 0%) or different
cytokines (PDGF, FGF, IGF, EGF), individually or in combinations. Serum reduced
media were supplemented with ITA: a mixture of insulin, transferrin and albumin. WST-
1 was measured after 9 days in culture. Values of the absorbance are shown as
percentages from the mean value of absorbance of cells cultivated in 15% serum
supplemented medium. Error bars, means ± standard deviation n≥3. 
 
 
 
 
 
 
 
 
Cell Differentiation Media  
 
The potential of the serum reduced media to induce osteogenic differentiation 
was assessed via measurement of alkaline phosphatase activity and compared 
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to differentiation in serum rich media. The highest increase in ALP activity 
was found to be for the cells previously expanded in ZKT-1 medium, 
supplemented with 15% human serum followed by the medium supplemented 
with 10 % human serum (Figure 24).  
 1) 15% HS
 
 
Figure 24 Osteogenic differentiation of human trabecular bone derived cells
in twenty different media combinations. Comparing serum rich medium to
cytokine supplemented serum reduced media. Cells were seeded at 5x103
cells/cm2 in ZKT-1 basal medium supplemented with either human serum (15%, 10%,
0%, 1%) or different cytokines (PDGF, FGF, IGF, EGF) individually or in combinations.
Serum reduced media were supplemented with ITA: a mixture of insulin, transferrin
and albumin. Osteogenic supplements were added at day 9 to all media. The black bars
represent ALPase activity at day 9 and the grey bars represent ALPase activity at day
12. Error bars, means ± standard deviation n≥3. 
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Although, some growth factors individually or in combination showed a 
promising effect in terms of proliferation, differentiation was affected rather 
negatively by substituting human serum with growth factors. Data suggest 
that PDGF was the most active in increasing growth rate, whereas EGF and 
FGF-2 were the most active in promoting bone formation (indicated by higher 
ALP activity).  
For the final three dimensional tissue reconstruction in vitro, in the 
experiments to follow (Chapter 3), the medium delivering the fastest 
expansion as well as the best osteogenic differentiation was chosen to be the 
most suitable. Therefore, ZKT-1 basal medium supplemented with 15% human 
serum was thereafter used for expansion of human trabecular bone derived 
cells as well as for human bone marrow derived cells. 
-54- 
Chapter 2  Results and Discussion I 
    
 
In this study human serum supplementation was chosen, as it was a readily 
available source from the local blood bank of Hannover Medical School (HS-4) 
and very satisfactory levels of proliferation and differentiation were reached. 
As the eventual goal of bone tissue engineering is to implant a patients own 
isolated cells grafted on a suitable biomaterial back into the same patient, it is 
more appropriate to establish the protocols for in vitro tissue engineering 
purposes using human serum, ideally autologous human serum. 
Moreover, an array of serum free media for growing mesenchymal like stem 
cell have already been developed by companies like Miltenyi Biotec GmbH, 
Cambrex and Stem Cell Technologies for various cell types. The development 
for a serum free medium is by far a more complicated task than what was 
attempted in the experiments above. However, the price of these media 
excluded them for further use within this study. 
 
2.3.4. Large Scale Cell Expansion  
 
Having identified the most suitable expansion medium for human 
mesenchymal like stem cells, a suitable expansion method next to the 
conventional adherent cell culture in T culture flasks for the production of up 
to10x108 cells to meet the needs for in vitro tissue engineering experiments 
(Chapter 3) was to be developed. For this purpose, the following two methods 
were investigated. 
 
2.3.4.1. Spinner Flask-Microcarrier Culture 
 
Two different types of microcarrier were tested, namely Microhex™ (Figure 
25A) and Cytodex® (Figure 25B). Cells were observed to attach on the bead 
surface after 24 hours and spread out on the surface of the microcarrier with a 
fibroblast like appearance. Cell proliferation was monitored throughout the 
period of cultivation by measuring glucose (Figure 26A) and lactate 
concentration (Figure 26B) in the medium. Higher glucose utilization, the 
main energy source, by cells cultivated on Microhex™ indicated better cell 
growth as was later confirmed by a higher cell harvest as well. Cells cultivated 
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as a control, in suspension without the adherence on a microcarrier, utilized 
almost no glucose. 
 
B A 
 
 
 
Figure 25 Phase contrast micrographs of microcarriers for adherent cell
culture. A monolayer of well spread and attached cells was observed on the surface of
(A) Microhex™ and (B) Cytodex®. The microcarriers were inoculated with
10x103cells/cm2 human mesenchymal-like stem cells and cultivated in a spinner flask
in ZKT-1 basal medium supplemented with 15% human serum. Original magnification:
x100, scale bar=10*10µm=100 µm. 
 
At harvest, cells were separated from the microcarrier beads by trypsin-EDTA 
digestion and filtration. Only 3.95x106 cells were retrieved from the spinner in 
the case of Microhex™ and only 1.73x106 with respect to Cytodex®. To ensure 
that this low cell number was not due to growth inhibition through the 
microcarrier beads, the harvest was replated in a T175 flask at 1x104 cells/cm² 
and growth was monitored by calculating the population doubling rate, which 
was found to be very similar compared to cells of the same passage cultivated 
in parallel in T flasks. 
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 Figure 26 Glucose utilization and lactate production in microcarrier cel
culture. Cells were cultivated either in conjunction with a microcarrier; Microhex™
(red line) and Cytodex® (black line) or without a microcarrier as a control (green line) in
suspension spinner culture in ZKT-1 medium supplemented with 15% human serum
(A) Glucose and (B) lactate concentration (g/l) were measured in the supernatan
throughout the cultivation period by the YSI 2700 Select biochemistry analyzer. -56- 
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The population doubling rate was calculated to be 0.43 population doublings 
per day for the cells replated in a T flask after being separated from the 
microcarrier beads and 0.46 from the continuous T flask culture. It was 
demonstrated that cells were successfully cultivated and expanded on both 
microcarrier types with slightly better proliferation on Microhex™. These 
results are consistent with the findings of other investigators as well (Granet 
et al., 1998; Sautier et al., 1992), who have postulated that it was the charge of 
the surface (negative) rather than the affinity for collagen that is responsible 
for cell attachment on the microcarrier. However, final conclusions could not 
be drawn due to problems encountered in the final harvesting of the cells at 
the end of the cultivation period. As an alternative to the trypsin method, 
collagenase in addition to the use of various sieves was applied (data not 
shown) but complete separation of the cultivated expanded cells from the 
microcarriers was not achieved. In general, the use of the microcarriers as an 
alternative to cultivate adherent cells in large amounts did not meet the 
expectations and a novel method for expanding mesenchymal-like stem cells in 
vitro was sought, so the use of cell factories as an alternative for large scale 
cell expansion was investigated in the following section. 
 
2.3.4.2. Cell Factories™  
 
The growth kinetics of cells cultivated in the cell factories were very similar to 
T flask cell culture and the optimized growing conditions of the lab scale 
culture could be transferred without any further developmental work 
concerning seeding density and expansion medium. In Table 4, the culture of 
human trabecular bone derived cells in conventional T flask culture is 
compared to culture in a four-tray cell factory in terms of population doubling 
rate. Similar population doubling rates and morphology (data not shown) could 
be noted between the two cultivation systems. However, with the use of the 
cell factory, the amount of time required for repeated passaging of the cells 
and the demand in incubator space and cost could be drastically reduced, 
considering that the surface culture area of one four tray cell factory (2528 
cm2) is equivalent to approximately fifteen T175 culture flasks. A further 
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advantage of the cell factory is the minimized risk of microbial contamination 
with the cells kept in one closed system. An inoculation density of 10x103 
cells/cm² in a four-tray cell factory yielded a harvest of up to approximately 
115x106 cells per cell factory (and an average of 85 x106 cells). 
Table 4 
 Initial cell 
number 
Confluent cell 
number 
PD Rate 
T175 flasks (7x) 12x106 32 x106 0.28 
Cell Factory (1x) 25.28 x 106 112.5 x 106 0.31 
PD Rate = Number of population doublings per day 
Table 4 Population doubling rate of human trabecular bone derived cells
cultivated in T175 flasks versus a four tray cell factory. Cells were seeded at
10x103cells/cm2 in seven T175 flasks parallel to a four-tray cell factory and cell number was
determined after expansion in ZKT-1 basal medium supplemented with 15% human
serum. 
 
 
 
 
 
 
2.3.5. Cell Characterization  
 
Since the cells derived from human trabecular bone displayed a large 
expansion potential, similar to cells derived from human bone marrow, in 
addition to being morphologically very similar, the isolated cell population was 
further examined concerning the ability to undergo differentiation into fat 
(adipogenesis), cartilage (chondrogenesis) and bone (osteogenesis). 
 
2.3.5.1. Multipotentiality of Human Trabecular Bone Derived 
Cells 
 
The cells were shown to differentiate into cartilage, fat and bone like tissue. 
Chondrogenic differentiation was demonstrated by Alcian blue, staining 
the proteoglycans produced by the chondrocytes light blue. Adipogenic 
differentiation was first evident after 14 days in culture, when first intra-
cytoplasmic lipid droplets started to appear, visualized by Nile red staining. 
Osteogenic differentiation was evident in cells treated with osteogenic 
medium, which underwent a change in their shape, namely, from spindle 
shaped to the typical cuboidal shape, which could be demonstrated clearly with 
alkaline phosphatase staining. Figure 27 shows the multipotentiality of 
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trabecular bone derived cells of a representative patient sample (male, age: 60 
years). As expected, control cultures maintained without supplements did not 
stain positive.Adipogenesis and osteogenesis were induced and observed in all 
tested patient samples. Chondrogenesis, on the other hand, was not routinely 
performed because of the complexities involved. No correlation could be drawn 
between with donor age, gender, passage number and the ability to undergo 
differentiation into the different lineages. Multipotentiality was always 
successfully performed on cryopreserved cultures. Therefore, cryopreservation 
did not alter the ability of these cells to differentiate into various tissue 
lineages.  
 
C B 
A 
B' C' D' 
D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 27 Multipotentiality of human trabecular bone derived cells. (A) Cells
obtained from human trabecular bone explantation were seeded at 10x103cells/cm2
until sub-confluence in expansion medium (ZKT-1+15%HS) and then changed to
chondrogenic, adipogenic and osteogenic medium. Control cultures were cultivated in
expansion medium in parallel. (B) Adipogenesis was verified with Nile red staining,
visualising the intra-cytoplasmically accumulated lipid vacuoles in the typical round
adipocytic cell shape at day 21 of cultivation in adipogenic medium. (C) Osteogenic
potential is shown by alkaline phosphatase staining. (D) Chondrogenic potential was
visualised by Alcian blue staining after 21 days in chondrocyte induction medium.
Parallel control cultures maintained without the respective inductive supplements did
not stain positive for all three lineages (B’), (C’) and (D’). Original magnification:
x100; scale bar=100µm.  
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2.3.6. Osteogenic Differentiation of Trabecular Bone Derived 
Cells vs. Human Bone Marrow Derived Cell 
 
The osteogenic differentiation potential of human trabecular bone derived cells 
was compared to that of human bone marrow derived cells. Osteogenesis was 
biochemically assessed over a 40-day time course study in parallel cell cultures. 
Cells were seeded at 5x103 cells/cm2 in 48-well-plates, cultivated in expansion 
medium for 5 days until confluence after which the medium was exchanged 
with osteogenic medium (Appendix II). 
 
2.3.6.1.  Collagen I Production: Matrix Formation  
 
Expression of collagen I was determined by collagen type I COOH terminal 
propeptide (CICP) secretion in the supernatant (section 2.2.11.). In Figure 28, 
CICP levels in both cell types showed that the synthesis of new collagen type I 
protein was initially high, distinctive for osteoblasts in their proliferative 
phase (Owen et al., 1990) reaching a maximum level followed by a down 
regulation in collagen production between day 15 and day 20 indicating the 
transition of the cells into the matrix maturation phase. Both cell types 
displayed a similar pattern, decreasing the production rate in collagen I, 
however, human bone marrow derived cells appeared to have laid down a 
higher total amount of collagen I than trabecular bone derived cells. 
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 Figure 28 Collagen I production in trabecular bone derived cells versus
human bone marrow derived cells. Both cell types were cultivated in parallel at
5x103 cells/cm2 in 48-well pates in expansion medium (ZKT-1+15%HS) followed by
osteoinductive medium (ZKT-1+10%HS+osteogenic supplements) at confluence. CICP
was determined in the supernatant throughout the cultivation period and expressed in
ng/ml. The black line shows collagen I production in trabecular bone derived cells and
the red line in bone marrow derived cells. Error bars, means ± standard deviation n=2. 
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2.3.6.2. Alkaline Phosphatase Activity: Matrix Maturation 
Phase 
 
Alkaline phosphatase activity was determined in human trabecular bone 
derived cells cultivated in parallel to cells derived from human bone marrow 
under identical osteogenic conditions. Both cell types displayed a very similar 
pattern, the classical rise and fall pattern in ALP activity (Figure 29). These 
data are in agreement with what has been reported in the literature about 
osteogenic cells, showing maximum alkaline phosphatase activity following the 
down regulation of collagen I production. The higher peak value in ALP 
activity in human trabecular bone derived cells, indicative for the matrix 
maturation phase (Owen et al., 1990; Stein and Lian, 1993) might be explained 
by the higher activity of the individual cells. Considering the CICP levels in 
Figure 28, the proliferation phase of trabecular bone derived cells reached an 
earlier endpoint and the cells have transited into the matrix maturation phase 
before human bone marrow derived cells, which continued to lie down matrix.  
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 Figure 29 Comparison of alkaline phosphatase activity in human trabecular
bone derived cells to human bone marrow derived cells. Cells were seeded at
5x103cells/cm2 in 48-well plates and cultivated in parallel in osteoinductive medium.
Alkaline phosphatase activity was determined as milli units/min per well and
normalized to the total protein content of the cell layer. The black bars represent
ALPase in trabecular bone derived cells and the red bars the ALPase in human bone
marrow derived cells. Error bars, means ± standard deviation n=3. 
 
 
 
 
 
Histochemically, both cell types stained negative for alkaline phosphatase 
after 4 days in osteoinductive medium, indicating still ongoing proliferation 
and more intense staining was noted after 15 days of osteoinduction, a sign for 
cell maturation and the development of the osteoblastic phenotype (Figure 30). 
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Figure 30 Alkaline phosphatase staining of human trabecular bone derived
cells vs. human bone marrow derived cells. Alkaline phosphatase staining was
performed in human bone marrow derived cells (A) after 4 days and (B) after 15days of
culture in osteogenic medium and in human trabecular bone derived cells at the same
time points (C) after 4 days and (D) after 15 days in osteogenic medium. Original
magnification: x100; scale bar=100µm. 
 
 
 
 
2.3.6.3. Extracellular Matrix Mineralization Phase 
 
Mineralization, the terminal marker for osteoblastic differentiation, was 
quantified by measuring the amount of calcium deposited in the extracellular 
matrix (section 2.2.12.) throughout the cultivation period (Figure 31). Human 
bone marrow derived cells were observed to lie down greater amounts of 
calcium deposits compared to trabecular bone derived cells, which seemed to 
“catch up” in matrix mineralization with detectable amounts becoming 
apparent at a later time point (a delay of ca. 5 days), when compared to the 
human bone marrow derived cells.  
The steep increase in calcein levels (calcium deposition) coincided well with the 
fall in collagen I production levels (Figure 28), indicating that cells start the 
mineralization process once enough collagen has been laid own.  
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 Figure 31 Calcium accumulation in the extracellular matrix of trabecular
bone derived cells versus human bone marrow derived cells. Cells were seeded
at 5x103cells/cm2 in 48-well plates and cultivated in parallel in osteoinductive medium
Calcein binding to calcium deposits was detected through recording absorbance of the
fluorescent calcein (at 450nm), which is proportional to the amount of calcium laid
down throughout the cultivation period. The red line represents the calcium amounts
in human bone marrow derived cells and the black line of trabecular bone derived cells
Error bars, means ± standard deviation n=3. -63- 
.6.4. Mineralization in Histology  
further unveil the process of mineralization of human bone marrow 
ived- and trabecular bone derived cells, cells were fixed at day 8, 15, 18, 23, 
and 32 for histological staining (section 2.2.13.) to visualize the mineral 
osition pattern in the cell cultures. 
st signs of mineralization in the form of nodules or vesicles were evident 
r approximately 8 days of cultivation in osteogenic induction medium in 
h cell types (Figure 32). Light microscopy revealed vesicular structures 
ng the collagen fibrils in both cell types and light positive von Kossa 
ining. After 15 days, mineralized spots scattered across the cell layer were 
ected with alizarin red staining in both cell types (Figure 32).  
 onset of mineralization observed histologically coincided with the steep 
rease in collagen I production noted in Figure 28. Genge et al. (1988) have 
nd that a loss in alkaline phosphatase activity correlated with the initiation 
mineralization of the matrix vesicles. Both cell types were observed to 
over a similar pattern in mineral deposition and staining, indicating de 
o in vitro bone formation.  
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Figure 32 Phase contrast micrographs showing first signs of mineralisation in
human trabecular bone derived cells and bone marrow derived cells. Cells were
seeded at 5x103cells/cm2 and induced with osteogenic medium at confluence. Cell layers were
fixed at day 8 and 15. Light microscopy revealed structures vesicular in shape along the
collagen fibrils in both trabecular bone derived cells (A) and human bone marrow derived
cells (D) (Original magnification: x 1000; scale bar=10µm). Von kossa staining after 10 days
in osteoinduction medium showed a few mineral depositions along the collagen fibres in both
trabecular bone derived (B) and human bone marrow derived cells (E). (Original
magnification: x100; scale bar=100 µm). Alizarin red staining at day 15 revealed a few
scattered mineralised spots stained in red in trabecular bone derived (C) and bone marrow
derived cells. Original magnification: x100; scale bar =100 µm). 
 
The vesicular structures and the stained nodules were continuously examined 
under the light microscope throughout the cultivation period. They were 
observed to increase in number with time correlating with the intensity of 
mineral staining demonstrated by von Kossa staining in Figure 33.  
Both cell types were observed to form these typical vesicles along the collagen 
fibrils of the extracellular matrix, however, more frequently observed in the 
case of human bone marrow derived cells.  
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 Human bone marrow derived cells day 18 
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Figure 33 Phase contrast micrographs showing human trabecular bone
derived cells and human bone marrow derived cells in the process of bone
formation. Cells were seeded at 5x103 cells/cm2 and induced with osteogenic medium
at confluence. Cell layers were fixed at day 18. The vesicular structures along the
collagen fibrils were noted to increase in number for both trabecular bone derived
cells (A) and human bone marrow derived cells (C) revealed with light microscopy.
(Original magnification: x1000; scale bar=10µm). Von Kossa staining after 18 days in
osteoinduction medium showed more intense staining with black nodules increasing
in number along the collagen fibrils in both trabecular bone derived (B) and human
bone marrow derived cells (D). (Original magnification: x100; scale bar=100 µm).  
 
 
 
 
 
 
 
 
 
 
 
 
The vesicular structures were found to increase further in size and number 
accompanied by more extensive extracellular matrix mineralization upon 
longer exposure of the cells to osteogenic medium in both cell types. Mineral 
deposition was observed to occur along the collagen fibrils in and/or around 
theses vesicular structures, which apparently formed the initial loci for 
mineralization. Those areas in the cell layer, which underwent mineralization 
could be observed as red vesicles by alizarin red staining, black-brown clusters 
visualized by von Kossa and green emitted fluorescence by bound calcein after 
32 days cultivation in osteogenic medium (Figure 34). More intense staining 
was noted in human bone marrow derived cells, which is in agreement with 
the greater amounts of calcium deposited by these cells as shown in Figure 31. 
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Figure 34 Terminal and complete mineralisation of the extracellular matrix in
human trabecular bone derived and bone marrow derived cells. Light microscopy of
the mineralised extracellular matrix revealed the vesicular structures decorating the
collagen fibrils in both trabecular bone derived cells (A) and in bone marrow derived cells
(G) Original magnification: x100; scale bar=100 µm. (B) and (H) showing these vesicular
structures at a larger magnification:x1000; scale bar =10µm. Calcein binding pattern
revealed more intense calcification (green fluorescence) of the bone marrow derived cells (I)
compared to cells from trabecular bone (C). Classical alizarin red staining patterns were
noted to occur around these vesicular structures in trabecular bone derived cells (D) and
bone marrow derived (J). (E) and (K) show these at a larger magnification x1000; scale bar
=10µm .Von Kossa stain in both trabecular bone derived cells (F) and bone marrow derived
cells (L) verified the extensive mineralisation across the vesicular structures. Original
magnification: x1000; scale bar=10 µm 
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2.3.6.5. Interpatient Variation  
 
Like other authors, interpatient variability was observed in the ability of the 
cells to undergo osteogenesis. The mineralization patterns of cells isolated 
from three patients were compared in terms of alizarin red staining after 25 
days of osteoinduction. The cell layers displayed various degrees of staining 
(Figure 35). To exclude the effect of the age factor (Martinez et al., 1999a; 
Martinez et al., 1999b) on osteogenic differentiation, cells were isolated form 
patient samples with an average age of 63±7 years. 
B C A 
Figure 35 Alizarin red staining in trabecular bone derived cells from three patients.
Cells isolated from three patients were osteoinduced for 23-28 days, fixed and stained for
alizarin red.  Patients (A) and (B) showed red stained calcium accumulations, indicating
terminal mineralisation,  whereas cells from patient (C) showed almost no mineralisation,
staining negative. Original magnification: x100; scale bar=100µm. 
 
These differences in patients are in line with data reported in the literature 
(Siggelkow et al., 1999; Kassem et al., 2003; Stenderup et al., 2003). Based on 
the developmental sequence described earlier in the introduction (chapter 1, 
section 1.1.5.), terminal differentiation of an osteoblast culminating in 
mineralization is preceded by a peak in alkaline phosphatase activity (typical 
rise and fall pattern). Civitelli et al. (1993) and Jaiswal et al. (1997) have also 
demonstrated that the decrease in ALP activity correlated with advanced 
matrix mineralization. So the peak in alkaline phosphatase is a prerequisite 
for osteogenic cells to transit into the final mineralization phase. Cells isolated 
from the above three patients were cultivated in osteoinductive medium and 
analyzed for ALP activity throughout the cultivation period (Figure 36). Cells 
from patients (A) and (B) both peaked in ALP, while the activity in cells from 
patient C increased linearly with ongoing cultivation. 
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 Figure 36 Alkaline phosphatase activity in three different patients. Cells were
cultivated in osteogenic medium and soluble ALP activity was measured using a
biochemical assay (Sigma) based on conversion of p-nitrophenyl phosphate to
p-nitrophenol, which was measured spectrophotometrically at 405 nm. Patients A (black
line), B (red line) showed the typical rise and fall pattern while the absorption in cultures
of cells form patient (C) kept rising. Error bars, means ± standard deviation n=3. -68- 
se results need to be confirmed by further biochemical analysis. As the 
lementation of a thorough biochemical analysis for osteogenic 
erentiation for each patient sample in this study was not feasible. An easy 
perform and fast screening test for ALP activity was performed in an 
empt to explain the differences in mineralization. This variability reflects 
 well known heterogeneity within cells isolated from different donors. 
wever, these results could be applied in establishing a screening method to 
ure that cells will eventually mineralize. As for cells to undergo terminal 
eogenic differentiation, reaching a peak in ALP activity appears to be an 
vitable transition point the cells must go through. 
te:  
ailed investigation for basic research purposes usually requires the 
ilability of a consistent batch of serum throughout the experiments. As 
an serum might not be available in sufficient amounts for a series of 
eriments, mineralization of human bone marrow derived cells was also 
estigated using fetal bovine serum instead. A similar mineralization 
tern was successfully obtained as demonstrated by alizarin red, calcein and 
 Kossa staining (data shown in Appendix II, section 7.5.). 
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2.3.6.6. Discussion: Osteogenesis in Trabecular Bone Derived 
Cells vs. Bone Marrow Derived Cells 
 
Human trabecular bone derived cells as well as human bone marrow derived 
cells, showed an expression pattern of bone related proteins during the 
proliferation phase and matrix maturation phase very similar to the classical 
developmental sequence (Genge et al., 1988; Jaiswal et al., 1997; Lian et al., 
1998; Owen et al., 1990; Stein and Lian, 1993). Initially, there was a period of 
active proliferation, in which collagen I levels increased following a down 
regulation of this phase, when alkaline phosphatase activity reached 
maximum levels and the extracellular matrix was rendered competent for the 
third and final stage of the developmental sequence, terminal mineralization. 
Although both cell types displayed similar patterns in osteoblast maturation, 
the onset of mineralization, the final stage for bone formation in vitro, was 
slightly delayed in the case of trabecular bone derived cells and the intensity of 
mineralization was observed to be higher for human bone marrow derived cells. 
A possible explanation for this could be the higher levels in collagen type I 
production (Figure 28) in the human bone marrow derived cell cultures. This 
could be attributed to the fact that prior to osteoinduction, both cell types were 
seeded at 5x103 cells/cm2 in 48-well plates and cultivated for 5 days in 
expansion medium (ZKT-1 basal medium supplemented with 15% human 
serum). Considering that the average population doubling rate for human bone 
marrow derived cells was calculated as 0.4 compared to 0.22 population 
doublings per day for human trabecular bone derived cells, it can be inferred 
that the amount of cells available after expansion in the case of the human 
bone marrow derived cells are higher in number than the trabecular bone 
derived ones. Bearing in mind that proliferation is down regulated gradually 
upon the addition of the osteogenic supplements, directing the cells towards 
differentiation. Thus, human trabecular bone derived cells might have started 
out with a lower cell density, which led to the higher ALP activity per cell 
observed in Figure 29 and to less collagen production, which is an essential 
requirement for mineralization to occur. Still, trabecular bone derived cells did 
manifest a fully differentiated phenotype, culminating in a mineralized matrix. 
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The data suggest that a prolonged initial expansion period prior to 
osteoinduction might render the mineralization intensity more similar to that 
observed in human bone marrow derived cells. 
Altogether, the data suggest that the mineralization process in both cell types 
follows the well accepted pattern of osteogenic differentiation in the literature 
and that similarities do exist between both cell types. These similarities 
include:  
Firstly, the down regulation of collagen I levels. Secondly, the alkaline 
phosphatase peak, and lastly the positive histological staining revealing a 
similar mineralization pattern by the formation of vesicular like structures 
(matrix vesicles). The differences observed, between the intensity and onset of 
mineralization in trabecular bone versus human bone marrow cells can be 
explained by the higher initial proliferation by human bone marrow derived 
cells, which is in line with what has been reported by Jaiswal et al. (1997). The 
group has shown that, while initial higher seeding densities did not result in 
significant different cell numbers beyond a certain time point, there was 
significantly more mineral deposited in cultures seeded at higher densities.  
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2.4. Conclusions 
 
 Trabecular bone was demonstrated to be a good and readily available 
source of mesenchymal progenitor cells. A simple and high yield 
isolation procedure was established from small bone tissue biopsies. It 
was shown to be of comparable efficiency to bone marrow aspirates with 
the characteristics of self-renewal with a high expansion potential, 
demonstrating a stable phenotype over the passages. Their multilineage 
differentiation potential, displaying the ability to differentiate into the 
adipogenic, chondrogenic and osteoblastic lineage is very similar to that 
of bone marrow derived cells. Further, this study supports the 
hypothesis that multipotential mesenchymal-like cells are present in 
many connective tissues in the adult human and that the isolation and 
manipulation of these adult stem cell-reserves represent a promising 
tool of candidate cells for engineering, repair and regeneration of tissues 
and organ systems.   
 
 A suitable expansion medium for expanding human mesenchymal like 
cells ensuring maximum proliferation without the loss of differentiation 
capacity was successfully developed. 15% human serum supplementing 
the basal medium was found to be optimal for isolation and expansion 
purposes.  
 
 Human mesenchymal-like stem cells were successfully expanded in cell 
factories, a disposable single batch closed system to generate a large 
amount of cells in a reproducible way. It was shown that using the cell 
factory, up to 115 million human mesenchymal-like cells in a single 
batch were harvested from one four tray cell factory. The cellular 
morphology and growth kinetics were unaltered from the T-flask 
laboratory scale culture and the multipotential of the isolated cells was 
unaffected. Therefore, it was found to be a good way to reproducibly 
expand primitive cells in vitro. Being a closed system, it has a very low 
contamination risk as well as providing a large growth surface in 
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limited space areas. Further, it is easy to handle as well as cost efficient 
and can be predictably up-scaled. For large scale expansion purposes, T 
culture flasks were entirely replaced by the cell factory expansion 
method. Theoretically, the cultivation can be up-scaled to a 
commercially available forty-tray cell factory™ (Nunc, Wiesbaden), for 
instance, whereby a total surface area of 10 m2 can be obtained which is 
operated as one single unit. The equipment and surface quality of the 
cell factory and the necessary handling equipment are suitable for work 
in aseptic conditions or clean rooms so that the production of human 
mesenchymal-like stem cells could eventually be cultivated under GMP 
conform conditions using this method. Cultivation of human 
mesenchymal like cells at this scale is a novel application as cell 
factories are mainly used for industrial scale production of vaccines, 
monoclonal antibodies or pharmaceuticals. For cell expansion purposes, 
it has so far only been applied for the generation of dendritic cells 
(Berger et al., 2002; Tuyaerts et al., 2002). 
 
 In this study, a model for osteogenic differentiation from human patient 
samples was established, demonstrating the three classical phases of 
osteogenic differentiation in vitro, providing a useful model for 
evaluating multiple factors affecting the progression of cells from 
undifferentiated precursors to mature osteoblasts and eventually 
terminated osteocytes. This model could be useful in studying cellular 
response to a variety of drugs, hormones and cytokines known to affect 
bone tissue formation in vivo or metabolic or genetic diseases leading to 
bone dysfunction as an alternative to animal models for instance. 
Moreover, studying and visualizing the mineralization of matrix vesicles 
in vitro, might help us understand the reasons behind decreased 
mineralization in diseases like hereditary skeletal dysplasias (e.g. 
hypophosphatasia), where the basic clinical manifestation is defective 
bone and cartilage mineralization and its mechanism of occurrence still 
being unclear. 
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3. Improved in vitro Bone-like Tissue Formation by 
Trabecular Bone Derived Cells in Three 
Dimensional Culture 
3.1. Introduction  
 
In the previous chapter, it was demonstrated that human trabecular bone cells 
have mesenchymal-like characters, including a high expansion potential and 
multilineage capacity. The osteogenic differentiation in particular, was 
examined in detail to ensure the ability of these cells to form bone tissue in 
vitro, in a two dimensional culture environment. Having successfully isolated 
and expanded a large amount of osteogenic cells from a small bone biopsy, the 
approach of using autologous cells for clinically applicable bone tissue 
engineering was to be examined next.  
The objective of this chapter is to develop a bone tissue engineering strategy 
for bone tissue repair by the creation of an appropriate osteoinductive 
microenvironment to later facilitate the capacity of an in vitro reconstructed 
tissue transplant to be integrated in vivo. The major drawback associated with 
three dimensional cultures of cell seeded constructs so far, pertains to the 
limited diffusion of nutrients throughout the whole scaffold structure, 
especially when cultivated statically. To overcome this limitation, two different 
dynamic cultivation modes were investigated besides stationary culture: a 
fixed bed perfusion bioreactor (Jaeger and Barthold, 2004) and a novel tilted 
rotating bioreactor system for the three dimensional cultivation of human 
trabecular bone derived cells in conjunction with a poly (lactide-co-glycolide)-
calcium phosphate composite scaffold. 
Currently available bioreactors include spinner flask, rotating and perfusion 
bioreactors. All improve mass transfer of nutrients and oxygen, yet, 
inadequacies and disadvantages remain in each system: whether it be the 
decreased internal medium transport in the spinner flasks leading to growth 
on the peripheries and leaving the interior empty or the potential limitation of 
insufficient medium mixing at the surface of the scaffold in the rotating 
bioreactor also leading to decreased medium transfer to the interior of the 
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scaffold or the relative complexity and difficulty in assembling and operating a 
perfusion bioreactor (Glodstein et al., 2001; Sikavitsas et al., 2002; Bancroft et 
al., 2003; Meinel et al., 2004a). With the rotating bioreactor, showing the most 
promising results in generating bone-like constructs in vitro (Vunjak-
-Novakovic, 2003; Marolt et al. 2006; Martin et al., 2004; Kasper et al., 2007), 
it was to be investigated whether introducing a further dimension to the 
rotating movement, namely, a tilted rotating motion would improve medium 
mixing and nutrient transport to the interior of the scaffold. To generate this 
type of motion, a commercially available tube rotator (Miltenyi Biotec GmbH) 
designed for sample mixing was used. 
Briefly, regarding the experimental set up, after expanding the cells as 
previously described, they were seeded onto a poly (lactide-co-glycolide)-
calcium phosphate composite scaffold (PLGA/CaP) and cultivated under either 
static or dynamic conditions for up to 35 days in vitro and subsequently 
assayed for cell attachment and proliferation using phase contrast light, 
confocal laser and scanning electron microscopy. Osteogenic differentiation 
was analyzed further biochemically by determining the expression of alkaline 
phosphatase and collagen type I production. 
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3.2. Materials and Methods  
3.2.1. Poly (lactide-co-glycolide)-Calcium Phosphate Composite 
Scaffold 
 
A commercially available scaffold (OsteoScaf™) was obtained from BoneTec 
(Toronto, Canada). Briefly, the composite scaffold was made by combining 
biodegradable poly (lactide-co-glycolide) (PLGA, 11.5%) with bioresorbable 
calcium phosphate (CaP) cement particles (2 parts CaP with 1 part PLGA by 
weight) as described by Guan and Davies (2004). The PLGA/CaP scaffold 
dimensions are approximately 10x10 mm (Figure 37) with ~90% porosity. The 
interconnective pores form a network of macropores (100-approx.2000 µm) as 
well as micropores (< 100 µm), which mimics trabecular bone in structure. 
Further, the PLGA/CaP scaffold degrades into nontoxic components that can 
be eliminated from the body.  
 
10 mm 
Figure 37 Poly (lactide-co-glycolide)/calcium phosphate composite scaffold.
Dimensions are 10x10 mm with a pore range of <100 µm-2000 µm. 
 
 
 
 
 
 
 
 
 
3.2.2. Scaffold Sterilization  
 
The PLGA/CaP scaffolds were sterilized by dipping in 100% ethanol for 1 
minute and then consecutively three times in 70% ethanol, each time for 10 
minutes. Scaffolds were then washed in 1x PBS, followed by immersion in an 
appropriate coating solution as described below for 24 hours prior to seeding.  
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3.2.3. Scaffold Surface Coating  
 
Scaffolds were pre-coated overnight with various purified extracellular matrix 
proteins including human serum, collagen type I, fibronectin and gelatin to 
assess the optimal surface coating for the individual cell type.  
3.2.3.1. Serum Coating 
For serum coating, the sterilized scaffolds were immersed in human serum or 
fetal bovine serum and incubated overnight. Prior to cell seeding, the excess 
serum was removed and the cell suspension was applied. 
3.2.3.2. Collagen I  
Scaffolds were covered with sterile 0.1% collagen type I solution (in 0.1% N 
acetic acid) from calf skin, overnight at 4ºC. Excess collagen solution was 
removed and the coated scaffolds were washed with ZKT-1 basal medium 
before cell seeding. 
3.2.3.3. Fibronectin 
Scaffolds were coated with fibronectin according to the manufacturer’s 
instructions. The lyophilized fibronectin was re-suspended with 1 ml sterile 
deionized water. The solution was diluted to 2.5 µg/ml, washed with ZKT-1 
basal medium and immediately used for cell seeding. 
3.2.3.4. Gelatin 
Scaffolds were immersed in 0.1% gelatin solution and incubated overnight at 
4ºC. The solution was aspirated off and the scaffolds washed with ZKT-1 basal 
medium and immediately used for cell seeding. 
 
3.2.4. Scaffold Seeding or Cell Culture on Scaffolds  
 
A seeding density of 5x106 cells per PLGA/CaP scaffold was applied for 
osteogenic cells. Cells were harvested from cell factories (as described earlier 
in chapter 2) and the cell pellet was re-suspended in a volume, predetermined 
as the amount of medium needed to completely fill the pores of the foam-like 
PLGA/CaP scaffold. For cell seeding, the scaffolds were placed in individual 
wells of a 24-well plate and each inoculated drop wise with 0.4 ml cell 
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suspension. For cell adhesion, the freshly seeded scaffolds were then incubated 
for 90 minutes at 37ºC and 12% CO2 and then each carefully transferred to a 
50 ml tube containing 15 ml expansion medium (ZKT-1, 15% human serum, 
1% penicillin-streptomycin). The medium was filled up to 30ml after 24 hours. 
 
3.2.5. Three Dimensional Cultivation Systems for in vitro Tissue 
Reconstruction 
 
After cell seeding, the cell-scaffold construct was further cultivated in one of 
the following three dimensional cultivation systems for up to 35 days. Two 
dynamic systems were compared to the classic static culture with the cell-
scaffold constructs being assayed for alkaline phosphatase activity, total 
protein content and viability via the WST-1 test. Detailed histological analysis 
including light -, confocal laser- and scanning electron-microscopy was also 
performed.  
 
3.2.5.1. Static Culture 
 
For static culture, the seeded scaffolds were carefully placed in aerated 50 ml 
tubes (Figure 38) containing 30 ml osteogenic medium (see Appendix II) and 
placed upright in the incubator (37ºC, 12% CO2) with medium being sampled 
and exchanged every 72 hours. Medium samples were frozen at -20ºC and cell-
scaffold constructs were fixed and analyzed at day 7, 15, 27 and 35. 
 
 
 
 
 
Figure 38 Picture and drawing of the aerated tube used for three dimensional
cultures. A 50 ml tube supplied with a filter cap allowing exchange of oxygen, carbon
dioxide (and humidity) through the openings. Sterility is maintained at all times by means of
the additional filter membrane (0.22 µm). The picture is adapted from TPP product website:
http://www.tpp.ch/tissue_culture/filter_and%20pcv_tubes/filter_pcv_tubes.html 
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3.2.5.2. The Tilted Rotating Bioreactor System 
 
To tilt the medium from one side to the other in addition to continuously rotate 
it, the commercially available tube rotor (MACSmix™ Miltenyi Biotec GmbH) 
was applied. It is equipped with a rack to hold 15 ml or 50 ml tubes and can be 
placed in the incubator at 37ºC for cultivation. A schematic illustration of the 
generated motion is shown in Figure 39. The freshly seeded cell-scaffold 
construct was placed in an aerated 50 ml tube (section 3.2.5.1.) and immersed 
in 30 ml osteogenic medium. Following a 24 hour static cultivation period, the 
tube was built into the tube rotor in a tilted position and rotated continuously 
at 12 rpm for 35 days with medium being sampled and exchanged every 72 
hours. Gas exchange is supported by the aerated filter cap of the tube. The 
motion generated in the aerated tube is illustrated in Figure 40. The cell-
scaffold construct is continuously gently swirled in the medium in a rotating 
manner when tilting upwards and downwards with the whole bulk of the 
medium volume flushing through the cell-scaffold construct ensuring nutrient 
and oxygen delivery to cells deep within the interior of the scaffold. 
 
 
 
 
 
 
 
 
 
 
Figure 39 Schematic illustration of the generated movement in the tilted
rotating bioreactor system. The medium is swirled in a rotating manner in addition
to being gently tilted from one side of the tube to the other. 
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suFigure 40 The tilted rotating cultivation system. (A)-(D) show the various
positions of the aerated vessel during the dynamic cultivation. The cell scaffold
construct is continuously exposed to a tilting and rotating motion with the medium
flushing nutrients into and around the construct.  -79- 
.5.3.  The Fixed Bed Perfusion Bioreactor System 
 bioreactor system consists of individual bioreactors, connected in a group 
hree, to a control unit (mcU 2000, Medorex, Bovenden), which is further 
nected to a computer with LINUX based control-software (mfs, Medorex), 
bling network connection and exchange (Figure 41). 
B A 
igure 41 The fixed bed perfusion bioreactor assembled in the laboratory. (A)
o control and gas mixing units, each connected to a computer and a group of three
oreactors supplying each bioreactor with a constant gas mixture. Each bioreactor in turn
 connected to three pumps a fresh medium supply bottle, a waste bottle and kept at 37°C
rough a water jacket. (B) A close up of one bioreactor showing the various ports, gas
pply and sampling port in front. 
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A schematic diagram of a bioreactor system is shown in Figure 42 (adapted 
from Barthold, 2003). Each bioreactor consists of a cylindrical glass vessel with 
connectors to a temperated water bath, maintaining the bioreactor at 37ºC 
throughout the cultivation period. Inside the outer glass vessel, an inner 
conical glass vessel contains the cultivation medium and the scaffold perfusion 
chamber. The cultivation medium is continuously mixed through a magnetic 
stirrer at 120 rpm. Both vessels are screwed to and sealed with the reactor lid, 
which contains ports for temperature, dissolved oxygen and filling level 
sensors. The port in the middle connects the perfusion chamber to a peristaltic 
pump (1), which draws medium out of the cultivation reservoir through the 
scaffold chamber and back into the cultivation reservoir (inner vessel) at 0.2 
ml/min. The perfusion chamber was designed to have a conical shape with 
minimized dead space in the upper part, directing the flow perfusion path 
through the scaffold and not confined to running down only at the edges 
surrounding the cell-scaffold construct (Barthold, 2003). 
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Balance
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Bottle
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temperature, filling level
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2
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Fur
me
con
botFigure 42 Schematic Illustration of the fixed bed perfusion bioreactor 
adapted from Barthold (2003). ther, two more pumps were connected to the ports on the lid as well. The 
dium input pump (2) connected to the fresh medium reservoir set at a 
tinuous rate of 7 µl/min and a peristaltic pump connected to the waste 
tle (3), which is set to pump upon receiving a signal from the filling level 
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sensor. The pumps are connected to the control computer via RS-232 serial 
ports. The sensors were linked to the digitally controlled measurement and 
control unit via connecting cables. Therefore, the control unit is able to 
measure and monitor the temperature and dissolved oxygen. The station 
allows the mixing of air, oxygen, carbon dioxide and nitrogen in preset 
proportions. For all experiments in this study, a constant mixture of gas 
containing 20% dissolved oxygen was supplied through one of the ports on the 
bioreactor lid. Sampling can be performed continuously through a sampling 
port without stopping the cultivation (Figure 41B).  
The scaffold-chamber was manufactured from PEEK™ (polyarylether-ether-
ketone) as well as the ports and the lid. PEEK™ can withstand heat 
sterilization and offers the advantage of being molded easily into different 
sizes and shapes, allowing the cultivation of different shapes of biomaterials 
(Figure 43). Figure 43B shows the medium outlet boring at the bottom of the 
scaffold perfusion chamber through which medium flows out after being 
pumped in through the medium inlet connected to the lid of the cultivation 
vessel.  
 
B A 
Figure 43 Photomicrographs showing the PEEK™ scaffold chamber. (A)
custom built for three different biomaterial shapes and (B) the outlet boring at the
bottom of the chamber through which medium flows  out into the medium reservoir of
the  bioreactor.  
 
 
 
 
 
 
 
 
Prior to a cultivation experiment, the bioreactor was assembled and heat 
sterilized at 115ºC for 20 minutes. The freshly seeded cell scaffold construct 
was first cultured statically for 24 hours for complete cell adherence to occur in 
an aerated 50 ml tube with 30 ml osteogenic medium. Subsequently the 
bioreactor system was placed in a laminar flow hood to unscrew the perfusion 
chamber and carefully load it with the cell-scaffold construct. For all 
experiments, the following parameters were chosen: perfusion rate 0.2 ml/min, 
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medium input rate (7 µl/min) and partial oxygen pressure of 20% (Barthold, 
2003). 
 
3.2.6. Alkaline Phosphatase Determination in Cell-Scaffold Constructs 
 
For alkaline phosphatase analysis, cell-scaffold constructs were harvested at 
predetermined time points, washed with 1x PBS and stored at -70ºC. The 
supernatant was sampled over the 35-day cultivation period as well and stored 
at -20ºC until assayed. For the analysis, the constructs were crushed using a 
disperser (Ultra Turrax® T 25) in 1 ml 0.1% (v/v) Triton X-100 solution 
(Meinel, 2004b) for cell lysis. The resulting lysate was then clarified by 
centrifugation (10 minutes at 800rpm) and the supernatant was assayed for 
ALP by using the biochemical assay from Sigma, based on the conversion of 
p-nitrophenyl phosphate to p-nitrophenol in the presence of alkaline 
phosphatase as described in chapter 2 (section 2.2.10.). Briefly, 50 µl of the 
supernatant were mixed with 50 µl of the reagent and incubated for 30 
minutes at 37ºC. The production of 
p-nitrophenol was measured at 405 nm. Alkaline phosphatase specific activity 
was expressed as milli-units per milligram of protein (mU/mg). Samples were 
measured in at least doublets. 
 
3.2.7. Total Protein Determination in Cell-Scaffold Constructs 
 
For the determination of total protein, the cell lysate (prepared as described in 
the above section) was assayed with the Micro BCA™ protein assay kit 
(section 2.2.4, chapter 2.). Briefly, 100 µl of the cell lysate supernatant was 
mixed with the protein assay reagent and incubated for 2 hours at 37ºC. 
Samples were measured in at least doublets. 
 
3.2.8. WST-1 Assay for Cell-Scaffold Constructs 
 
For the assessment of cell viability and proliferation of human osteogenic cells 
in conjunction with a PLGA/CaP scaffold, WST-1 was measured by adapting 
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the colorimetric assay described earlier in chapter 2 (section 2.2.3.) for the two 
dimensional culture. The cell-scaffold constructs were removed from the 
culture system at predetermined time points, cut in half with a surgical blade, 
and washed twice with 1x PBS. They were then placed in 15 ml tubes and 
immersed with 2 ml WST-1 working solution (1:10) and incubated at 37°C for 2 
hours. A naked scaffold without cells was incubated as well for a negative 
control. 75 µl of the supernatant were pipetted into 96-well plates and the 
absorbance of the supernatant was measured at 450nm in at least doublets, 
subtracting the control value of the non-seeded scaffold. 
 
3.2.9. Histological Analysis 
 
For histological processing, the constructs were washed with 1x PBS and 
divided in the centre with a surgical blade into two halves where necessary. 
The constructs were fixed in 4% buffered paraformaldehyde solution (PFA, see 
Appendix II) overnight at 4ºC. If not processed immediately, they were 
immersed in 1x PBS and stored at 4ºC. 
For paraffin embedding, the tissue samples were put into appropriate plastic 
cassettes and placed into an automatic paraffin infiltration instrument 
(Shandon Citadel™ TissueProcessor 1000) for the ease of handling several 
samples simultaneously and to ensure complete and thorough infiltration of 
the porous biomaterial. The program chosen included the following steps: the 
tissue samples were first washed in water for 2 hours, dehydrated in 
successive ethanol washes (70%, 80%, two changes of 96%), each wash for one 
hour. Then transferred to 100% ethanol (2 washes) before they were immersed 
in a xylene substitute (Histoclear™) for two washes, each lasting one hour. 
Then the fixed cell-scaffold constructs were finally immersed into liquidized 
paraffin at 56ºC for two subsequent immersions, each for two hours. The 
paraffin infiltrated cell-scaffold constructs were then taken out of the 
embedding machine to be molded into readily sliceable paraffin blocks using 
an embedding instrument (Histocentre 2, Tissue Embedding System, 
Shandon) by carefully casting warm liquid paraffin onto the tissue samples, 
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placed in stainless steel moulds. The resulting paraffin blocks were left to 
congeal on a cooling plate (CP-4, Kunze Instruments) and released from the 
moulds for sectioning. 4, 10 and 20 µm thick tissue sections were cut with a 
rotary microtome (Shandon 0325), horizontal to the front face of the disc. The 
transverse sections were stretched in a pre-warmed (45ºC) flotation bath 
(Histotherm water bath Hir-3, Kunz Instruments), filled with distilled water to 
remove wrinkles and distortions created during the sectioning.  
The sections were mounted on poly-L-lysine coated slides to improve adhesion 
(see Appendix II). The sections were then left on a thermo hot plate (Shandon) 
at 50°C to avoid wrinkles. Finally, sections were left to dry in an oven at 60°C 
for 30-40 minutes The tissue section mounted slides were dried at room 
temperature, first by standing them up vertically and allowing them to drain 
to be then transferred to an oven for 30-40 minutes at 60ºC. 
 
3.2.10. Scanning Electron Microscopy 
 
For topographical morphological analysis and to analyze cell attachment and 
detect collagen fibril formation, cultivated cell-scaffold constructs were washed 
with 1x PBS and then fixed in a mixture of 2% glutaraldehyde and 5% 
formaldehyde in cacodylate buffer (see Appendix II) for one hour at 4ºC. 
Samples were washed with 1x PBS and stored in 1x PBS at 4ºC until further 
processing by the department of Microbiology, Helmholtz Centre for Infection 
Research (Braunschweig). The fixed samples were dehydrated through the 
following series of acetone concentrations: 10%, 30%, 50%, 70%, 90%, and 
100%, each for 15 minutes at 4ºC with the final dehydration step in 100% 
acetone at room temperature (repeated 2-3 times). Samples were then 
critically dried and sputtered with gold to be then analyzed with the electron 
microscope DSM 982 Gemin (Zeiss, Jena).  
 
3.2.11. Haematoxylin & Eosin, van Gieson and Toluidine Blue 
 
Prior to staining, sections were de-paraffinized and re-hydrated to enable dye 
uptake. De-paraffinization was performed by dipping the sections in two 
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consecutive washes, each for 10 minutes in a xylene substitute (Histoclear™), 
followed by 100% ethanol, 90% ethanol, 80% ethanol, 70% ethanol, each step 
for 5 minutes. Sections were then rinsed in distilled water (1-5 minutes) for re-
hydration and stained with either van Gieson, toluidine blue or with 
haematoxylin (see Appendix II for detailed staining procedure). Sections were 
viewed under a BX51 System Microscope (Olympus, Tokyo, Japan) and 
photomicrographs were taken with ColorView IIIu digital camera, U-CMAD3 
(Soft Imaging System, Olympus, Muenster). 
 
3.2.12. Immunohistochemical Staining and Confocal Laser 
Scanning Microscopy of Paraffin Sections 
 
To perform immunohistochemical staining on paraffin sections, a heat induced 
epitope retrieval step was performed using an antigen retrieval solution 
(DakoCytomation, S1700) according to the instructions of the manufacturer. 
Briefly, sections were de-paraffinized (section 3.2.11.) and after the re-
hydration step in distilled water, the sections were immersed into a glass 
trough filled with the pre-heated target retrieval solution (95-99ºC) and 
incubated for 40 minutes in a water-bath at 95-99ºC. The solution was allowed 
to cool and the sections were then rinsed in 0.02% Triton X for 10 minutes at 
room temperature for permeabilization. Confocal imaging was performed on 
the sections with an LSM META510 confocal scanning laser system (Zeiss, 
Jena) on an Axiovert 200M microscope (Zeiss, Jena). Images were viewed and 
edited using LSM 5 Image Browser (Zeiss, Jena). 
 
3.2.12.1. Collagen Type I  
 
Permeabilized sections were incubated with 2% blocking goat serum (in 1x 
PBS), which decreases subsequent non-specific binding. The primary 
monoclonal mouse IgG1 anti-human collagen I antibody was applied at 1:200 
in 1x PBS for one hour and then washed with 0.02% Triton X three times for 
one minute, then 3 minutes and after that for 10 minutes. The antibody 
recognizes the native (helical) form of human collagen type I and shows no 
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cross reactivity with other collagen types (e.g. II or III). The secondary 
antibody goat-anti-mouse conjugated to Alexa 488 was applied for 30 minutes 
in a humid chamber to visualize the collagen-I fibrils green upon excitation. 
Sections were washed with 1x PBS three times (1 min, 3 min and 10 minutes). 
For actin staining, the sections were incubated with Alexa 546 labeled 
phalloidin at 1:400 in 1x PBS, visualizing the cytoskeletal actin component in 
red. Nuclei were counterstained with DRAQ5™ at 1:100 in PBS for 15 
minutes, staining the DNA blue and then the section was washed again three 
times in 1x PBS. Slides were mounted in glycerol gelatin. As a negative 
control, a section was treated as above, without administration of the primary 
antibody and replacing it with 1x PBS.  
 
3.2.12.2.  Connexin 43 
 
Triton X-100-permeabilised samples were blocked with 2% goat serum and 
then incubated with the primary monoclonal rabbit antibody against human 
connexin 43 at 1:2000 in 1x PBS followed by the secondary antibody Alexa 488-
conjugated goat-anti-rabbit IgG, to later visualize connexin 43 positive sites in 
green after excitation. Sections were thereafter treated as mentioned in the 
section above. 
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3.3. Results and Discussion  
 
3.3.1. Characterization of the Biomaterial: the PLGA/CaP Scaffold  
 
The surface morphology of the scaffold alone was analyzed by scanning 
electron microscopy, which revealed micropores (< 100 µm) as small as 50 µm 
in size to macropores of up to 2000 µm large (Figure 44). A highly porous 
scaffold was chosen as the cells were meant to migrate into the whole material 
and cover the scaffold. 
 
 B A 
 
 
 
 
 
 
 
 
 
 
Figure 44 SEM micrographs of the naked surface (without cells) of the
PLGA/CaP scaffold. (A) Micropores as well as macropores in an interconnected
network mimicking trabecular bone in structure ranging in size from 50 to 2000 µm.
Scale bar = 2mm. (B) Pores at a larger magnification. Scale bar= 500 µm. 
 
 
 
 
 
3.3.2. Cell Growth and Differentiation on Surface Modified 
PLGA/CaP Scaffolds: Determination of the Optimal Surface 
Coating 
 
Trabecular bone derived cells were cultured on PLGA/CaP scaffolds (5x106 
cells/scaffold) coated with either collagen Type I, fibronectin, medium or 
human serum for 7 days in expansion medium (ZKT-1 basal medium+15% 
human serum). Best proliferation, as was indicated by the highest protein 
content and highest metabolic activity, was achieved with human serum 
coating (Figure 45A and B). 
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The effect of the surface coating was further tested on differentiation of the 
osteogenic cells by measuring the levels of newly produced collagen type I after 
6 and 10 days of culturing the cell-scaffold construct in osteogenic medium. 
The quantitative determination of CICP levels in the supernatant revealed 
higher collagen I production rate by cells cultured on a human serum treated 
surface (Figure 46). 
 
 
Collagen Fibronectin Medium Serum 
0
10
20
30
40
50
60
70
80
90
C
IC
P,
 n
g/
m
l
Surface Coating
 Day 6
 Day10
 
 
 
 
 
 
 
 
 
 
 
F
b
r
b
h
 
 
 
 igure 46 The effect of surface coating on differentiation of human trabecular
one derived cells measured by collagen Type I levels (CICP). The bars in grey
epresent CICP levels after 6 days of treatment in osteogenic medium and the black
ars after 10 days. Osteoprogenitors cultured on human serum coated scaffolds yielded
ighest collagen I levels. Error bars, means ± standard deviation for n=2. Figure 45 Total protein content and cell viability of human trabecular bone
derived cells in conjunction with PLGA/CaP scaffolds coated with either
collagen, fibronectin, medium or human serum. Cell-scaffold constructs were
cultivated statically for 7 days in expansion medium (ZKT-1 basal medium supplemented
with 15% human serum and 1% Pen/Strep). (A) Total protein content was highest for
human serum coated scaffolds compared to the other surface coatings. The highest vitality
was as well measured for PLGA/CaP scaffolds coated with human serum (B). Error bars,
means ± standard deviation for n=2 scaffolds, each measured in at least triplets. -88- 
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Note : PLGA/CaP scaffolds were also coated with fetal bovine serum, 
displaying very similar results to human serum coating, leading to improved 
attachment and proliferation of cells compared to the other surface coatings 
(data not shown). 
 
3.3.3. The Tilted Rotating Bioreactor 
 
In the tilted rotating bioreactor, the cell-scaffold construct was kept in 
continuous motion at 12 rpm. The tilted rotating movement generated 
fluctuations in the medium flow around the free falling cell-scaffold construct, 
exposing the cells to improved mass transfer and low levels of shear stress.  
 
3.3.3.1. Three Dimensional Osteogenic Differentiation in the Tilted 
Rotating Bioreactor System: Alkaline Phosphatase Activity 
 
Alkaline phosphatase activity of the cell-scaffold construct was determined 
throughout the 35 day cultivation period in osteogenic medium (Figure 47). 
Cells cultured in the tilted rotating bioreactor appeared to have lower initial 
alkaline phosphatase activity on day 7 and 14 compared to the static culture, 
followed by a steep increase peaking on day 27 (12.89 ± 0.25 mU/mg). The 
static culture reached a maximum value as well but at an earlier time point 
(5.29 ± 0.03 mU/mg) on day 14. Cells in both culture modes displayed higher 
ALP activity than the control cultures cultivated statically in expansion 
medium (ZKT-1 basal medium + 15 % human serum) without the addition of 
osteogenic factors. The control culture is represented as hatched bars in Figure 
47.  
The reciprocal relationship between the decline in proliferative activity and 
the subsequent matrix maturation and eventual mineralization, with an 
enhanced expression of alkaline phosphatase following the down regulation of 
collagen I production, was elaborated in Chapter 2 on two dimensional 
cultures. Translating this to the three dimensional cultivation, the later peak 
in ALP activity for cells cultivated dynamically in the tilted rotating system 
could be explained by still ongoing proliferation (matrix formation, i.e. ongoing 
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collagen I production) until some time point between day 14 and day 27, where 
matrix maturation took place.  
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 igure 47 Alkaline phosphatase activity of human trabecular bone derived
ells over 35 days of culture on PLGA/CaP scaffolds in osteogenic medium.
he ALP activity of cells after 7, 14, 27 and 35 days cultured in the tilted rotating
ystem under dynamic conditions (dark black bars) was significantly higher than
ells cultured under static conditions (grey shaded bars) over time. The hatched bars
epresent human trabecular bone derived cells cultured on PLGA/CaP scaffolds in
xpansion medium without the addition of osteogenic factors. Error bars, means ±
tandard deviation for n=3. .  Viability of the Cell-Scaffold Construct: WST-1 an Indicator for 
Proliferation and Metabolic Activity of the Cells 
tion was determined on both day 7 and day 14. Human trabecular bone 
 cells cultured dynamically in the tilted rotating system demonstrated 
WST-1 values corresponding to higher metabolic activity and thus 
y than those cultivated under static conditions (Figure 48). Further, the 
 absorption for cells cultivated statically showed a lower value on day 14 
 0.04) compared to day 7 (1.23 ± 0.03), coinciding with a peak in specific 
e phosphatase activity on day 14 (Figure 47), while the dynamically 
ted cells in the tilted rotating bioreactor system showed an increase 
ay 7 (1.34 0.06) to day 14 (1.62 ± 0.052). This being in accordance with 
er peak in alkaline phosphatase activity noted above (on day 27 or at a 
oint between day 14 and day 27), indicating a later onset of 
tiation probably due to still ongoing proliferation. 
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Figure 48 WST-1 of human trabecular bone derived cells cultured in
conjunction with a PLGA/CaP scaffold after 7 and 14 days of culture in
osteogenic medium as a function of culture conditions. The cell-scaffold
construct cultivated in the tube rotor under dynamic conditions (dark black bars)
demonstrated higher absorption values than those in the static system (grey shaded
bars). Error bars, means ± standard deviation, n=2-3 scaffolds each measured in at
least triplets. 
 
 
 
 
 
 
3.3.3.3. Histological Analysis: Cell Growth Pattern and Distribution as 
a Function of the Cultivation System  
 
To reveal the growth pattern and distribution of the human trabecular bone 
derived cells in and througout the PLGA/CaP scaffold, paraffin transverse 
sections at similar depths (approx. 200 µm deep) were stained with 
haematoxillin and eosin for a general histological overview. Section from 
constructs cultivated in the tilted rotating bioreactor system under dynamic 
conditions were compared to statically cultivated constructs after 35 days of 
cultivation in osteogenic medium. From the  representative section in Figure 
49, an even cell distribution towards the interior of the PLGA/CaP scaffold was 
achieved by culturing the cell-scaffold construct dynamically with cells 
migrating and proliferating as deep as 5 mm from the outer scaffold surface 
deep into the pores (Figure 49A). While the static cultivation led only to cell 
acculumation at the rim of the scaffold, leaving the interior empty (Figure 
49B).  
To further elaborate the intensive and uniform cell ingrowth of the human 
trabecular bone derived cells, cultured in the tilted rotating system, a cut out 
of a transverse section, representing the central part of the scaffold was 
investigated closer (Figure 50). An overview staining with haematoxylin and 
eosin shows completely filled pores throughout the cross section, revealing 
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migratory and proliferative abilities of the human trabecular bone derived 
cells throughout the whole PLGA/CaP scaffold. 
 
 
B A 
 
 
 
 
 
 
 
 
 
 
 Figure 49 Micrographs of paraffin transverse cross sections for human
trabecular bone derived cells cultured in conjunction with a PLGA/CaP
scaffold for 35 days in the tilted rotating bioreactor versus static culture.
Haematoxylin and eosin staining (10µm thick section) showing cell distribution (pink
areas) in the PLGA/CaP scaffold (dark areas) after cultivation (A) in the tilting rotating
bioreactor under dynamic conditions and (B) under static conditions. (Original
magnification: x 12.5; scale bar 2 mm). 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 Micrograph showing a cut out of the central part of a transverse
section for human trabecular bone derived cells cultured in conjunction with a
PLGA/CaP scaffold for 35 days in the tilted rotating bioreactor.  A close-up of a
Haematoxylin and Eosin stained cross section showing ubiquitous cell and tissue
distribution (pink areas) in the PLGA/CaP scaffold (dark grey flecks). (Original
magnification: x 4; scale bar 5mm). 
 
 
 
 
 
3.3.3.4. Connective Tissue Staining: Identifying de novo Formed Tissue 
with van Gieson; Tilted Rotating vs. Static Culture.  
 
To further examine the trabecular bone derived cells cultured on the 
PLGA/CaP scaffold in the tilted rotating system and the newly laid down 
tissue, paraffin cross sections were stained with van Gieson. A connective 
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tissue stain known to react with collagen and osteoid, staining these violet or 
reddish (Bancroft and Gamble, 2001). Cells were observed to completely fill the 
pores, laying down a fibrous extracellular matrix in an organized manner, with 
cells embedded within this matrix, aligned to the flow direction (Figure 51A 
and B). In Figure 51C, the cells can be seen to connect to each other through 
filapodia (long cellular processes) forming a network through which the cells 
can communicate, adhering apparently very strongly to the PLGA/CaP surface, 
as cells are seen to almost invade the biomaterial (indicated by the arrow). 
Examining the cells closer at higher magnification (x40) in Figure 51D, the 
typical osteocytic cell shape (van der Plas and Nijweide, 2005) could be 
identified at several locations. 
 
CF 
D *
OC 
B 
*
*
A 
*
*
*
C 
*
Figure 51 Van Gieson staining of human trabecular bone derived cells seeded
on PLGA/CaP scaffolds after 35 day cultivation in the tilt-rotating bioreactor
system. (A) A representative cross section shows completely filled pores with positive
van Gieson staining the intercellular spaces, indicating de novo laid down tissue
matrix. Cell nuclei stained dark violet and the PLGA/CaP biomaterial stained pink is
indicated by the asterisk*. Original magnification: x100; scale bar 200µm. (B) Higher
magnification of the rectangular area in A, cells organising themselves in the
collagenous rich matrix, squeezing through a pore alongside the medium flow. Original
magnification: x200, scale bar 100µm. (C) A network of cells, in contact with each other
through short processes and attaching very strongly to the PLGA/CaP surface as
indicated by the arrow. Original magnification: x200, scale bar 100 µm. (D) Osteocyte
like cells with their branching filapodia could be identified at several locations.
Original magnification: x400, scale bar 50 µm. OC= Osteocyte-like cell. CF= Collagen-
like fibres.  
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Van Gieson staining of cells cultured under static conditions on the other hand, 
revealed a less organized appearance (Figure 52). Cells were only observed at 
the rim of the PLGA/CaP scaffold with several layers of cells concentrated on 
the edges of the scaffold, forming a tissue-like capsule around the biomaterial 
~200µm thick (Figure 52A). The connective tissue staining confirmed, that cell 
ingrowth only took place at the peripheries filling the first row of pores faced 
by the cells, without able to invade deeper towards the interior. 
Morphologically, the cells appeared to acquire a weak and brittle appearance 
the further away the cell was from the edge of the scaffold. The edges of the 
section in Figure 52A are shown at a higher magnification in Figure 52B and C. 
Pink stained intercellular space indicating newly laid down collagenous matrix 
was also observed to a lesser extent than in the tilted rotating system. 
 
Figure17 Van Gieson staining of human trabecular
bone derived cells seeded on PLGA/CaP scaffolds after
35 day cultivation under static conditions. (A) An outer
thick capsule of cells surrounding the scaffold leaving the
interior empty. Original magnification x 1.25; scale bar=2mm.
(B) Higher magnification of section (A) showing cells grown in
dense layers predominantly concentrated at the rim. *
=PLGA/CaP scaffold. P=pore. CL=cell layer. Original
magnification: x4; scale bar= 500µm. (C) Lose unorganized
cell structures (pointed to by the arrow) the further away
from the edges of the scaffold. Original magnification: x10;
scale bar = 200 µm. 
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In Figure 53, the results of the two three-dimensional cultivation models are 
summarized. Representative transverse cross sections of the upper, central 
and lower part of the cylindrical PLGA/CaP scaffold after 35 days cultivation 
in the tilted rotating bioreactor system are compared to static cultivation. In 
case of the tilted rotating system, cells reached almost 5000 µm below the 
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surface with ostecyte-like cells entrapped within the collagenous rich laid 
down extracellular matrix, while the cells in the case of the static system are 
mostly concentrated at the peripheries of the scaffolds near the edges, leaving 
the interior empty at all depths.  
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 igure 53 Representative transverse sections of paraffin embedded human
rabecular bone derived cells cultured in conjunction with a PLGA/CaP scaffold
or 35 days in osteogenic medium either under static or dynamic conditions (tilting
otating) at different depths within the scaffold. (A-D) Representing static culture. (E-
) Tilting rotating culture. A and E represent the upper part of the cylindrical PLGA/CaP
caffold. (B,C) and (F,G) the central part and (D) and (H) the bottom part of the scaffold.
ery high cell densities were found near the edges in all cross sections cultivated under
tatic conditions. While the dynamic cultivation model led to ubiquitous cell distribution
hroughout the scaffold. Original magnification: x 12.5. Scale bar= 2 mm. H&E staining:
,B,E,F. Toluidine blue staining: C,D,G,H. -95- 
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3.3.3.5. Connexin 43 Immunohistochemistry; Gap Junctions in 
Dynamically Cultivated Cell-Scaffold Constructs 
 
To confirm the osteogenic character of the in vitro connective tissue that was 
identified histologically to contain networks of cells communicating through 
long slender processes, paraffin embedded sections were stained with an 
antibody specific for human connexin 43.  
Observations under the confocal microscope revealed differentiated osteocyte-
like cells organized in a network demonstrating strong positive staining with 
anti- connexin 43 (Figure 54). Stained green dots indicate two adjacent cells 
communicating through gap junctional channels made up mainly of connexin 
43. The cell nuclei were stained with DRAQ5™ (appearing blue) and the 
cytoskeleton stained red with Phalloidin 546. 
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Figure 54 Connexin-43 immunohistochemical staining of human trabecular
bone derived cells cultured in conjunction with a PLGA/CaP scaffold for 35
days in the tilting rotating bioreactor system. (A) At cell-cell contact, positive
staining of the gap junctional protein Connexin-43 was identified and visualised as
green fluorescent dots with Alexa 488 as a secondary antibody. Some points of contact
are pointed to by the arrows. Nuclei stained blue with DRAQ5™ and cell bodies were
stained red with Phalloidin 546. The red autofluorescence of the PLGA/CaP
biomaterial can be seen at several spots indicated by the asterisk.(B) represents a
cropped region of the upper left corner in (A).(Original magnification : x400).  
 
3.3.3.6. Scanning Electron Microscopy of the Cell-PLGA/CaP 
Constructs after Dynamic Cultivation in the Tilted Rotating 
Bioreactor (tiltator) vs. Static Cultivation 
 
Scanning electron microscopy of the cell-scaffold constructs after 35 days 
cultivation in osteogenic medium (Figure 55) strengthened the observations of 
the paraffin histology described earlier. A thin layer of extracellular matrix 
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and of cells as well as collagen fibrils appeared under static conditions (Figure 
55A). In contrast, in the tilted rotating system, a continuous thick fibrous 
matrix layer was detected with clusters of crystal-like structures bulging out 
and aligning the collagen fibrils (Figure 55B). The bulges were also detected in 
the statically cultivated scaffolds but occurring less frequently and smaller in 
size. Similar structures were observed in two dimensional cultivation of 
osteogenic cells where these accumulations stained positive with alizarin red, 
calcein and von Kossa, indicating mineralization, the final stage of the 
osteoblastic phenotype (chapter 2 section 2.3.6.4.). 
 B A 
 
 
 
 
 
 
Figure 55 Scanning electron micrographs of human trabecular bone derived
cells cultured in conjunction with a PLGA/CaP scaffold for 35 days in
osteogenic medium. (A) In static culture, cells formed a thin layer of extracellular
matrix with lose collagen fibrils while (B) in the dynamic tilting rotor cultivation, a
thick fibrous organised layer of collagen fibrils was detected. Crystal-like
accumulations were detected in both culture models, however, with them being smaller
and less frequent in the static cultivation model. 
 
3.3.3.7.  Discussion of the Novel Tilted Rotating Bioreactor System 
 
The choice of using the tilted rotating bioreactor system was inspired by the 
Wave Bioreactor® design (GE Healthcare Bioscience Bioprocess Corp., New 
Jersey, USA), which is simply made up of a sterile plastic bag on a rocking 
base developed by Vijay Singh in 1996. Waves are generated inside a bag by 
rocking it back and forth at a resonant frequency with the direction of flow 
being reversed, each rock leading to a turbulent wave motion providing 
uniform mixing, with oxygen being transferred from the headspace into the 
liquid phase. This motion appeared to be optimal for production of 
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recombinant proteins for instance, replacing steel bioreactors and enabling the 
use of a disposable system for cultivation of cell volumes up to 500 liters. 
In translating this idea for use in tissue engineering, and in trying to simulate 
the wave-like turbulent motion to provide a scaffold with gentle uniform 
mixing, enabling cells to migrate deep into the pores, the simple set-up of the 
tube rotating system seemed to be ideal for investigating, whether a gentle 
tilting combined with rotation improved spatial and uniform cell distribution 
and extracellular matrix formation, especially as the use of rotating 
bioreactors has been shown to improve the formation of bone and cartilage-like 
tissue in vitro. 
Not only was the spatial distribution of cells and their produced extracellular 
matrix improved by the combined tilting and rotating movement, but cells 
cultivated in this system also showed significantly higher alkaline 
phosphatase activities than cells in stationary culture, indicating improved 
osteogenesis. As exposing the cell-scaffold construct to the tilted rotating was 
the only variable introduced into the three dimensional cultivation mode, it 
was clearly demonstrated how the right mechanical stimulation improves in 
vitro bone formation. 
Moreover, cells cultivated in the tilted rotating system were shown to actively 
communicate with each other through gap junctional proteins, the same gap 
junctions expressed by osteocytes and osteoblasts in vivo (connexin 43). These 
results are very promising, as the integration of a tissue engineered construct 
with an already “social” network of cells (or biosynthetically active cells), 
similar to the site of repair, is very probable to actually lead to defect 
regeneration. 
Static cultivation on the other hand, only leads to formation of a thick layer of 
cells at the peripheries of the scaffold, leaving the interior empty the limiting 
factor being nutrient diffusion and this being in agreement with other studies 
(Goldstein et al., 2001).  
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3.3.4. The Fixed Bed Perfusion Bioreactor System 
 
The suitability of the fixed bed perfusion bioreactor for cultivating human 
trabecular bone derived cells in conjunction with a PLGA/CaP scaffold is 
demonstrated in the following sections.  
 
3.3.4.1. Early Osteogenic Differentiation Markers in the Perfusion 
Bioreactor: Soluble Alkaline Phosphatase and Collagen I 
Formation 
 
Advantages of the fixed bed perfusion bioreactor include the possibility of 
online sampling throughout the cultivation period without terminating the 
culture. Samples were drawn through the sampling port and concentrations of 
the C-terminal propeptide of collagen Type I, CICP, as well as soluble alkaline 
phosphatase were determined. The classic rise and fall pattern in alkaline 
phosphatase was observed in the perfusion culture to occur, peaking at around 
day 14 and coinciding with the fall in collagen type I production rate as 
indicated by Figure 56. CICP production was initially measured to be very 
high and was observed to decrease with time, indicating the initial active 
phase of osteogenic cells laying down new extracellular matrix until the cells 
transit into the mineralization phase.  
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 Figure 56 Early osteogenic differentiation markers in human trabecular bone
derived cells cultivated in conjunction with a PLGA/CaP scaffold in the fixed
bed perfusion bioreactor. Alkaline phosphatase activity reached a maximum after
13 days (red line) coincident with the decline in C-terminal propeptide of collagen type
I,  (black line) indicating the transition into the mineralisation phase. Error bars,
means ± standard deviation. n=3.-99- 
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3.3.4.2. Cell Proliferation of the Cell-Scaffold Construct Cultured in 
the Perfusion Bioreactor; WST-1 and Protein Content. 
 
The viability of the cell scaffold-construct was assessed with the WST-1 test 
throughout the cultivation period (Figure 57). The increase in absorption 
values from day 5 to day 10 potentially indicates cells actively producing 
extracellular matrix proteins, typical of the first phase in osteogenic 
differentiation, the matrix formation phase. The absorption levels reached a 
maximum and leveled out thereafter. This coinciding with the peak in alkaline 
phosphatase activity, indicating transition of the cells into the differentiation 
phase with high viability maintained. 
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Figure 57 Viability of human trabecular bone derived cells in conjunction
with a PLGA/CaP construct throughout 20 days of culture in osteogenic
medium in the fixed bed perfusion bioreactor. Viability of the cells on the scaffold
was determined with the WST-1 test with an increase in absorption from day 5 until
day 10, indicating ongoing proliferation and reaching a plateau thereafter. Error bars,
means ± standard deviation. n= 2 scaffolds with each measured in at least triplets. 
 
Total protein determination of the cell-scaffold constructs cultivated in the 
fixed bed perfusion bioreactor augmented this further (Figure 58). The clear 
increase in protein content in the initial cultivation phase (form day 7 to day 
14) indicates actively proliferating cells laying down extracellular matrix and 
reaching constant levels thereafter. 
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Figure 58 Total protein content in the cell-scaffold construct cultivated in the
fixed bed perfusion bioreactor over 35 days cultivation in osteogenic medium.
Total protein (mg) was observed to increase in the initial cultivation phase up until day
14, reaching a plateau thereafter. Error bars, means ± standard deviation. n=2
scaffolds with each measured in at least triplets. 
 
 
 
 
 
 
 
 
 
 
3.3.4.3. Cell and Tissue Distribution Pattern throughout the PLGA/CaP 
Scaffold in the Fixed Bed Perfusion Bioreactor 
 
Paraffin transverse cross sections at a depth ranging between 100 to 5000 µm 
were analysed to investigate cell and tissue distribution within the PLGA/CaP 
scaffold after 35 days cultivation in the fixed bed perfusion bioreactor. A 
representative section at approximately 1000 µm below the surface of the 
biomaterial was stained with Toluidine Blue and is shown in Figure 59. 
Surprisingly, only scattered patches of cells and their matrix distributed non 
uniformly at the periphery and in the centre of the scaffold could be detected.  
 
Figure 59 Representative transverse
section of human trabecular bone
derived cells cultured in conjunction
with a PLGA/CaP scaffold in the fixed
bed perfusion bioreactor for 35 days
in osteogenic medium. Toluidine blue
stained patches of cell and matrix were
detected scattered throughout the
PLGA/CaP porous network. Original
magnification: 12.5; scale bar=2mm. 
 
 
 
 
 
 
 
Although, cultivation in the perfusion bioreactor only led to the formation of 
patches of tissue scattered throughout the scaffold, cells did manage to migrate 
as deep as 5 mm towards the center, away from the surface, indicating that 
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continuous perfusion must have provided the cells with opimal nutrient and 
oxygen supply, keeping these cells vital for as long as 35 days.  
Stationary culture ,on the other hand, only led to cell distribution at the rim of 
the biomaterial, leaving the central core empty due to limted nutrient diffusion 
(Figure 60). Despite the thick and dense cell layer that was detected 
surrounding the biomaterial, cells did not leave the periphery and those that 
were detected below the surface only managed to migrate 200-400 µm with a 
rather necrotic appearance. 
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Figure 60 Micrographs showing an overview of a toluidine blue stained
transverse section for human trabecular bone derived cells cultivated
statically in conjunction with a PLGA/CaP scaffold for 35 days. (A) A
transverse section showing extensive cell growth around the scaffold and
metachromatic areas once these cells try to migrate deeper into the scaffold. Original
magnification: x12.5; scale bar =2mm. (B) Higher magnification from the edge of the
section in (A), showing a thick layer of cells around the scaffold intensely blue stained
and metachromatic purplish areas indicating changes in the cells and potentially in
their viability once trying to surpass the first pore wall of the biomaterial. Original
magnification: x100. Scale bar= 200µm. Asterisk *=PLGA/CaP scaffold, dark grey
flecks. 
 
A closer microscopical examination of the patches formed in the perfusion 
bioreactor, especially in comparison to cell-scaffold constructs cultivated under 
static conditions, revealed a remarkably organized and vital osteoblastic 
phenotype as opposed to the thin, necrotic appearance of cells cultured 
statically (Figure 61). The positive effect of the perfusion strain was clearly 
seen on cellular organization and morphology.  
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Figure 61 Toluidine blue staining of human trabecular bone derived cells
cultured in conjunction with a PLGA/CaP scaffold in the fixed bed perfusion
bioreactor versus static cultivation. (A)Transverse section at ~2000µm depth
revealing osteocyte-like cells communicating with each other and strongly adhering to
the PLGA/CaP surface (*) at adhesion points. Original magnification: x200; scale
bar=100µm. (B) Larger magnification of an area in (A) showing the typical osteocyte-
like stellate shape of one cell communicating through its processes with neighbouring
cells. Original magnification: x600; scale bar=20µm. (C) Statically cultivated cells at
~2000µm below the scaffold surface. Random cells with a rather necrotic cell
morphology. Original magnification: x200; scale bar=100µm. (D) A magnified close up
of an area of the section (C) showing a flattened cell shape. Original magnification:
x600; scale bar=20µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.4.4. Connective Tissue Formation in the Fixed Bed Perfusion 
Bioreactor; van Gieson Staining 
 
The bone-like matrix deposited by the osteogenic cells after 35 days cultivation 
in the perfusion bioreactor was characterized with van Gieson staining. 
Sections at depths between 1000-2000 µm from the top surface of the scaffold, 
revealed that cells were organized in a dense extracellular matrix made up of 
bundles of collagen fibrils filling the pores (Figure 62A). Furthermore, in the 
organized cell layers, at least two different cell types could be identified: 
osteoblast-like cells with a cuboidal morphology were observed at several 
locations organizing themselves in the matrix as well as more stellate-like 
shaped (Thi et al., 2003) cells with numerous long processes resembling 
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osteocytes (Figure 62D). These osteocyte-like cells were observed lining the 
scaffold surface and attaching strongly through focal contacts, offering strong 
adsorption points of the cellular plasma membrane to the biomaterial surface 
pointed to in Figure 62C. The focal adhesion contacts, can also be seen among 
the cells within the extracellular matrix in Figure 62D at a higher 
magnification.  
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shFigure 62 Van Gieson staining of human trabecular bone derived cells cultured
in conjunction with a PLGA/CaP scaffold in the process of bone tissue formation
in the fixed bed perfusion bioreactor. (A) Cells filling a pore laying down extracellular
matrix in ordered collagen bundles following the flow direction. CF=Collagen fibrils.
Original magnification: x200; scale bar=100 µm. (B) Osteocyte-like (OC) cells as well
osteoblast-like cells (OB) could be identified organizing themselves within the dense
extracellular matrix. Original magnification: x100; scale bar= 200 µm. (C) Osteocyte-like
cells strongly adhere to the surface of the PLGA/CaP biomaterial through local adhesion
points. Original magnification: x100; scale bar= 200 µm.(D) Enlargement of the boxed area
in (C) showing numerous osteocyte-like cells communicating with each other through their
long extended slender processes. Original magnification: x200; scale bar=100 µm.  The
PLGA/CaP scaffold is designated by an asterisk*.  e cell-biomaterial interaction demonstrated above by the organized cell 
yers and strong adhesion points through cultivation in the perfusion 
oreactor is in line with what was reported by Pavalko et al. (1998), who have 
udied the effect of fluid shear stress on focal adhesion points. They have 
own that fluid shear induced changes in actin organization (increased stress 
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fibers and focal adhesion development) and that cells respond to fluid flow by 
increasing their formation, so that the perfusion produced in the fixed bed 
bioreactor actually leads to cytoskeletal reorganization.  
 
3.3.4.5.  Immunohistochemical Staining of Collagen I and Connexin 43: 
de novo Bone-like Tissue Formation in the Fixed Bed Perfusion 
Bioreactor  
 
The mature osteoblastic phenotype of the cells cultured in conjunction with the 
PLGA/CaP scaffold was confirmed by detecting the bone specific markers: type 
I collagen and connexin 43 in paraffin embedded cell-scaffold constructs 
cultivated for 35 days in osteogenic medium in the perfusion bioreactor.  
Collagen fibrils of type I were detected within the matrix with an anti-human 
collagen antibody (Figure 63).  
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Figure 63 Type I collagen immunohistochemistry in paraffin sections of
human trabecular bone derived cells cultivated in conjunction with a
PLGA/CaP scaffold in the fixed bed perfusion bioreactor for 35 days in
osteogenic medium. (A) The matrix laid down by the cells stained positive with
anti Collagen type I visualised in green fluorescence by the secondary antibody
conjugated to Alexa 488, cell nuclei stained blue with DRAQ5™ and the cytoskeleton
is stained red with Phalloidin Alexa 546. (B) Negative control by omitting the
primary antibody on a parallel paraffin section.  Original magnification: x400; scale
bar=50µm.  
 
 
 
 
 
 
 
 
 
Further, gap junction-mediated cell-cell communication between the bone 
forming cells within the PLGA/CaP scaffold was detected through connexin 43 
immunohistochemistry. Representative transverse sections from the cell-
PLGA/CaP construct were immunostained with antihuman connexin 43 and 
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visualized with a secondary antibody conjugated to Alexa 488 as green dots, 
concentrated at the tips of the cell processes at points of contact with 
neighboring cells throughout the matrix (Figure 64).  
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Figure 64 Connexin-43 immunohistochemistry showing gap junctional
communication between bone forming cells within the PLGA/CaP scaffold
cultivated in the fixed bed perfusion bioreactor for 35 days in osteogenic
medium. (A) Connexin-43 is visualised by Alexa 488 conjugated to the secondary
antibody against anti-connexin-43 as green dots at cell-cell contact. Cell nuclei are
stained blue with DRAQ5™. Original magnification: x 400; scale bar=50µm. (B)
Cropped region of A (a) showing a close up of the intracellular communication. Scale
bar=50µm.  
 
Thi et al. (2003) have shown that fluid shear stress modifies the expression 
and distribution of connexin 43 as well as its de novo formation, depending on 
the magnitude of the shear stress experienced by osteocytic and osteoblastic 
cells. The group has reported on the change in the cell processes, which 
became smaller in diameter and increased in numbers by changing the applied 
shear stress. The morphological changes that were observed in the cell-
network formed in the perfusion bioreactor (Figure 64) compared to that 
formed in the tube rotor (Figure 54) might be explained by this hypothesis that 
different shear forces led to different rearrangement of bone cells within the 
matrix, leading to a different pattern of communication between cells in the 
perfusion bioreactor. 
 
 
 
-106- 
Chapter 3    Results and Discussion II 
 
 
3.3.4.6. Scanning Electron Microscopy of Cell-Scaffold Constructs in 
Fixed Bed Perfusion Bioreactor Cultivation  
 
Corroborating with what was observed in the light and confocal microscopical 
analysis, scanning electron microscopy revealed that cells attached strongly to 
the surface of the PLGA/CaP scaffold, however, only at selected sites (Figure 
65A). These cells formed organized collagen fibrils (Figure 65B) and along 
these fibrils, accumulations of crystal-like structures could be detected (Figure 
65C and D), aligning themselves parallel to the collagen axis- these acting as a 
nucleation site for the formation and growth of mineralized structures as 
described by Boskey (2005). 
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Figure 65 Scanning electron micrographs of human trabecular bone derived
cells cultured in conjunction with a PLGA/CaP scaffold in the fixed bed
perfusion bioreactor for 20 days in osteogenic medium. (A) A cell layer strongly
attaching to the PLGA/CaP scaffold covering parts of the pore surface, while patches of
‘naked’ biomaterial could also be detected. (B) Cross-banded collagen fibrils forming
the extracellular matrix. (C) Crystal-like structures alongside the collagen fibrils
indicating mineralization. (D) Collagen fibrils decorated with the mineral-like
structures at a higher magnification. 
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3.3.4.7. Discussion of the Fixed Bed Perfusion Bioreactor Cultivation 
 
The results revealed by the detailed histological analysis, showing that cells 
cultivated in the perfusion bioreactor only formed patches of tissue scattered 
throughout the porous structure of the PLGA/CaP scaffold, came against all 
expectations. Especially when compared to the simple tilted rotating model, 
which led to completely uniform cellular distribution. 
Several studies have shown that perfusion induces osteogenesis and improves 
cellular distribution in a three dimensional environment (Wendt et al., 2003; 
Wendt et al., 2006), however, histological analysis of sections as deep as 5000 
µm was never demonstrated in detail in these studies. Further, Barthold in his 
doctoral thesis (2003) developed and evaluated the fixed bed perfusion 
bioreactor system using rat derived cells. Rat cells are known to proliferate 
and differentiate faster with more intense mineralization in vitro than human 
derived cells (Rickard et al., 1994), producing a stronger extracellular matrix 
which might withstand the continuous perfusion in the bioreactor. 
Despite the fact that not the whole scaffold was uniformly filled with tissue, 
those parts that were filled with patches, contained organized cell layers 
spatially distributed in a newly laid down matrix and strongly attaching to the 
surface of the scaffold via focal adhesion points. The cells did demonstrate de 
novo bone formation shown by positive collagen type I staining and connexin 
43 staining, revealing actively communicating osteocyte-like cells within the 
extracellular matrix. Moreover, the mechanical stimulation by the flow 
perfusion was demonstrated to affect cellular morphology, leading to 
cytoskeletal reorganization when compared to static cultivation, which showed 
a rather flattened cell morphology. Actual osteogenesis was also augmented by 
the biochemical analysis undertaken, revealing the typical osteogenic 
differentiation pattern. Moreover, the organized structure of collagen fibrils 
revealed by scanning electron microscopy confirmed the potential for de novo 
bone formation with the collagenous matrix acting as a nucleation site for the 
formation and growth of mineral crystals. Finally, cells were shown to migrate 
towards the interior central part of the scaffold, as far as 5 mm away from the 
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surface. There was no cell concentration in a certain area due to diffusion 
nutrient limitation as in static culture, where cells only stay at the peripheries.  
Therefore, the goal of delivering nourishing medium and dissolved oxygen 
reaching the core of a three dimensional scaffold was achieved in the fixed bed 
perfusion bioreactor. Although, no spatial and uniform cell and tissue 
distribution was achieved throughout the whole PLGA/CaP scaffold, those 
cellular patches that filled parts of the porous network did reach terminal 
osteogenic differentiation. 
The scattered patch formation in the bioreactor indicated that through the 
types of mechanical stimulation produced in continuous perfusion through a 
fixed bed holding the scaffold, medium flow was successfully directed to reach 
the central part of the scaffold. However, the shear stress produced by the flow 
was not enough to spatially distribute the cells uniformly throughout the 
porous network of the PLGA/CaP scaffold, taking into consideration that the 
dimensions of 10x10 mm are relatively high compared to what has been mostly 
studied (Vunjak-Novakovic, 2003; Meinel et al., 2004a; Marolt et al., 2006). So 
that probably a supportive motion for optimizing seeding efficiency prior to the 
fixed bed perfusion process might be needed to distribute the cells throughout 
the whole porous structure of the scaffold or exchanging the initial static 
seeding of cells with a dynamic one. 
Alternatively, another explanation for the patch formation might be due to the 
fact that not enough cells were there to start with. The experimental design of 
this bioreactor perfusion culture included seeding the cells on the scaffold for 
24 hours statically and then placing the cell-scaffold construct in the fixed 
matrix holder, starting pump-generated perfusion directly at a rate of 0.2 
ml/min in a continuous mode. The initial shear stress produced by the 
perfusion could have been too high, affecting cell attachment negatively, in 
that some cells might have been flushed away once placed in the bioreactor 
and only those cells that attached heartedly to the surface of the material 
actually could withstand the continuous perfusion thereafter. Osteogenic 
differentiation is known to be accelerated by mechanical stimulation especially 
perfusion (Bancroft et al., 2002; Goldstein et al., 2001). They showed that at a 
0.3 ml/min perfusion rate, osteoblastic differentiation was increased by 
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increased levels of alkaline phosphatase activity as well as increased 
expression of osteopontin. Having initiated differentiation in the PLGA/CaP at 
an earlier time point in the bioreactor perfusion model, is evident from the 
ALP/CICP graph (Figure 56), where the rise and fall in alkaline phosphatase 
activity happened at a relatively early time point.  
It can be postulated that perfusion leads to redistribution of cells within a 
porous network, inducing cells to produce an extracellular matrix around them, 
rather than promoting cell doubling. From the WST-1 values and the protein 
content, cells did undergo an initial cell proliferation or matrix formation 
phase before transiting into differentiation but only in those areas to which 
cells have migrated. 
Overall, this study has shown that perfusion does induce osteogenesis and 
with directed medium flow, nutrients can be delivered towards the central 
interior of the scaffold. The postulations to why only patches of tissue have 
formed and the scaffold was not uniformly filled will have to be examined 
further by either increasing initial cell seeding density or to start at a lower 
perfusion rate progressing gradually to 0.2 ml/min at a later stage, or by 
introducing intermittent perfusion. All these factors are worth considering in 
future studies and would need further elaboration.  
 
3.4. Conclusion  
 
In summary, both dynamic systems improved cell distribution and 
osteogenesis, when compared to stationary culture, overcoming a major 
limitation in current bone tissue engineering protocols involving the 
homogenous delivery and diffusion of nutrients in large porous scaffolds. 
However, uniform and spatial cell and tissue distribution was observed to 
occur consistently throughout the PLGA/CaP scaffold, when cultivated in the 
tilted rotating system. The tilting and rotating motion generated and the free 
fall of the scaffold was shown to be superior compared to holding the scaffold 
fixed in place with directed medium perfusion.  
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This type of motion generated in the simple tube rotator could serve as a 
prototype bioreactor version for bone tissue engineering. Supplying the system 
with features like automated medium supply and exchange, monitoring and 
control of O2, CO2 as well as the pH can lead to the development of a closed 
system for the automated and controlled production of bone tissue in vitro.  
The clinical relevance of the in vitro generated bone-tissue was qualitatively 
high, considering the fact that the constructs were histologically shown to be 
quite similar to in vivo bone. The cells embedded within the de novo generated 
extracellular matrix were shown to communicate trough connexin 43 gap 
junctions which are known to be the major gap junctional protein that 
mediates cell-cell communication within osteoblasts and osteocytes in vivo 
(Donahue et al., 1995; You et al., 2000). Furthermore, this approaches 
functional restoration of bone in vivo to an extent that, to our knowledge, has 
not been shown before. Sikavitsas et al. (2001) have elaborated the role of 
communication in osteocytes, via gap junctions in that the transfer of signals 
through the gap junctions of the osteocytic network might lead to osteoblast 
recruitment and in turn result in bone growth. This is exactly the role that an 
in vitro engineered bone construct is to play if implanted in the body to help 
the body regenerate a defect that otherwise would have been too large for 
spontaneous intrinsic healing. 
Moreover, the tissue-engineered constructs may be used for further in vitro 
studies of osteogenesis, drug efficacy, bone metabolism as well as an 
alternative to animal models to study orthopedic diseases. 
Concluding, this study has successfully demonstrated the reconstruction of a 
three dimensional bone-like construct with a very high chance of being 
integrated in vivo, representing a highly promising tool for bone regeneration 
therapy options.  
Ultimately, to elucidate the positive effects of suitable dynamic culture 
conditions on osteogenesis, bone forming capability will have to be confirmed 
by in vivo implantation of the cell-scaffold construct, primarily in an adequate 
animal model.  
 
             Outlook 
 
 
4. Outlook 
 
This study has demonstrated the conversion of osteoprogenitor cells derived 
from human adult tissue to a viable bone-like tissue construct generated in 
vitro. The tissue engineered construct showed high resemblance to native bone 
tissue in terms of osteocyte-like cell shape and gap junctional communication. 
Despite of the promising results obtained, the true clinical potential of using 
the right cells in the right medium with the right scaffold in the right 
cultivation model (microenvironment) can only be highlighted by 
complimenting this study with in vivo bone regeneration studies. Bone forming 
capability is to be confirmed by in vivo implantation of the cell-scaffold 
construct hoping that the in vitro generated bone-like construct will give early 
support at site of repair or defect of the host bone tissue facilitating intrinsic 
regeneration. This inevitability will have to be applied in preclinical relevant 
animal models. 
However, before a tissue engineered construct is ready for clinical 
transplantation, there are still scientific and technical obstacles that need to 
be overcome including the following (Nerem 2006): 
 
 The optimal cell source: whether the cells are to be autologous or 
allogenic, whether differentiated or still in the progenitor stage (stem 
cells).  
 Off the shelf availability of the cells in case implantation is to be carried 
out on short notice not leaving enough time for cell expansion. 
 The suitable microenvironment for the generation of a tissue constructs 
in vitro (regulatory approved bioreactor). 
 Storage and delivery of the constructs (fresh or cryopreserved) as well 
as maintaining sterility contamination control. 
 At what point should the in vitro generated scaffold be implanted and 
moved from the laboratory bioreactor to the body; the in vivo bioreactor. 
 Regulating the immune response of the body after implantation. 
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 GMP conformity and regulatory approval of the methods and 
appliancations essential for the generation of clinically relevant tissue 
engineered constructs. 
Moreover, for optimal in vivo remodelling to occur two main issues that still 
need attention are: vascularisation and innervation of the tissue engineered 
construct requiring co-culture of vascular cells along with osteoprogenitor cells 
and eventually the incorporation of neuronal cell (Nerem 2006).  
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6. Appendix I 
 
6.1. Chemicals and Reagents 
 
 
Name Manufacturer 
  
 Acetic acid, glacial 100%  Merck, Darmstadt 
 AdipoRed™ Assay reagent Cambrex Bio Science Inc., Walkersville, USA 
 Albumax I 10% Solution Invitrogen Corporation, Paisley, UK 
 Alcian Blue  Sigma Aldrich Chemie GmbH, Steinheim  
 Alexa Fluor®488 goat anti-mouse IgG Molecular Probes/Invitrogen, Karlsruhe 
 Alexa Fluor®488 goat anti-rabbit IgG Molecular Probes/Invitrogen, Karlsruhe 
 Alexa Fluor®594 goat anti-mouse IgG   Molecular Probes/Invitrogen, Karlsruhe 
 Alizarin Red Sodium Sulfonate ICN biomedicals Inc., Aurora, USA 
 Calcein, Anhydrous  Sigma Aldrich Chemie GmbH, Steinheim 
 Calcium chloride Sigma Aldrich Chemie GmbH, Steinheim 
 Collagen I antibody mouse anti-human Abcam Limited, Cambridge, UK 
 Collagen Solution, Type1, 0.1%  Sigma Aldrich Chemie GmbH, Steinheim 
 Collagenase, lyophillized Invitrogen Corporation, Paisley, UK 
 Connexin 43 antibody rabbit anti-human Sigma Aldrich Chemie GmbH, Steinheim 
 CyQUANT® Cell Proliferation Assay Kit  Invitrogen Corporation, Paisley, UK 
 Dexamethasone Sigma Aldrich Chemie GmbH, Steinheim 
 Dimethyl sulfoxide  Sigma Aldrich Chemie GmbH, Steinheim 
 DRAQ5™ Biostatus Limited, Shepshed, UK 
 Eosin Y solution 0.5%  Carl Roth GmbH, Karlsruhe 
 Epidermal growth factor, recombinant human RELIATech GmbH, Braunschweig 
 Ethanol, 100% p.A. 
 Fetal bovine serum, lot 40G5311K 
J.T.Baker, Phillipsburg, USA 
Invitrogen Corporation, Paisley, UK 
 Fibroblast growth factor, recombinant human RELIATech GmbH, Braunschweig 
 Fibronectin  Sigma Aldrich Chemie GmbH, Steinheim 
 Formaldehyde 37% Carl Roth GmbH, Karlsruhe 
 Glutaraldehyde solution, 25% Sigma Aldrich Chemie GmbH, Steinheim 
 Glycerol-Gelatine, Kaiser’s Merck, Darmstadt 
 Goat serum  Invitrogen Corporation, Paisley, UK 
 Hematoxylin, Hem alum solution acid acc. to 
Mayer 
Carl Roth GmbH, Karlsruhe 
 HEPES buffer Sigma Aldrich Chemie GmbH, Steinheim 
 Histoclear™ Thermo electron corporation, Dreieich 
 Human Serum Medical School Hannover, Hannover  
 Human Serum , PAA Lot CO 2104-0167  PAA, Paschingen, Austria 
 Human Serum, Pan Biotech Lot  P50208, P520221 Pan Biotech, Aidenbach 
 HybridoMed Dif 1000 with L-Glutamin, w/o bovine 
serum albumin, w/o bovine transferrin, w/o bovine 
insulin, w/o oleic acid (ZKT-1) 
Biochrom AG, Berlin  
 Hydrochloric acid, 37% Carl Roth GmbH, Karlsruhe 
 Hydrocortisone, 98% Sigma Aldrich Chemie GmbH, Steinheim 
 Indomethacin Sigma Aldrich Chemie GmbH, Steinheim 
 Insulin Invitrogen corporation, UK 
 Insulin like growth factor, recombinant human Peprotech, Rocky Hill, USA 
 Isobutylmethylxanthin 99% Sigma Aldrich Chemie GmbH, Steinheim 
 Isopropanol J.T.Baker, Phillipsburg, USA 
 ITS+3 Liquid Media Supplement Sigma Aldrich Chemie GmbH, Steinheim 
 L-Ascorbic acid 2-phosphate  Sesquimagnesium 
salt 
Sigma Aldrich Chemie GmbH, Steinheim  
 L-Proline Sigma Aldrich Chemie GmbH, Steinheim 
 Magnesium chloride Sigma Aldrich Chemie GmbH, Steinheim 
 Methanol  J.T.Baker, Phillipsburg, USA 
 Metra CICP EIA kit  OSTEOmedical Group, Buende 
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 Micro BCA™ Protein Assay Reagent Kit Pierce, Rockford, USA 
 Nitrophenyl phosphate disodium salt hexahydrate Fluka, Seelze 
 Paraformaldehyde Sigma Aldrich Chemie GmbH, Steinheim 
 Penicillin-Streptomycin solution Invitrogen Corporation, Paisley, UK 
 Picric acid  Merck, Darmstadt 
 Platelet derived growth factor, recombinant human RELIATech GmbH, Braunschweig 
 p-Nitrophenol Standard Solution, 10mM  Sigma Aldrich Chemie GmbH, Steinheim 
 Poly-L-Lysine solution  Sigma Aldrich Chemie GmbH, Steinheim  
 Potassium chloride salt  Fluka, Seelze 
 Potassium phosphate monobasic Fluka, Seelze 
 Proline  Sigma Aldrich Chemie GmbH, Steinheim  
 Pyronin-G  Fluka, Seelze 
 Resorcin-Fuchsin-solution according to Weigert Carl Roth GmbH, Karlruhe 
 Saccharose Sigma Aldrich Chemie GmbH, Steinheim 
 Shandon Histoclear –Xylolersatz Thermo electron corporation, Dreieich 
 Shandon Histoplast, paraffin pellets 56-57°C  Thermo electron corporation, Dreieich 
 Shandon Xylene substitute mountant Thermo Electron Corporation, Dreieich 
 SigmaFast ™,pNPP Alkaline phosphatase 
substrate tablet set 
Sigma Aldrich Chemie GmbH, Steinheim 
 Sigma Fast™, BCIP/NBT Alkaline phosphatase 
substrate tablet set 
Sigma Aldrich Chemie GmbH, Steinheim 
 Sigmacote®, Sl-2 Sigma Aldrich Chemie GmbH, Steinheim 
 Silver nitrate Sigma Aldrich Chemie GmbH, Steinheim 
 Sodium bicarbonate Biochrom AG, Berlin  
 Sodium cacodylate trihydrate  Sigma Aldrich Chemie GmbH, Steinheim 
 Sodium carbonate anhydrous Carl Roth GmbH, Karlsruhe 
 Sodium chloride  Merck, Darmstadt 
 Sodium hydroxide pellets Sigma Aldrich Chemie GmbH, Steinheim 
 Sodium Pyruvate, 100mM solution Sigma Aldrich Chemie GmbH, Steinheim 
 Sodium tetraborate decahydrate Sigma Aldrich Chemie GmbH, Steinheim 
 Tareget Retrieval solution DakoCytomation, Hamburg 
 Toluidine Blue O Sigma Aldrich Chemie GmbH, Steinheim 
 Transferrin Biotest, Dreieich 
 Transforming growth factor-beta 1, recombinant 
human 
R&Dsystems, Minneapolis, USA 
 Triton X-100 Sigma Aldrich Chemie GmbH, Steinheim 
 Trypan blue Merck, Darmstadt 
 Trypsin/EDTA (1x)   Invitrogen Corporation, Paisley, UK 
 Weigert’s Hematoxylin solution A Carl Roth GmbH, Karlsruhe 
 Weigert’s Hematoxylin solutionB Carl Roth GmbH, Karlsruhe 
 WST-1, Cell Proliferation Reagent Roche, Mannheim 
 β-Glycerophosphate disodium salt Sigma Aldrich Chemie GmbH, Steinheim 
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6.2. Consumables 
 
 
Consumable Manufacturer 
 
 Cell culture well plates, 12, 24,48,96 Becton Dickinson, Heidelberg 
 Cell strainer, 70µm Nylon Becton Dickinson, Heidelberg 
 Cryo-vials  Nalgene, Rochester, USA 
 Embedding cassettes (double) with lids bio Optica, Milan, Italy 
 Filter AcroCap™ 0.1 µm, for liquid filtration  Pall Life Sciences Ann Arbor, USA 
 Filter, 0.2µm, 25 mm disposable syringe filter Nalgene, Rochester, USA 
 Filter, Millex®-FG,0.2µm,for sterile venting of autoclaved 
vessels 
Millipore Corporation, Bedford, USA 
 Pall, Acrodisc Syringe Filter, 0.1µm Pall Life Sciences, Ann Arbor, USA 
 Pharmed tubing, ID:1.02mm, Wall:0.85mm  (pumps) Ismatec, Zuerich, Switzerland 
 Pharmed tubing, ID:1.52mm, Wall:0.85mm, (sampling 
port) 
Ismatec, Zuerich, Switzerland 
 Polysine™, Microscope slides Menzel-Gläser, Braunschweig 
 Safe-lock tubes (1.5ml, 2 ml)  Eppendorf, Hamburg 
 Scalpel B.Braun, Melsungen  
 Shandon MB35 Premier blades Thermo electron corporation, Dreieich 
 Silicon tubing (perfusion bioreactor) TIP, Braunschweig 
 Syringes 2, 20,50 ml B.Braun, Melsungen  
 Tissue culture flasks, 25, 75,175 cm2  Becton Dickinson, Heidelberg 
 TPP, tissue culture tubes  TPP AG, Trasadingen, Switzerland 
 Universals, polystyrene conical tubes (15ml,50ml) Becton Dickinson, Heidelberg 
 
6.3. Instruments 
 
 
Instrument Manufacturer 
 
 ELISA-Reader, Spectrophotometer, SLT 340, ATTC ATTC Labinstruments, Crailsheim 
 Fluorescence microplate reader, CytoFlourII Applied Biosystems, Foster City, USA 
 IKA-Ultra-Turrax® T25 basic IKA-Werke, Staufen 
 Incubator Biocentre 2001  Integra, Fernwald, Switzerland 
 Incubator Cytoperm2 Heraeus/Kendro, Hanau  
 MACSmix™ tube rotator Miltenyi Biotec GmbH, Bergisch Gladbach  
 Neubauer chamber  Omnilab, Braunschweig 
 Plateshaker, Thermomixer comfort  Eppendorf, Hamburg 
 Scalpel , knife to prepare bone samples  Aesculap, Tuttlingen 
 Scanning electron microscope DSM 982 Gemin  Zeiss, Jena 
 Shandon Citadel™ Tissue Processor (Citadel 1000) Thermo electron corporation, Dreieich 
 Shandon Histocentre 2, Tissue Embedding System Thermo electron corporation, Dreieich 
 Shandon Microtome 0325 Thermo electron corporation, Dreieich 
 Stainless steel embedding moulds, BIO-MOLD 
33x24x12mm 
bio Optica, Milan Italy  
 Variomag®,Magnetic stirrer base  H+P Labortechnik GmbH, Oberschleissheim 
 YSI 2700 Biochemistry Analyzer Yellow Springs, USA 
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7. Appendix II  
 
7.1. General Cell Culture Methodology  
7.1.1. Cryopreservation and Resuscitation of Cryopreserved Cells 
 
To enable stocks of cells to be stored cells were cryopreserved. Sub-confluent 
cell monolayers were trypsinised as described above and centrifuged. The 
pellet was thereafter re-suspended, counted and centrifuged again to re-
suspend 3-5 x106 cells in 1ml freezing medium (10% DMSO as a 
cryoprotectant, 10% ZKT-1 medium and 80% human serum), transferred to a 
cryo-vial and slowly frozen over night at -70ºC inside a passive freezer (Mr 
Frosty, Nalgene) filled with 70% isopropanol) to be then transferred to a liquid 
nitrogen cryotank for long term storage.  
For thawing, the vials were collected from the cryotank, and dipped for 1 
minute in a 37°C water bath to thaw. The contents of the vial were then re-
suspended by drawing them up carefully using a 1 ml sterile pipette and 
transferred to a universal containing fresh supplemented culture medium, 
centrifuged as above and the pellet re-suspended in fresh medium to dilute out 
the DMSO and start a new stock culture swirling the cell suspension upon 
seeding for uniform distribution in the culture vessel. 
 
7.1.2. Subculture of Adherent Human cells 
 
At sub-confluence (80-90% confluence) the cell monolayer was trypsinised by 
carefully removing the spent medium and washing the cell layer with 1xPBS 
(ca.300 µl/cm2) by gently swirling the culture flask for about 30 seconds to 
wash away any medium or serum residuals. PBS was completely removed and 
the cell layer was covered with 0.25% Trypsin/EDTA solution (ca.300 µl/cm2) *, 
completely covering the monolayer and then incubated for 5 minutes at 37°C. 
Cell detachment was confirmed microscopically (Axiovert 120, Zeiss, Jena) as 
adherent cells float becoming round once dislodged. To loosen any attached cell 
remainders, the culture container was gently tapped at the side to ensure 
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complete separation from the culture surface. The enzyme reaction was 
neutralized after maximum 5 minutes using an equal volume of serum 
supplemented medium**. The cell suspension was then transferred with a 
sterile pipette to a 15 ml (or 50 ml) conical tube and centrifuged at 800 rpm for 
three minutes at room temperature. The clear supernatant was removed and 
the pellet carefully re-suspended in a determined volume of fresh medium to 
determine the cell number in a haemocytometer (Trypan blue exclusion). Cells 
were then either cryopreserved or further sub-cultured at 5x103 or 1x104 
cells/cm2. 
*The amount of trypsin varied according to the cell culture area from 1.5 ml for a T25 
flask, 3 ml for a T75 flask and 5 ml for a T175 flask and 20 ml per layer in a cell 
factory. 
**For cell detachment solutions (PBS, Trypsin/EDTA and medium were all pre-
warmed in a 37°C water bath 
 
7.1.3. Determination of Cell Number (Trypan Blue Exclusion) 
 
Adherent cells were brought into suspension as described above using 
Trypsin/EDTA and re-suspened in a volume of fresh medium, gently pipetting 
up and down to break up any clumps. 100-200 µl of cell suspension were 
aseptically removed and diluted with an equal volume of Trypan Blue solution 
(dilution factor=2)*. Cells were counted using an improved Neubauer chamber, 
filling both sides of the chamber (ca.10 µl) with cell suspension and then 
viewed under a phase contrast light microscope (Axiovert 120, Zeiss, Jena) 
using x10 magnification. Viable cells, appearing as round bright cells in the 4 
squares of the Neubauer chamber were counted and non-viable cells stained 
blue** were counted as well. The concentration of cells (cells/ml) was 
calculated using the following equation: 
(Cell number x dilution factor) / Number of squares counted.  
Total number of cells= concentration of viable cells (cells/ml) x volume of cell 
suspension (ml).  
*The cell suspension was diluted depending on cell density (i.e. a higher dilution 
factor in case of a high cell density). 
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**Trypan blue is a dye that would penetrate only dead cells because of the ruptured 
cell membrane. 
 
 
 
7.2. Cell Culture Media 
 
All solutions and buffers were prepared using deionized water (Milli-Q-Water 
filtration system, Millipore) and either autoclaved at 121ºC for heat 
sterilisation or if heat labile, solutions filtered through 0.1µm AcroCap™ filters 
or through 0.2µm syringe filters.  
 
7.2.1. ZKT-1 Basal Medium  
 
ZKT-1 refers to the following medium composition:  
 
Hybridomed Dif 1000  12.1 g 
NaHCO3    3.6 g 
Deionized water  ad 1000 ml 
The medium was filtered through a 0.1 µm filter and stored at 4ºC.  
 
Hybridomed Dif 1000 is based on a 1:1 mixture of lscove's Modified Dulbecco's 
Medium and Ham's Medium F12 medium and was developed in the cell 
culture technology department of the Helmholtz Centre for Infection Research 
(Jaeger 1988).  
 
7.2.2. Osteogenic Differentiation Medium  
 
ZKT-1 basal medium was supplemented with the following at a final 
concentration in the cultivation medium:  
 
Human Serum or Fetal bovine 
serum  
10% (v/v) 
β-Glycerophosphat    10 mM 
L-Ascorbat  0.20 mM  
Dexamethasone     10 nM  
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7.2.3. Adipogenic Differentiation Medium 
 
ZKT-1 basal medium was supplemented with the following at a final 
concentration in the cultivation medium:   
FBS  10% (v/v) 
Isobutylmethylxanthine    0.5 mM 
Indomethacin  
Insulin                            
   200 µM 
    5  µg/ml 
Hydrocortisone     0.5 mM 
7.2.4. Chondrogenic Differentiation Medium  
 
ZKT-1 basal medium was supplemented with the following at the final 
concentration in the cultivation medium:  
 
 
 
Albumin     1 mg/ml  
Sodium Pyruvate 100 µg/ml 
Proline   40 µg/ml 
L-Ascorbate   50 µg/ml 
Dexamethasone  100 nM 
TGF-β   10 ng/ml 
1x ITS (Insulin+Transferrin+ Seleneous 
acid) 
6.25 µg/ml 
7.3. Buffers, Supplements and Working Solutions  
 
7.3.1. Cacodylate Buffer, 0.1M 
 
To prepare one liter of 0.1M cacodylate buffer, the following protocol was 
applied:   
 
Sodium cacodylate 21.41 g 
Saccahrose 38.80 g 
MgCl2   2.04 g 
CaCl2    1.48 g 
Deionized water ad 1000 ml 
 
The pH was adjusted with to 6.9 and the solution stored at 4ºC.  
 
7.3.2. Human Serum Inactivation 
 
To remove complement from serum, inactivate potentially available viruses 
and reduce the cytotoxic action of immunoglobulins, human serum was pooled 
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and heat inactivated at 56°C for 30 minutes (Hankey et al., 2001). Aliquots 
were stored at -20°C. 
7.3.3. Paraformaldehyde Fixative Solution, 4% 
 
To prepare 4% paraformaldehyde solution the following protocol (Bancroft and 
Gamble, 2001) was applied: 
Solution A Solution B 
NaH2PO4        2.26 g NaOH       2.52 g 
Deionized water ad 100 ml  Deionized water ad 100 ml  
 
 
 
Paraformaldehyde    4 g 
Solution A   83 ml 
Solution B  ad 100 ml  
 
The solution was stirred under a fume hood and warmed up to 60°C, filtered 
and cooled (pH 7.2-7.4). Aliquots were stored at –20°C. 
 
7.3.4. Penicillin-streptomycin  
 
Refers to a ready made solution ordered from Invitrogen Corporation prepared 
with 10,000 units/ml penicillin G sodium and 10,000µg/ml streptomycin 
sulphate in 0.85% saline. Medium was supplemented with the antibiotic 
mixture at a final concentration of 1% (v/v) (antibiotic mixture/complete 
medium). 
 
7.3.5. Phosphate Buffered Saline (PBS) 
 
PBS was prepared according to the following protocol:  
 
NaCl 150 mM 
Na2HPO4      8 mM 
KCl      3 mM 
KH2PO4  1.5  mM 
 
The solution (pH 7.4) was heat sterilized at 121ºC and stored at 4ºC. 
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7.3.6. Triton-X Solution 
 
A 2% Triton-X solution was prepared in deionized water according to the 
following protocol:  
Triton X-100 2% (v/v) 
HEPES 50  mM 
NaCl  100 mM 
 
7.3.7. Trypan Blue Solution, 0.25% 
 
Trypan blue      0.2 g 
NaCl       0.9 g 
Deionized water ad 100 ml 
 
 
7.4. Histological Methods and Staining Solutions  
 
7.4.1. Calcein Solution  
 
Calcein solution for the calcium quantification assay as well as for histological 
staining was prepared after the following protocol:  
  
Calcein       5 µg 
Deionized water  ad 100ml  
 
The solution was stored at 4ºC in the dark.  
 
7.4.2. Haematoxylin-Eosin Staining  
 
After sections were deparaffinized and rehydrated, haematoxylin and eosin 
staining was performed according to the following protocol: 
Haematoxylin solution (according to 
Mayer)   
5 min  
Tap water rinsing 15 min  
1% acetic acid solution  1 min  
Deionized water   1 min  
70% ethanol 2 min 
90% ethanol 2 min 
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Eosin Y solution 0.5% 5 min 
90% ethanol a quick dip 
100% ethanol  3x 2min 
Xylene substitute 2x 10min  
Xylene substitute mountant  
 
7.4.3. von Kossa staining 
 
5% silver nitrate solution (stored dark) 
AgNO3 5 g 
Deionized water ad 100 ml 
 
5 % sodium carbonate solution (containing 0.2% Formaldehyde) 
Na2CO3 5 g 
Formaldehyde 37% 0.55 ml 
Deionized water ad 100 ml 
 
7.4.4. Toluidine Blue Staining  
 
After sections were deparaffinized and rehydrated, Toluidine Blue staining 
was performed according to the following protocol: 
Toluidine Blue solution* 15 min 
Deionized water 1 min  
96% ethanol  2x a quick dip 
100% ethanol  2x 1 min  
Xylene substitute  2x 10 min  
Xylene substitute 
mountant 
 
 
*Toluidine Blue Solution: 
Solution A Solution B 
Sodium tetraborate 8 g Pyronin G 2 g 
Toluidine blue 8 g Deionized water ad 200 ml 
Deionized water ad 800 ml  
Toluidine Blue solution was prepared by mixing solution A with solution B for 
15 minutes on a magnetic stirrer. 
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7.4.5. Van Gieson Staining 
 
After sections were deparaffinized and rehydrated, van Gieson staining was 
performed according to the following protocol: 
Resorcin Fuchsin solution 
(Weigert) 
30 min 
Rinse under tap water  5-10 min 
95% ethanol  quick dip  
100% ethanol. quick dip 
Deionized water 1 min 
Weigert’s iron haematoxylin * 5 min 
Rinse under tap water   5-10 min 
Deionized water  1 min  
van Gieson solution**  5 min  
96% ethanol 1 min  
100% ethanol  1 min  
Xylene substitute  2x 10 min  
Xylene substitute mountant  
 
*Weigert’s iron hematoxylin : 
40 ml of Weigert’s solution A (5 g Hematoxylin in 500 ml Ethanol p.A.) were 
added to 30 ml of Weigert’s solution B (475 ml deionized water and 5 ml 25% 
HCl and 20 ml liquoferrisesquinchlorati). 
 
**van Gieson solution:  
A 3% picric acid solution was prepared:  
30 g picric acid ad 1000 ml deionized water, dissolved on a hot plate under a 
fume hood, cooled and filtered. 
50 ml 2% Acid Fuchsin solution and 5 ml 2% acetic acid solution were added. 
 
7.4.6. Poly-L-Lysine Slide Coating  
 
To minimize the loss of the tissue section from the slide during the histological 
staining procedure, the glass slides were coated with a tissue adhesive. Briefly, 
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the poly-l-lysine solution (0.1% w/v) was diluted 1:10 with deionized water 
(Bancroft and Gamble, 2001) the slides were placed in a trough filled with the 
solution and left for 5 minutes at room temperature. Slides were then drained 
and dried at 60ºC in an oven for 1 hour.  
 
7.5. Osteogenic Differentiation of Human Mesenchymal 
Cells using Fetal Bovine Serum  
 
Since the concept of inducing osteogenesis with a mineralisation pattern 
involving the formation of vesicular like structure in medium containing 
human serum has been proven (chapter 2, section 2.3.6. ), it was investigated 
whether cells show a similar mineralisation pattern in fetal bovine serum 
(FBS) supplemented medium (Figure 66). Cryopreserved human bone marrow 
cells (male, age: 19 years) were cultivated and expanded in ZKT-1 basal 
medium containing 15% FBS instead of 15% human serum until passage three 
(section 2.2.1.). Osteogenic differentiation was investigated by seeding the cells 
in 48-well plates at a plating density of 5x10³ cells/cm² in osteogenic medium 
containing 10% FBS instead of 10% human serum The osteogenic 
differentiation was assessed over a 35 day time course study. Cells were 
seeded at 5x103 cells/cm2 in 48-well-plates kept in expansion medium for 5 
days until confluence and then changed to osteogenic medium (section 7.2.2.).  
Mineralisation of the extracellular matrix is demonstrated in Figure 66 by 
Alizarin red, von Kossa and calcein staining showing an almost identical 
eventual pattern of mineralization observed with human serum. However, it 
was noted that the onset of mineralisation was noted to be earlier in case of 
the cells cultivated in FBS. In all three histological staining methods, 
mineralized nodules were observed as early as day 14, this could be explained 
by either the presence of mitogenic factors in FBS not found in human serum 
or due to the fact that human bone marrow derived cells used for the assessing 
experiment were obtained from a young donor (age 19 years). 
It can be concluded that both sera can be used interchangeably for osteogenic 
differentiation studies and essentially proof of concept was demonstrated with 
human serum. 
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 day 14 day 35 day 7 
A B C
day 35 day 7 day 10 
D E F
day 14 day 25 day 35 
G H IFigure 66 Phase contrast micrographs showing terminal and complete
mineralization of the extracellular matrix in human bone marrow derived cells
cultivated in foetal bovine serum in the process of bone formation. Cells were seeded
at 5x103cells/cm2 and induced with osteogenic medium at confluence Cell layers were fixed at
days 7,10,14,25 and 35. (A), (B) and (C) show a strong Alizarin red staining pattern from day
7 with progressed intensity on days 14 and 35 with mineralised nodules appearing in red. (D),
(E) and (F) Von Kossa staining after 7, 10 and 35 days in osteogenic medium showing black
mineral depositions increasing in number and size with time. (G), (H) and (I) Fluorescence
microscopy of the mineralised extracellular matrix revealed the calcein binding pattern
showing intense calcification (green fluorescence) of the bone marrow derived cells. Original
magnification: x100; scale bar=100 µm. -134- 
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8. Abbreviations 
 
 
ALP 
 
Alkaline Phosphatase  
BCA Bicinchoninic Acid 
BCIP 5-Bromo-4-Chloro-3-Indolyl Phosphate 
BSE Bovine Spongiform Encephalopathy 
CaP Calcium Phosphate 
CF Collagen Fibers 
CICP Collagen type I COOH terminal Propeptide 
DMSO Dimethyl Sulfoxide 
DNA Deoxyribonucleic Acid 
ECM Extracellular Matrix 
EDTA Ethylenediaminetetraacetic acid Disodium salt Dihydrat 
EGF Epidermal Growth Factor 
FBS Fetal Bovine Serum  
FCS Fetal Calf Serum 
FGF Fibroblast Growth Factor 
H&E Haematoxylin and Eosin 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
HS Human Serum  
IGF Insulin like Growth Factor 
IgG Immunoglobulin G  
IRB Institutional Review Board 
ITA Insulin, Transferrin, Albumin  
ITS Insulin, Transferrin, Seleneous acid 
MSC Mesenchymal Stem Cell 
NASA National Aeronautics and Space Administration 
NBT  Nitro Blue Tetrazolium  
OB Osteoblast 
OC  Osteocyte 
PBS Phosphate Buffered Saline  
PCL Polycaprolactone 
PDGF Platelet Derived Growth Factor 
PEEK Polyarylether Ether Ketone 
PFA Paraformaldehyde 
PGA Polyglycolide 
PLA Polylactide 
PLGA Poly-(lactic-co-glycolic acid) 
pNPP p-Nitrophenyl Phosphate 
rpm  Revolutions per minute 
SEM Scanning Electron Microscopy  
TGF-β Transforming Growth Factor beta 
WHO  World Health Organization  
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